bcell_id,pubmed_id,reference_id,host_taxon_id,host_age,iv1_process_type,iv1_adjuvants,iv1_route,iv1_dose_schedule,iv1_immunogen_type,iv1_immunogen_sub_type,iv1_immunogen_description,iv1_immunogen_organism_id,iv1_container_type,iv1_container_sub_type,iv1_container_description,ab_type,ab_materials_assayed,ab_immunoglobulin_domain,antigen_type,antigen_sub_type,antigen_description,antigen_organism_id,assay_type,assay_type_name,num_subjects,num_responded,response_frequency,location,char_value,num_value,inequality,type_id
1605395,19047411,1013678,10000067,"6-7 weeks","Administration in vivo",;Imiquimod;,"Subcutaneous (s.c.)","3 to 4 doses of 50 μg peptide at 2 week intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",DPNANPNVDPNANPNVNANPNANPNANPEYLNKIQNSLSTEWSPCSVT,NULL,NULL,NULL,NULL,Polyclonal,NULL,"Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 7",Positive,NULL,NULL,125
1936170,8643522,1009629,10000019,"6-10 weeks","Administration in vivo to prevent or reduce disease",NULL,"Intravenous (i.v.)","1 dose of 1 mg of epitope-IgG fusion protein","Fragment of a Natural Sequence Molecule","Peptide from protein",LEDARRLKAIYEKKK,NULL,"Complexed Molecule","Protein conjugate","immunoglobulin gamma 1 heavy chain precursor (Mus musculus)",Polyclonal,"Culture Supernatant","Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",LEDARRLKAIYEKKK,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,361
24116,9673294,1466,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intranasal,"Three doses of 10<sup>5</sup> PFU at 2 week-interval intranasally followed by 2 doses intramuscularly (10<sup>5</sup> PFU).","Fragment of a Natural Sequence Molecule","Peptide from protein",AEGRAINRRVE,NULL,"Recombinant Organism","Recombinant Organism","Influenza A virus",Polyclonal,Serum,NULL,Organism,Organism,"Pseudomonas aeruginosa",287,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",27,12,44.4,"Table 4",Positive,NULL,NULL,125
1327100,16703510,1002168,10000263,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 30-60 µg of LCP construct s.c. in CFA or without CFA.","Fragment of a Natural Sequence Molecule","Peptide from protein",DNGKAIYERARERALQELGP,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Streptococcus pyogenes",1314,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 6 and 7",Positive,NULL,NULL,124
1244308,12034109,1001168,10000263,"4-6 weeks","Administration in vivo to prevent or reduce disease",";Cholera toxin;",Intranasal,"3 dose(s) of 30 ug conjugated peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",SREAKKQVEKAL,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus pyogenes",1314,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",11,10,90.9,"Table 2, Figure 1",Positive,NULL,NULL,124
1244307,12034109,1001168,10000263,"4-6 weeks","Administration in vivo to prevent or reduce disease",";Cholera toxin;",Intranasal,"3 dose(s) of 30 ug conjugated peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",ASREAKKQVEKALE,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus pyogenes",1314,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,7,70,"Table 2, Figure 1",Positive,NULL,NULL,124
1007733,8585293,1000351,10000000,"8-12 weeks-old","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"Mice were immunized intranasally three times with three-week intervals between each immunization.  Four weeks later, the mice were challenged with virus.","Fragment of a Natural Sequence Molecule","Peptide from protein",SKAFSNCYPYDVPDYASL,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Texas/1/1977(H3N2))",444318,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3, Table 1",Positive,NULL,NULL,125
1806617,21028828,1021229,10000263,"4-6 weeks","Administration in vivo",NULL,Intranasal,"Three doses of 60 µg at a three-week interval.","Fragment of a Natural Sequence Molecule","Peptide from protein",ASREAKKQVEKALE,NULL,"Complexed Molecule","Other Complexed Molecule","5-amino-4-oxo-2-tetradecylnonadecanamide linked to KLIPNASLIENCTKAEL (fusion protein, Canine distemper virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Streptococcus pyogenes M1 GAS",160490,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1338020,10580206,1002572,10090,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"3 doses of 50-70 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",SNTFINNA,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii 265BY",10000555,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,125
1338017,10580206,1002572,10090,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"3 doses of 50-70 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",SNTFINNA,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii 265BY",10000555,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,125
1818779,19559116,1016532,10000000,"7 weeks old","Administration in vivo",;Liposomes;,Intramuscular,"4 doses 3-4 weeks apart","Fragment of a Natural Non-Sequence Molecule","Carbohydrate fragment",alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Shigella flexneri 2a",42897,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,559
1271872,16713037,1001359,10000000,"8-12 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","1 s.c. dose followed by 1 intranasal dose 8 weeks later, 15 μg/dose.","Fragment of a Natural Sequence Molecule","Peptide from protein",MSLLTEVETPIRNEWGCRCNDSSD,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 4, 5 and 7.",Positive,100,NULL,124
1587757,15080822,1006740,10000000,"6-8 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"3 doses of 100, 400, 800, 1000, or 2000 µg epitope on days 0, 1, and 2","Fragment of a Natural Sequence Molecule","Peptide from protein",ISQAVHAAHAEINEAGR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,ovalbumin,9031,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1277775,14550926,1001638,10000631,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,"All animals received a total of six immunizations at intervals of 3-4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",KTNLKHVAGAAAAGAVVGGLG,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Major prion protein precursor",10090,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,124
1006983,10195628,1000201,10000597,NULL,"Administration in vivo to prevent or reduce disease",;Liposomes;,Intranasal,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",WTGVTQN,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Aichi/2/1968(H3N2))",387139,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1506990,9607021,1000799,10000000,"6-8 weeks","Administration in vivo",";Cholera toxin;",Intranasal,"6 doses of 50ug, administered at intervals of 2, 2, 21, 40 and 67days.","Fragment of a Natural Sequence Molecule","Peptide from protein",INQDPDKILTY,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing LSEIKGVIVHRLEGVLSEIKGVIVHRLEGVGG",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Measles virus",11234,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1191108,7504858,1000838,10000067,"3 weeks","Administration in vivo to prevent or reduce disease",NULL,Oral,7,"Fragment of a Natural Sequence Molecule","Peptide from protein",VEVPGSQHIDSQKKAIERMKNTLRIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Cholera enterotoxin subunit B",666,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,125
1278385,10816497,1001697,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)",5,"Fragment of a Natural Sequence Molecule","Peptide from protein",VEGMQFDRGYLSPYF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Helicobacter pylori TK1402",10000719,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,125
2106011,24841626,1027925,10000642,"7 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","Doses of 10 pg, 11 pg, and 12 pg at 0, 2 and 4 weeks, respectively","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",SRTLGCSWEFIPVDDGWGERPL,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,361
2105994,24841626,1027925,10000642,"7 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","Doses of 10 pg, 11 pg, and 12 pg at 0, 2 and 4 weeks, respectively","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,361
2367939,10698744,1186,10000000,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","3 doses of 2X10<sup>6</sup> FFU of VEE-GP at 1-month intervals","Accession Sequence Molecule",Protein,"surface glycoprotein GP",186538,"Recombinant Organism","Recombinant Organism","Venezuelan equine encephalitis virus",NULL,NULL,NULL,Organism,Organism,"Zaire ebolavirus",186538,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,10,100,"Table 1",Positive,NULL,NULL,124
1771362,19406992,1014973,10001446,"8-10 weeks","Administration in vivo to cause disease",";Freund's complete;",Intramuscular,"1 dose of 100 µg","Accession Sequence Molecule",Protein,"similar to procollagen, type IV, alpha 3",10116,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"similar to procollagen, type IV, alpha 3",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 1, 2, 3 and 4",Positive,NULL,NULL,326
1642621,15755621,1008555,10001278,"9-10 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
1617954,17264212,1003692,10001240,"4 months","Administration in vivo to prevent or reduce disease",NULL,Transcutaneous,"4 doses of 200 ug weekly, followed by 6 more doses of 100 ug biweekly","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1607089,17264212,1003692,10001240,"4 months","Administration in vivo to prevent or reduce disease",NULL,Transcutaneous,"4 doses of 200 ug weekly, followed by 6 more doses of 100 ug biweekly","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1032363,1700835,1000173,10000000,Four-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","Mice were boosted three and six weeks after immunization.  Mice were challenged with virus two weeks after final booster.","Fragment of a Natural Sequence Molecule","Peptide from protein",SPLLGCIGSTCAE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,0,0,"Table 2",Negative,NULL,NULL,124
1031769,1700835,1000173,10000000,Four-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","Mice were boosted three and six weeks after immunization.  Mice were challenged with virus two weeks after final booster.","Fragment of a Natural Sequence Molecule","Peptide from protein",SPLLGCIGSTCAE,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",15,14,93.3,"Table 2",Positive,93,NULL,124
1279025,15908434,1001734,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intradermal,"3 doses of 10^11 cells, at weeks 0, 3 and 5.","Sequence Molecule No Natural Source","Peptide, no natural source",SWFDNFLYPTHD,NULL,"Object Library","Bacterial display",NULL,NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus RN6390B",10000771,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1, Figure 8",Positive,NULL,NULL,125
1279023,15908434,1001734,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intradermal,"3 doses of 10^11 cells, at weeks 0, 3 and 5.","Sequence Molecule No Natural Source","Peptide, no natural source",TPFHHQHSTGFT,NULL,"Object Library","Bacterial display",NULL,NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus RN6390B",10000771,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1484220,16931331,1006061,10000668,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 0.5 mg epitope in CFA on day 0 and in IFA on days 21 and 42","Sequence Molecule No Natural Source","Peptide, no natural source",CTGDKENVYPSQNFGHMHKSEKDRGC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus",12110,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,1,25,"Table 1",Positive,NULL,NULL,125
16263,11906771,1162,10000000,"4-6 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were given four injections, each 15 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",LTTRNGEPHMIVMRQEKGKSLLFKTGDGV,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,Other,NULL,Organism,Organism,"Dengue virus 2",11060,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
16279,11906771,1162,10000000,"4-6 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were given four injections, each 15 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",LETRTETWMSSEGAWKHAQRIE,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,Other,NULL,Organism,Organism,"Dengue virus 2",11060,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,124
15349,15994800,1108,9606,NULL,"Administration in vivo",NULL,NULL,"3 doses.",Organism,Organism,"Rabies virus PM",11297,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Rabies virus strain Street",31613,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1318217,11854261,1065,10000253,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,"Mice were immunized with 10 µg of protein adsorbed to Alhydrogel on days 1 and 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",FHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVE...,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis STI",10000292,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",20,20,100,"Table 1",Positive,NULL,NULL,124
1318220,11854261,1065,10000253,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,"Mice were immunized with 10 µg of protein adsorbed to Alhydrogel on days 1 and 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",TARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPN...,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis STI",10000292,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,5,100,"Table 1",Positive,NULL,NULL,124
1313614,11854261,1065,10000253,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,"Mice were immunized with 10 µg of protein adsorbed to Alhydrogel on days 1 and 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",EVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSEL...,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis STI",10000292,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,3,60,"Table 1",Positive,NULL,NULL,124
1318223,11854261,1065,10000253,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,"Mice were immunized with 10 µg of protein adsorbed to Alhydrogel on days 1 and 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",STSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLT...,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis STI",10000292,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,1,20,"Table 1",Positive,NULL,NULL,124
1318225,11854261,1065,10000253,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,"Mice were immunized with 10 µg of protein adsorbed to Alhydrogel on days 1 and 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",STSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLT...,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis STI",10000292,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,3,60,"Table 1",Positive,NULL,NULL,124
1491637,17890123,1005940,10000000,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 50ug, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",YPTFGEHKQEKDLEY,NULL,"Complexed Molecule","Protein conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Enterovirus 5865/sin/000009",150846,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2, 3, 4, 5 and table 1",Positive,NULL,NULL,125
1244182,16476510,1001080,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 30 μg B-T peptide conjugate, boost of 10μg.","Fragment of a Natural Sequence Molecule","Peptide from protein",TSQDGNNHQFT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Yersinia pestis 195/P",10000757,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,0,0,"Tables 6 and 7",Negative,NULL,NULL,124
1244181,16476510,1001080,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 30 μg B-T peptide conjugate, boost of 10μg.","Fragment of a Natural Sequence Molecule","Peptide from protein",FFVRSIGSKGGKLAAGKYTDAVTV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Yersinia pestis 195/P",10000757,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,5,83.3,"Tables 6 and 7",Positive,NULL,NULL,124
1244232,16476510,1001080,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 30 μg B-T peptide conjugate, boost of 10μg.","Fragment of a Natural Sequence Molecule","Peptide from protein",ITIMDNGNIDTELLVGTLTLGGY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Yersinia pestis 195/P",10000757,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,0,0,"Tables 6 and 7",Negative,NULL,NULL,124
1811461,11081758,1020594,10001597,NULL,"Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","2 doses of 10E7 RRBC, administered at intervals of 14 days.","Accession Non-Sequence Molecule",Carbohydrate,"alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc-yl group",9986,NULL,NULL,NULL,NULL,NULL,NULL,"Derivative of Organism","Anatomical Entity","Heart (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figures 1, and 2",Positive,NULL,NULL,356
1270835,16545605,1001341,10000000,"5-6 weeks-old","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"4 doses of 10ug","Sequence Molecule No Natural Source","Peptide, no natural source",GTVCKRDQSDRGWGNHAGLFGKGSIVTCVKA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Tick-borne encephalitis virus (STRAIN SOFJIN)",11087,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",12,7,58.3,"Table 1",Positive,58,NULL,124
1857725,15297047,1156,9544,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"3 doses of 10, 30, 100, or 300 µg, administered at weeks 0, 8 and 25.","Fragment of a Natural Sequence Molecule","Peptide from protein",MSLLTEVETPIRNEWGCRCNDSSD,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"H3N1 subtype Influenza A virus (A/Hong Kong/68HA-A/Puerto Rico/8/34NA)",10000841,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table 4",Positive,NULL,NULL,125
1032271,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",DKNIDISIKYDPRKDSEVFANRVITDDIEL,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032297,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",TAELKIYSVIQAEINKHLSSSGTINIHDKS,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032348,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",SRPLNDLVSQKTTQLSDITS,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 4",Negative,NULL,NULL,124
1032313,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",KASAEYKILEKMPQTTIQVDGSEKKIVSIK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032311,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",DKSINLMDKNLYGYTDEEIFKASAEYKILE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032305,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",SVIQAEINKHLSSSGTINIHDKSINLMDKN,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Tables 3, 4",Negative,NULL,NULL,124
1032267,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",VEQLTGHGSSVLEELVQLVKDKNIDISIKY,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032326,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",YSYNKDNNELSHFATTCSDKSRPLNDLVSQ,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032332,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",RFNSAIEALNRFIQKYDSVMQRLLDDTSGK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,0,0,"Table 3",Negative,NULL,NULL,124
1032345,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",VKEFLESSPNTQWELRAFMA,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,0,0,"Table 4",Negative,NULL,NULL,124
1032259,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",MIRAYEQNPQHFIEDLEKVRVEQLTGHGSS,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,4,44.4,"Tables 3, 4",Positive,44,NULL,124
1032278,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",EDAILKGGHYDNQLQNGIKRVKEFLESSPN,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032282,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",VKEFLESSPNTQWELRAFMAVMHFSLTADR,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032272,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",NRVITDDIELLKKILAYFLPEDAILKGGHY,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,0,0,"Table 3",Negative,NULL,NULL,124
1032291,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",DSMNHHGDARSKLREELAELTAELKIYSVI,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1032347,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",RAFMAVMHFSLTADRIDDDI,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 4",Negative,NULL,NULL,124
1032351,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",KTTQLSDITSRFNSAIEALN,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 4",Negative,NULL,NULL,124
1032320,9453605,1000491,10000629,8-9-weeks-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were immunized on days 0, 30, and 60.","Fragment of a Natural Sequence Molecule","Peptide from protein",GALGNLKNSYSYNKDNNELSHFATTCSD,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,NULL,Organism,Organism,"Yersinia pestis CO92",214092,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 3",Negative,NULL,NULL,124
1785536,8341656,1016255,10000033,"8 to 12 weeks","Administration in vivo",";Freund's complete;",NULL,"2 doses of 20 µg administered at intervals of 3 weeks.","Accession Sequence Molecule",Protein,"immunoglobulin heavy chain",9606,NULL,NULL,NULL,NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Egg from Mus musculus BALB/c",10000000,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 1, 2, and 3 and Tables 1, 2 and 3",Positive,NULL,NULL,356
2443074,25582167,1028910,10000000,"6 weeks","Administration in vivo",NULL,Intranasal,"3 doses of 30 µg, administered on days 0, 14, and 21.","Fragment of a Natural Sequence Molecule","Peptide from protein",KEQFFQFLQHLSADYPKQVQTVYEFLGWVADK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Toxoplasma gondii RH",383379,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,559
2443075,25582167,1028910,10000000,"6 weeks","Administration in vivo",NULL,Intranasal,"3 doses of 30 µg, administered on days 0, 14, and 21.","Fragment of a Natural Sequence Molecule","Peptide from protein",KEQFFQFLQHLSADYPKQVQTVYEFLGWVADK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Toxoplasma gondii RH",383379,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,2,20,"Figure 4",Positive,NULL,NULL,124
2443073,25582167,1028910,10000000,"6 weeks","Administration in vivo",NULL,Intranasal,"3 doses of 30 µg, administered on days 0, 14, and 21.","Fragment of a Natural Sequence Molecule","Peptide from protein",LTAGGPLPHGSWSWSGTPPEVQTTGGSQIS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Toxoplasma gondii RH",383379,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,4,40,"Figure 4",Positive,NULL,NULL,124
2443070,25582167,1028910,10000000,"6 weeks","Administration in vivo",NULL,Intranasal,"3 doses of 30 µg, administered on days 0, 14, and 21.","Fragment of a Natural Sequence Molecule","Peptide from protein",CAELCDPSNKPGHLL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Toxoplasma gondii RH",383379,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,559
2443071,25582167,1028910,10000000,"6 weeks","Administration in vivo",NULL,Intranasal,"3 doses of 30 µg, administered on days 0, 14, and 21.","Fragment of a Natural Sequence Molecule","Peptide from protein",CAELCDPSNKPGHLL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Toxoplasma gondii RH",383379,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,6,60,"Figure 4",Positive,NULL,NULL,124
2443072,25582167,1028910,10000000,"6 weeks","Administration in vivo",NULL,Intranasal,"3 doses of 30 µg, administered on days 0, 14, and 21.","Fragment of a Natural Sequence Molecule","Peptide from protein",LTAGGPLPHGSWSWSGTPPEVQTTGGSQIS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Toxoplasma gondii RH",383379,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,559
1237497,2146802,1000861,10000630,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",3-Feb,"Fragment of a Natural Sequence Molecule","Peptide from protein",STEELFKEYKLTRPYMARCIRCAVG,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Venezuelan equine encephalitis virus (strain Trinidad donkey)",11038,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",25,25,100,"Table 4",Positive,NULL,NULL,124
1237496,2146802,1000861,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",3-Feb,"Fragment of a Natural Sequence Molecule","Peptide from protein",STEELFNEYKLTRPYMARCIRCAVG,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Venezuelan equine encephalitis virus (strain Trinidad donkey)",11038,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",17,6,35.3,"Table 4",Positive,NULL,NULL,124
1209236,1701079,1000869,10000228,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",CNYSKYWYLNHTTTG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Lassa mammarenavirus",11620,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Text pp. 135-136",Negative,0,NULL,124
1244180,16476510,1001080,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 30 μg B-T peptide conjugate, boost of 10μg.","Fragment of a Natural Sequence Molecule","Peptide from protein",FTTKVIGKDSRDFDISPKV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Yersinia pestis 195/P",10000757,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,5,83.3,"Tables 6 and 7",Positive,NULL,NULL,124
1244183,16476510,1001080,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 30 μg B-T peptide conjugate, boost of 10μg.","Fragment of a Natural Sequence Molecule","Peptide from protein",DFFVRSIGSKGGKL,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Yersinia pestis 195/P",10000757,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,0,0,"Tables 6 and 7",Negative,NULL,NULL,124
1246339,2473217,1000634,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,4,"Fragment of a Natural Sequence Molecule","Peptide from protein",SAQIGIDKSDNHDYTKIRYA,NULL,"Complexed Molecule","Protein conjugate","Beta-galactosidase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 2",Negative,0,NULL,124
1246390,2473217,1000634,10000618,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,4,"Fragment of a Natural Sequence Molecule","Peptide from protein",EIPCTTYQQTTAETVEEIDMHMPPDTPDRTLLSQQSGNV,NULL,"Complexed Molecule","Protein conjugate","Beta-galactosidase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,1,10,"Table 2",Negative,10,NULL,124
1246340,2473217,1000634,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,4,"Fragment of a Natural Sequence Molecule","Peptide from protein",QVSIQDTRNAVRACRIQYHHDPQPVGREKFTIRPHYGK,NULL,"Complexed Molecule","Protein conjugate","Beta-galactosidase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,4,40,"Table 2",Positive,40,NULL,124
1246395,2473217,1000634,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,4,"Fragment of a Natural Sequence Molecule","Peptide from protein",KITVGGKKVKYNCTCGTGNVGTTNSDM,NULL,"Complexed Molecule","Protein conjugate","Beta-galactosidase (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,1,11.1,"Table 2",Negative,11,NULL,124
1244602,9795391,1001274,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)","4 doses of 40 µg 3 weeks apart","Fragment of a Natural Sequence Molecule","Peptide from protein",ALNDLCIKVNNWDLFFSPSEDNFTN,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,0,0,"Table 4",Negative,0,NULL,124
1244600,9795391,1001274,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 doses of 40 µg 3 weeks apart","Fragment of a Natural Sequence Molecule","Peptide from protein",GITNKCKMNLQDNNGNDIGFIGFHQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,2,40,"Table 4",Positive,40,NULL,124
1244594,9795391,1001274,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 doses of 40 µg 3 weeks apart","Fragment of a Natural Sequence Molecule","Peptide from protein",GTKFIIKKYASGNKDNIVRNNDRVY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,0,0,"Table 4",Negative,NULL,NULL,124
1459962,10725197,1004351,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",MDDDTERFPTHRSLP,NULL,"Object Library","Phage display",NULL,Polyclonal,Serum,NULL,Organism,Organism,"Human alphaherpesvirus 2",10310,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1459972,10725197,1004351,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",STTNTPLVSHLEHRS,NULL,"Object Library","Phage display",NULL,Polyclonal,Serum,NULL,Organism,Organism,"Human alphaherpesvirus 2",10310,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1459967,10725197,1004351,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",PPFTSAVGGVDHRS,NULL,"Object Library","Phage display",NULL,Polyclonal,Serum,NULL,Organism,Organism,"Human alphaherpesvirus 2",10310,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1278796,2037377,1001544,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",AVTRGTINDPQRAKE,NULL,"Recombinant Organism","Recombinant Organism",NULL,NULL,NULL,NULL,Organism,Organism,Streptococcus,1301,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 3",Negative,NULL,NULL,125
1275950,2037377,1001544,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",AVTRGTINDPQRAKE,NULL,"Recombinant Organism","Recombinant Organism",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus pyogenes serotype M5",301449,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,4,80,"Table 3",Positive,NULL,NULL,125
1772142,12829598,1017528,10000639,"6 weeks","Occurrence of autoimmune disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"band 3 anion transport protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1B and 7",Positive,NULL,NULL,356
1376683,12435690,1003836,10000653,"3-4 days","Administration in vivo to prevent or reduce disease",NULL,Oral,"1 dose(s) of 50 or 150 ug","Accession Non-Sequence Molecule","Other Non-Sequence","α-linked tetramannoside",NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Candida albicans ATCC 10261",10000336,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,125
1376676,12435690,1003836,10000653,"3-4 days","Administration in vivo to prevent or reduce disease",NULL,Oral,"1 dose(s) of 50 or 150 ug","Accession Non-Sequence Molecule","Other Non-Sequence","β-linked tetramannoside",5476,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Candida albicans ATCC 10261",10000336,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1335762,3479809,1002454,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);Saponin;","Intraperitoneal (i.p.)","Mice were immunized with 100 µg of conjugate in CFA or saponin and boosted every other week with 50 µg of conjugate in IFA or saponin.","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii yoelii 17XNL",352914,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",41,6,14.6,"Table 1",Negative,NULL,NULL,125
1276441,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",ELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNN...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,124
1276438,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",EIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYI...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,1,11.1,"Table 1",Negative,NULL,NULL,124
1276446,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",LNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQ...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",8,6,75,"Table 1",Positive,NULL,NULL,124
1276397,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",LKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLT...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,124
1276429,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",AMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGT...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",7,2,28.6,"Table 1",Negative,NULL,NULL,124
1340450,9041668,1002787,10090,"7-10 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","5 dose(s) of 60 ug lipopeptide","Fragment of a Natural Sequence Molecule","Peptide from protein",PPPPNPNDPPPPNPND,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figure 1, Table 2",Positive,NULL,NULL,125
1340449,9041668,1002787,10090,"7-10 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","5 dose(s) of 30 ug lipopeptide","Fragment of a Natural Sequence Molecule","Peptide from protein",PPPPNPNDPPPPNPND,NULL,"Complexed Molecule","Fatty acid conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Figure 1, Table 2",Negative,NULL,NULL,125
1813529,7680861,1012065,10001405,"20 weeks","Administration in vivo to cause disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"3 doses of 100-120 µg, administered on weeks 0, 1 and 3.","Fragment of a Natural Sequence Molecule","Peptide from protein",FYNQKFKGKATL,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Ig heavy chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,356
1936161,8643522,1009629,10000019,"6-10 weeks","Administration in vivo to prevent or reduce disease",NULL,"Intravenous (i.v.)","1 dose of 1 mg of epitope-IgG fusion protein","Fragment of a Natural Sequence Molecule","Peptide from protein",LEDARRLKAIYEKKK,NULL,"Complexed Molecule","Protein conjugate","immunoglobulin gamma 1 heavy chain precursor (Mus musculus)",Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",LEDARRLKAIYEKKK,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,361
1510664,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",CPSKKPYEEVTC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive-Intermediate,NULL,NULL,125
1510666,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",CSTDKCNHPPKRQPG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive-Intermediate,NULL,NULL,125
1510667,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",NHPPKRQPG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive,NULL,NULL,125
1510661,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",IVCHTTATIPSSAVTC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive-Intermediate,NULL,NULL,125
1335768,10195633,1002395,10090,"4-6 weeks","Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","2 immunizations with 100 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAP,NULL,"Complexed Molecule","Peptide conjugate",NULL,Polyclonal,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,6,75,"Table 3",Positive,NULL,NULL,125
2022117,18981095,1026087,10000252,"> 2 months","Administration in vivo",NULL,"Intraperitoneal (i.p.)","2 doses of 2 µg on days 0 and 2","Accession Non-Sequence Molecule",Glycolipid,1-O-(6-acetamido-6-deoxy-alpha-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]phytosphingosine,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Derivative of Organism",Cell,"Unknown/Unspecified from Other (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 3 and 5",Negative,NULL,NULL,326
2022118,18981095,1026087,10000252,"> 2 months","Administration in vivo",NULL,"Intraperitoneal (i.p.)","2 doses of 2 µg on days 0 and 2","Accession Non-Sequence Molecule",Glycolipid,1-O-(4-deoxy-alpha-D-xylo-hexopyranosyl)-N-hexacosanoylsphinganine,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Derivative of Organism",Cell,"Unknown/Unspecified from Other (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 3 and 5",Negative,NULL,NULL,326
2022113,18981095,1026087,10000067,"> 2 months","Administration in vivo",NULL,"Intraperitoneal (i.p.)","3 doses of 2 µg on days 0, 3 and 7","Accession Non-Sequence Molecule",Glycolipid,1-O-(6-acetamido-6-deoxy-alpha-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]phytosphingosine,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Derivative of Organism",Cell,"Unknown/Unspecified from Other (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
2022116,18981095,1026087,10000067,"> 2 months","Administration in vivo",NULL,"Intraperitoneal (i.p.)","3 doses of 2 µg on days 0, 3 and 7","Accession Non-Sequence Molecule",Glycolipid,1-O-(4-deoxy-alpha-D-xylo-hexopyranosyl)-N-hexacosanoylsphinganine,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Derivative of Organism",Cell,"Unknown/Unspecified from Other (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1700310,16271400,1007043,10000067,"7-8 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);Bordetella pertussis;","Subcutaneous (s.c.)","3 doses of 20 µg at weeks 0, 3, and 6","Fragment of a Natural Sequence Molecule","Peptide from protein",NSQPEILERTRAELD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",RGWKHWVYYTCCPDTPY,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,361
1815429,21297277,1021487,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 50 ug weekly, follwed by 1 dose of 30 ug after 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"amyloid beta (A4) precursor protein",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",9,9,100,"Figures 3, 4, 5",Positive,NULL,NULL,326
1466963,11085234,1006699,10000923,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"2 doses of 50 nmol 1 month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",DIETPRAGKKESTVMTSGSA,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Echinococcus granulosus",6210,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1333020,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KSYGSDDNDDKNKSLIHKHN,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1333050,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQKEMETLNEGTSGTA,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1333064,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MIKAAFLPTGAFMADRYKSH,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,2,25,"Table 1",Positive,NULL,NULL,125
1333054,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQKEMKTLNEGTSGTA,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,2,16.7,"Table 1",Positive,NULL,NULL,125
1333048,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",GYSLFQKEKMVLNEGTSGTA,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333094,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MHNISQLQTVKKQTDQNS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1332996,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",QIPYNLKIFAIMLDTHKMLV,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1333000,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",QIPYNLKIFANMLDTHKMG,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1333062,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KASFHVTGAFMSDRWKS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,0,0,"Table 1",Negative,NULL,NULL,125
1333082,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MTDVVFYRYSNNYEGQPHIS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333066,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",KNESKYSNTFINNAYNMSIR,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333034,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",DNIHVKMRKVIMNNDKSELI,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1333090,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MLNISQMQSVKKQSDQNS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1333068,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KIMSKWGNTFNINAYNMSNF,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Table 1",Negative,NULL,NULL,125
1333080,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",VIRYRYSNDYDANDHIS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1333056,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",MIKSAFLPTGAFKADRYKSH,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1333014,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",VIYHKPLAGVYRALKKQIG,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,0,0,"Table 1",Negative,NULL,NULL,125
1333046,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",GNSITAWIRASKYLLET,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,1,11.1,"Table 1",Positive,NULL,NULL,125
1333010,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",EVLYHKPLAGVYRALKKQLE,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1333024,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",YLKETNNAISFESNSGSLEKK,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333052,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQMEMKTLNEGTSGTA,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333006,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",EVLYLKPLAGVYRSLKKQLE,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333042,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",DQGNSDTSYIFASKYHE,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1333032,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",DNILVKMFKTNENNDKSELI,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333038,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",DNIHVKMFKVIENNDKSELI,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,2,22.2,"Table 1",Positive,NULL,NULL,125
1333092,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MLNISQHQSVMKMSDQNS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333030,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KETNNAISFMSNAGSLEKK,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,1,12.5,"Table 1",Positive,NULL,NULL,125
1332991,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",QIPYNLKIRANELDVLKKLV,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333008,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",EVLYHMPLAGVYRALKKQLE,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333004,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",QIPYNLKIRAGGLDGGKKLV,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,1,33.3,"Table 1",Positive,NULL,NULL,125
1333026,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",LKMTNNAISFMSISASLEKK,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,0,0,"Table 1",Negative,NULL,NULL,125
1333072,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KIMSKWVNVFNINAYIMSNF,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1333018,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",KSYGTPDNIDKNMSLIHKHN,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1333022,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MAYGSDDNDDKNKSLDHKHN,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Table 1",Positive,NULL,NULL,125
1333036,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",DNILVKMFKVIMNNDKSELI,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1339793,1704349,1002723,10090,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",KQIRDSITEEWS,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,4,80,"Table 2",Positive,NULL,NULL,124
1339795,1704349,1002723,10090,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",PPPPNPNDPPPPNPND,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,4,80,"Table 2",Positive,NULL,NULL,124
1607329,16460841,1011241,9615,"8.9-13.8 years","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",NULL,"4 doses of 0.5 mg at weeks 0, 2, 5, and 8","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein",9615,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 7, 8",Negative,NULL,NULL,326
1335388,2580025,1002401,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","Rabbits were immunized in the footpads with 800 µg of conjugate and boosted s.c. 2, 4, and 6 weeks later.","Fragment of a Natural Sequence Molecule","Peptide from protein",RRKAHAGNKKAEDLTMDDLE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Text P. 3446",Negative,NULL,NULL,125
1335387,2580025,1002401,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","Rabbits were immunized in the footpads with 800 µg of conjugate and boosted s.c. 2, 4, and 6 weeks later.","Fragment of a Natural Sequence Molecule","Peptide from protein",PKKPNENKLKQPNE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1511767,9276729,1006497,9986,NULL,"Administration in vivo",";Freund's complete;",Intramuscular,"2 doses of 150 μg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",CKTANGTAIPIGGGSANVYVNLAPV,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 4 and Figure 6",Positive,NULL,NULL,125
1511768,9276729,1006497,9986,NULL,"Administration in vivo",";Freund's complete;",Intramuscular,"2 doses of 150 μg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",NYARTGGQVTAG,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 4 and Figure 6",Negative,NULL,NULL,125
1404103,9067529,1005079,10000000,NULL,"Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","4 doses at 12-day intervals of 1 µg of rBet v 1","Accession Sequence Molecule",Protein,"major allergen Bet v 1",3505,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"major allergen Bet v 1",3505,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,326
1404102,9067529,1005079,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)",5,"Fragment of a Natural Sequence Molecule","Peptide from protein",MGETLLRAVESYLL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"major allergen Bet v 1",3505,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,326
1660899,361549,1012698,10000228,"6-12 weeks","Administration in vivo to prevent or reduce disease",NULL,"Intravenous (i.v.)","1 or 3 weekly doses of 5 mg","Accession Non-Sequence Molecule","Other Non-Sequence","2,4,6-trinitrobenzenesulfonic acid",NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","2,4,6-trinitrophenyl group",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,361
1685366,18388924,1012450,10001268,"2 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 3-8",Positive,NULL,NULL,326
1713514,1370297,1017039,10001211,"6-9 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",NSSSSQFQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",21,NULL,NULL,"Table III",Positive,NULL,NULL,356
1713384,1370297,1017039,10001211,"6-9 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",EKSAPTFHLGEVAH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table I",Negative,NULL,NULL,356
1713385,1370297,1017039,10001211,"6-9 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",LFVDHCVATPS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table I",Negative,NULL,NULL,356
1713333,1370297,1017039,10001211,"6-9 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",CSNSSSSQFQIHGPR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",56,48,85.7,"Tables I, III and figure 2",Positive,NULL,NULL,356
1713386,1370297,1017039,10001211,"6-9 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",KANDQTVEGWTASAQTS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table I",Negative,NULL,NULL,356
1713390,1370297,1017039,10000067,"6-9 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",CSNSSSSQFQIHGPR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table I",Negative,NULL,NULL,356
1483031,12890622,1006677,10000000,"6 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","4 doses of 10^5 PFU, administered at intervals of 3 weeks",Organism,Organism,"Human coxsackievirus A9 (strain Griggs)",12068,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Human coxsackievirus A9 (strain Griggs)",12068,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",14,14,100,"Table 3",Positive,NULL,NULL,125
1483032,12890622,1006677,10000000,"6 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","4 doses of 10^5 PFU, administered at intervals of 3 weeks",Organism,Organism,"Human coxsackievirus A9 (strain Griggs)",12068,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Human coxsackievirus A9 (strain Griggs)",12068,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",15,10,66.7,"Table 3",Positive,NULL,NULL,125
1483033,12890622,1006677,10000000,"6 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","4 doses of 10^5 PFU, administered at intervals of 3 weeks",Organism,Organism,"Human coxsackievirus A9 (strain Griggs)",12068,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Human coxsackievirus A9 (strain Griggs)",12068,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,8,100,"Table 3",Positive,NULL,NULL,125
1476187,11053254,1007895,10000000,"3-4 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 1.0 g, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",FVPCSICSNNPTCWAICKRIP,NULL,"Complexed Molecule","Protein conjugate","coat protein (Alfalfa mosaic virus)",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Table 1",Positive,NULL,NULL,125
1489551,17627594,1012259,10000000,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","3 doses of 50ug, every two weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",NHGNYSAQVGASQ,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing SVRTTTDSGKLITD (polyprotein, Japanese encephalitis virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",4,2,50,"Figure 6",Positive,NULL,NULL,124
1598553,17552096,1006150,10000638,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Two doses three weeks apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",MSLLTEVETLTRNGWGCRCSDSSD,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Fort Monmouth/1/1947(H1N1))",367120,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive,NULL,NULL,124
1598552,17552096,1006150,10000638,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Two doses three weeks apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",MSLLTEVETLTRNGWGCRCSDSSD,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2A",Positive,NULL,NULL,124
1598545,17552096,1006150,10000638,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Two doses three weeks apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",MSLLTEVETPTKNEWECRCNDSSD,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Fort Monmouth/1/1947(H1N1))",367120,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive,NULL,NULL,124
2382077,25381487,1028606,10141,NULL,"Administration in vivo",NULL,Intramuscular,"2 doses of 75 ug, administered 21 days apart.","Sequence Molecule No Natural Source","Peptide, no natural source",VYNGTCKYSAPATRRGDLGSLAARLAACLPASFNYGAIRAT,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing YDLDFEALKPHFKSLGQTITPADKSPPSVYNGTCKYSAPATRRGDLGSLA... ",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus A/HuBWH/CHA/2009",10002131,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,18,90,"Tables 2 and 3",Positive,NULL,NULL,125
1491641,17890123,1005940,10000000,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 50ug, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",VSSHRLDTGEVPALQ,NULL,"Complexed Molecule","Protein conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Enterovirus 5865/sin/000009",150846,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2, 4 and 5",Negative,NULL,NULL,125
1637750,10360970,1006876,10000635,"10 weeks","Occurrence of autoimmune disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"60 kDa heat shock protein, mitochondrial precursor",10090,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 9",Positive,NULL,NULL,361
1637751,10360970,1006876,10000635,"10 weeks","Occurrence of autoimmune disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"insulin I",10090,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 9",Positive,NULL,NULL,361
2467501,25822571,1029110,10000000,adult,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 100 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",KGKSLLFKTENGVNMC,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 New Guinea C",10001583,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 7",Positive,NULL,NULL,356
1467278,16083792,1005373,10000000,"7 weeks old","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","3 doses of 5 µg","Accession Sequence Molecule",Protein,"major allergen Phl p 5",15957,NULL,NULL,NULL,NULL,NULL,"Entire Antibody","Accession Sequence Molecule",Protein,"major allergen Phl p 5",15957,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
1716678,19923222,1019030,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive-High,NULL,NULL,326
1645382,17219449,1007062,10001240,"2 months","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"doses of 10E8 PFU every 3 weeks for 10 months","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRH,NULL,"Recombinant Organism","Recombinant Organism","unidentified adenovirus containing DAEFRHDAEFRHDAEFRHDAEFRHDAEFRHDAEFRHDAEFRHDAEFRHDA...  linked to exotoxin type A (Pseudomonas aeruginosa)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 4, 5",Positive,NULL,NULL,326
1473403,7543450,1006792,10000916,"6-8 weeks","Administration in vivo to prevent or reduce disease",NULL,Intradermal,"1 dose of 10 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",TINKPKGYVGKE,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Chlamydia trachomatis Serovar F strain NI1",10000846,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,5,62.5,"Tables 2, 3, and 4 and text page 12",Positive,NULL,NULL,125
1482206,11137241,1008106,10000206,"12 weeks","Administration in vivo",;nor-MDP;,Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",FLNTEPSQLPPTAPPLLPHSNLDHILEPSIPWKSKLLTLVQLTL,NULL,"Complexed Molecule","Other Complexed Molecule","Other Complexed Molecule containing KLLSLIKGVIVHRLEGVGPSL",NULL,NULL,NULL,Organism,Organism,"Human T-lymphotropic virus 1",11908,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2, Text page 1077",Negative,NULL,NULL,125
1771885,12032491,1007047,10001446,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 10 µmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",HGWISLWKGFSFIMF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,356
1340937,7876549,1002843,10090,"6-8 weeks","Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","Three doses of 50ug administered at 3 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table IV",Positive,NULL,NULL,125
1340927,7876549,1002843,10090,"6-8 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Liposomes;","Subcutaneous (s.c.)","Three doses of 50ug administered at 3 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,8,80,"Tables I, III, and IV",Positive,NULL,NULL,125
1340935,7876549,1002843,10090,"6-8 weeks","Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","Three doses of 50ug administered at 3 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,8,80,"Table IV",Positive,NULL,NULL,125
1341351,7876549,1002843,10090,"6-8 weeks","Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","Three doses of 50ug administered at 3 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Table V",Positive,NULL,NULL,125
1581675,9525458,1005213,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","3 doses of 20 to 60 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",NYKVGLQNSNFRKVGHYTQM,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Venom allergen 5.01",7441,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,326
1480093,8578804,1008204,10001998,"4-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"4 doses of 100 ug at intervals of 2 weeks","Sequence Molecule No Natural Source","Peptide, no natural source",KGYLVDKNTGCKY,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin 2, Cn2",6878,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Tables 3, 2",Negative,NULL,NULL,125
1473834,16603536,1006748,9521,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"4 doses of 500 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",FLNTEPSQLPPTAPPLLPHSNLDHILEPSIPWKSKLLTLVQLTL,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Human T-lymphotropic virus 1",11908,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,2,100,"Figure 3",Positive,NULL,NULL,125
1480048,8578804,1008204,10001998,"4-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"4 doses of 100 ug at intervals of 2 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",KEGYLVDKNTGCKY,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-mammal toxin Cn2 precursor (Toxin 2) (Toxin II.9.2.2)",6878,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Tables 3, 2",Negative,NULL,NULL,125
1356049,10393897,1003255,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Ribi;,"Subcutaneous (s.c.)","3 doses of 50 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",LLGCIGSTCA,NULL,"Recombinant Organism","Recombinant Organism","Tobacco mosaic virus",Polyclonal,NULL,"Entire Antibody",Organism,Organism,"Murine hepatitis virus strain JHM",11144,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,5,83.3,"Figure 8",Positive,NULL,NULL,124
1332717,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEAESHIS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1324070,16828529,1002088,10000000,"4 weeks","Administration in vivo to prevent or reduce disease",";Cholera toxin;Other;",Intranasal,"4 doses of 30ug every 7 days","Fragment of a Natural Sequence Molecule","Peptide from protein",ASREAKKQVEKALE,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Streptococcus pyogenes",1314,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1324091,16828529,1002088,10000000,"4 weeks","Administration in vivo to prevent or reduce disease",";Cholera toxin;Other;",Intranasal,"4 doses of 30ug every 7 days","Fragment of a Natural Sequence Molecule","Peptide from protein",VETEDTKEPGVLMGGQSESVEFTKDTQTGM,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Streptococcus pyogenes",1314,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1340012,7679652,1002750,10090,"5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"Mice were immunized at the base of the tail with 50 µg of MAP  T2-B in CFA and boosted with the same amount in IFA after 15 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",27,18,66.7,"Table 3",Positive,NULL,NULL,125
1340013,7679652,1002750,10090,"5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"Mice were immunized at the base of the tail with 50 µg of MAP T1-B in CFA and boosted with the same amount in IFA after 15 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",21,13,61.9,"Table 3",Positive,NULL,NULL,125
1340914,9160515,1002832,10000253,"7-9 weeks","Administration in vivo to prevent or reduce disease",";P1005 (non-ionic copolymer);","Subcutaneous (s.c.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",PPPPNPNDPPPPNPND,NULL,"Complexed Molecule","Peptide conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3 and 6",Positive,NULL,NULL,125
1340915,9160515,1002832,10000253,"7-9 weeks","Administration in vivo to prevent or reduce disease",";P1005 (non-ionic copolymer);","Subcutaneous (s.c.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQG,NULL,"Complexed Molecule","Peptide conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 5",Positive,NULL,NULL,125
1338897,8817831,1002585,10090,"7-9 weeks old","Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)","1 dose of 100 µg and 4 doses of 50 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 2",Positive,NULL,NULL,125
1338895,8817831,1002585,10090,"7-9 weeks old","Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)","2 immunizations with 100 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,125
1337467,3551073,1002574,10090,NULL,"Administration in vivo",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,12,100,"Table 2",Positive,NULL,NULL,125
1377134,15980398,1003837,9986,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",VDVPNGRGDSLAYGLRS,NULL,NULL,NULL,NULL,Polyclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Candida albicans",5476,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,124
1651183,19494285,1014980,10001240,"4 months","Occurrence of autoimmune disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 6, 7",Positive,NULL,NULL,326
1799297,1717928,1006255,10001041,"48 hours","Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)",NULL,"Accession Non-Sequence Molecule","Other Non-Sequence",phosphocholine,NULL,"Complexed Molecule","Protein conjugate","Ovalbumin (Gallus gallus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Fasciola hepatica",6192,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,326
2103527,24415460,1027598,10000000,"6 weeks","Administration in vivo",";Freund's incomplete (IFA);",Intranasal,"3 doses of 1 x 10E7 pfu, administered at intervals of 14 days.",Organism,Organism,"Human respiratory syncytial virus A2",11259,"Infected Cell","Infected Cell","Epithelial cell (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus (subgroup B / strain 8/60)",11258,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figure 5",Positive,NULL,NULL,125
1476710,18355123,1007941,9031,"10 weeks","Administration in vivo",NULL,Intramuscular,"4 doses","Fragment of a Natural Sequence Molecule","Peptide from protein",VDASSGSNRFAALPAF,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,Serum,NULL,Organism,Organism,"Avian hepatitis E virus",172851,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1, Figure 2",Negative,NULL,NULL,125
1341592,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDSIRFRYSNNYMSIDH,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341560,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYEQGPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341462,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEAIDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,1,16.7,"Table 1",Positive,NULL,NULL,125
1341578,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRWRYSNNYEGNDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341457,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",MTDVNRYRYSNNYEAIPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1341566,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVMMYRYSNNYEQGPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341474,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYESESHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1341468,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRWRYVNNYESNPHKS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,1,10,"Table 1",Positive,NULL,NULL,125
1341466,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYEQEPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,1,25,"Table 1",Positive,NULL,NULL,125
1341594,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSPDYEAIPLISE,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341541,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",IRYRYSNNYEANDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1341464,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEASDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,1,8.3,"Table 1",Positive,NULL,NULL,125
1341472,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEAESHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,0,0,"Table 1",Negative,NULL,NULL,125
1341588,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNIYESSDK,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341478,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVVFYRYSNNYEGQPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1341529,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYESSDK,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,0,0,"Table 1",Negative,NULL,NULL,125
1341586,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYESDK,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341590,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDSIRFRYSNNYMASDH,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341584,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",TDVNRWRYVNNYESNH,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341582,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRWRYSNNYEASDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341476,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",IRYRYSNDYDANDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1341574,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEGSDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341531,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYESNDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1341576,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEGNDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341572,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYESSDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341564,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVMFYRYSNNYEQGPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341568,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVMFYRYSNNYEGQPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341558,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYEWGPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341562,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYEGQPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341545,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYESTPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341539,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRFRYSNNYMSNPH,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,0,0,"Table 1",Negative,NULL,NULL,125
1341552,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYESNPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341554,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEANDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341547,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVLRYRYSNNYEAESHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341550,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEGESHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341543,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVGRYRYSNNYEAIPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341537,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRFRYSNNYEASDH,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1667219,858997,1012723,10000669,NULL,"Administration in vivo",";Freund's complete;","Intraepidermal (i.d.)","1 dose","Accession Non-Sequence Molecule","Other Non-Sequence","2,4-dinitrophenyl group",NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","N(6)-(2,4-dinitrophenyl)-L-lysine",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",12,11,91.7,"Table 4",Positive,NULL,NULL,361
1666821,858997,1012723,10000669,NULL,"Administration in vivo",";Freund's complete;","Intraepidermal (i.d.)","1 dose","Accession Non-Sequence Molecule","Other Non-Sequence","2,4-dinitrophenyl group",NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","N(6)-(2,4-dinitrophenyl)-L-lysine",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",12,11,91.7,"Table 4",Positive,NULL,NULL,361
1380626,1621894,1004837,37293,NULL,"Administration in vivo to prevent or reduce disease",";Syntex Adjuvant Formulation (SAF);",NULL,"1 dose of 6 nmoles  followed by 1 dose of 3 nmoles","Fragment of a Natural Sequence Molecule","Peptide from protein",DEIDRMVNDAEKYKAEDEENRKRIEA,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 4",Negative,NULL,NULL,125
1465684,9562426,1005206,10000000,"6-8 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","2 doses of 50-100 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",EEEDDDMGFGLFD,NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Trypanosoma cruzi",5693,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5, Table 1",Positive,NULL,NULL,125
2444788,25933001,1028955,10000067,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses: 20ug, 10ug and 10ug VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",DEDKRDGNNEDNEKLRKPKHKKL,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figure 2",Negative,NULL,NULL,125
2444785,25933001,1028955,10000067,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses: 20ug and 10ug VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",NANPNVDPNANPNANPNANP,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figure 2",Positive-High,NULL,NULL,125
2444786,25933001,1028955,10000067,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses: 20ug, 10ug and 10ug VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",KLKQPGDGNPDP,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figure 2",Positive-Low,NULL,NULL,125
2444787,25933001,1028955,10000067,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses: 20ug, 10ug and 10ug VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",HNMPNDPNRNVDENANAN,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figure 2",Positive-Intermediate,NULL,NULL,125
2830413,26684291,1030299,10000000,"6 weeks","Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","Several doses of 50 ug every 4 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",EPVVVHITDDNEEPIAPYHFDLSGHAFGAMA,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DLSGHAFGAMA,NULL,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,356
2118470,23549081,1025761,10001381,NULL,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 100 ug on days 0, 7 and 14.","Fragment of a Natural Sequence Molecule","Peptide from protein",LYQEARKIVGAMVQIITYR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myeloperoxidase precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",5,5,100,"Figure 6",Positive,NULL,NULL,356
82,15710332,285,10000000,"6 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","3 doses 2 wks apart with 50 μg conjugate, first in CFA, boosts in IFA.","Fragment of a Natural Sequence Molecule","Peptide from protein",EVETPIRN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,5,50,"Figure 3",Positive,50,NULL,124
2475901,26189681,1029196,10000000,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"envelope protein",11053,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 2",11060,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
2475617,26189681,1029196,10000000,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"envelope protein",11053,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 New Guinea C",10001583,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",15,15,100,"Figure 4A,D and Supplementary Figure S5",Positive,NULL,NULL,559
2485211,25964493,1029269,10000662,"6-7 weks","Administration in vivo to cause disease",";Freund's complete;",Intradermal,"1 dose of 1 mg",Organism,Organism,"Mycobacterium tuberculosis H37Ra",419947,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"fibrinogen beta chain precursor",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
2485213,25964493,1029269,10000662,"6-7 weks","Administration in vivo to cause disease",";Freund's complete;",Intradermal,"1 dose of 1 mg",Organism,Organism,"Mycobacterium tuberculosis H37Ra",419947,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"fibrinogen beta chain precursor",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1368383,17050046,1003569,9823,10-week-old,"Administration in vivo to prevent or reduce disease",";Freund's adjuvant;",NULL,"1 dose 500 ug of proteins, 3 weeks apart, 1st in CFA, boosts twice with 250 ug in IFA.","Fragment of a Natural Sequence Molecule","Peptide from protein",TAVSPTTLRTEVVK,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus",11096,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,5,100,"Text, page 7178",Positive,NULL,NULL,124
1368382,17050046,1003569,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's adjuvant;",NULL,"1 dose 500 ug of proteins, 3 weeks apart, 1st in CFA, boosts twice with 250 ug in IFA.","Fragment of a Natural Sequence Molecule","Peptide from protein",TAVSPTTLRTEVVK,NULL,"Complexed Molecule","Protein conjugate","Glutathione S-transferase (Escherichia coli)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus",11096,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1815091,21227607,1021461,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"4 doses","Fragment of a Natural Sequence Molecule","Peptide from protein",AEVSYVHVNGAK,NULL,"Complexed Molecule","Protein conjugate","CLIP-associating protein 2 c (Mus musculus)",Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Allergen Cry j 2 (Pollen allergen)",3369,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 9",Positive,NULL,NULL,326
1460908,12464955,1005456,10000067,"6-8 weeks","Administration in vivo to prevent or reduce disease",;Chitosan;,Intranasal,"5 doses of 100 µg epitope at 1 day intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",FGISNYCQIYPPNANKIREALAQPQRYCR,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Der P 1",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1460910,12464955,1005456,10000067,"6-8 weeks","Administration in vivo to prevent or reduce disease",;Chitosan;,Intranasal,"5 doses of 100 µg epitope at 1 day intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",FGISNYCQIYPPNANKIREALAQPQRYCR,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Der P 1",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1460909,12464955,1005456,10000067,"6-8 weeks","Administration in vivo to prevent or reduce disease",;Chitosan;,Intranasal,"5 doses of 100 µg epitope at 1 day intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",FGISNYCQIYPPNANKIREALAQPQRYCR,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Der P 1",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1499777,9712755,1006401,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Other,"11 doses of 50 µg.","Fragment of a Natural Sequence Molecule","Peptide from protein",GNHEYCVEVKYTAGVSPKVCKDVTV,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Porphyromonas gingivalis A7436",1403337,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",8,2,25,"Tables 1 and 2",Negative,NULL,NULL,124
1378289,2167930,1004006,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses at 3-week intervals of 50 µg of epitope coupled to OVA","Fragment of a Natural Sequence Molecule","Peptide from protein",LPVLDQLTDPPGVRRVY,NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",13,0,0,"Table 1",Negative,NULL,NULL,124
1378286,2167930,1004006,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses at 3-week intervals of 50 µg of epitope coupled to OVA","Fragment of a Natural Sequence Molecule","Peptide from protein","KYALADASLKMAD + NLeu(M11)",NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,5,55.6,"Table 1",Positive,NULL,NULL,124
1378285,2167930,1004006,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses at 3-week intervals of 50 µg of epitope coupled to OVA","Fragment of a Natural Sequence Molecule","Peptide from protein","LKMADPNRFRGKD + NLeu(M3)",NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",22,21,95.5,"Table 1",Positive,NULL,NULL,124
1378287,2167930,1004006,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses at 3-week intervals of 50 µg of epitope coupled to OVA","Fragment of a Natural Sequence Molecule","Peptide from protein",RGKDLPVLDQLTD,NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,6,60,"Table 1",Positive,NULL,NULL,124
1581321,1372679,1012188,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 10 μg in IFA, administered at intervals of two weeks. Four days before fusion, a booster dose of 30 μg of OMPs intravenously without adjuvant.","Accession Sequence Molecule",Protein,"Outer membrane protein P2",10001056,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae Serotype B",10000860,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1506969,11842304,1005506,10000067,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","2 doses","Fragment of a Natural Sequence Molecule","Peptide from protein",FGISNYCQIYPPNANKIREALAQPQRYCR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",FGISNYCQIYPPNANKIREALAQPQRYCR,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 3, 5",Positive,NULL,NULL,326
1687505,7511703,1006845,10000649,"8 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)","2 doses of 50 µg, administered 7 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",HCLGKWLGHPDKF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",6,3,50,"Table 1",Positive,NULL,NULL,356
1466386,12922108,1006757,10000193,"> 6 months","Administration in vivo to prevent or reduce disease",";Montanide ISA-51;",Intramuscular,"1 or 2 doses of 50 µg","Sequence Molecule No Natural Source","Peptide, no natural source",VYNGNCKYGENAVTNVRGDLQVLAQKAARCLPTSFNYGAIK,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Manisa)",10000806,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,0,0,"Table 2",Negative,NULL,NULL,125
1463258,3008333,1006818,9913,"6-8 months","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",VPNLRGDLQVLAQKVART,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,5,41.7,"Table 2",Positive,NULL,NULL,125
1463378,3008333,1006818,10000668,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)",1,"Fragment of a Natural Sequence Molecule","Peptide from protein",RHKQKIVAPVKQTL,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1463376,3008333,1006818,10000668,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)",1,"Fragment of a Natural Sequence Molecule","Peptide from protein",VPNLRGDLQVLAQKVART,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1475537,9400973,1006777,10000067,"3 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","1 doses of 100 micrograms and 1 dose of 50 microgams of peptide, administered at an interval of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",CYTTGTIINQDPDKILTYIAADHC,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Measles virus CAM/RB",10000462,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1970303,23221567,1025498,10000000,"4 to 6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 20 µg and 2 doses of 10 µg, administered at intervals of 21 days.","Accession Sequence Molecule",Protein,hemagglutinin,370810,"Complexed Molecule","Protein conjugate","immunoglobulin heavy chain IgG1 (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Vietnam/1194/2004(H5N1))",644788,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,124
1970304,23221567,1025498,10000000,"4 to 6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 20 µg and 2 doses of 10 µg, administered at intervals of 21 days.","Accession Sequence Molecule",Protein,hemagglutinin,370810,"Complexed Molecule","Protein conjugate","immunoglobulin heavy chain IgG1 (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Shenzhen/406H/2006(H5N1))",431158,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,124
2098412,23928993,1027541,9606,NULL,"No immunization",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Derivative of Organism",Cell,"Other from Breast (Homo sapiens)",9606,http://purl.obolibrary.org/obo/OBI_0002052,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4 and 5",Positive,NULL,NULL,560
2117479,25031354,1028062,10000000,NULL,"Administration in vivo",NULL,Intranasal,"1 dose 5 x 10<sup>3</sup> PFU",Organism,Organism,"Vaccinia virus WR",10254,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Vaccinia virus WR",10254,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Negative,NULL,NULL,125
1378290,2167930,1004006,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses at 3-week intervals of 50 µg of epitope coupled to OVA","Fragment of a Natural Sequence Molecule","Peptide from protein",YHIQAGLPDPFQPPSLPIT,NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",14,0,0,"Table 1",Negative,NULL,NULL,124
1509064,10463950,1005695,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Intragastral / Intracolonic","4 doses of 5 x 10<sup>7</sup> Bet mim 1 phage on days 0, 7, 14 and 35","Sequence Molecule No Natural Source","Peptide, no natural source",CFPYCYPSESA,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Major pollen allergen Bet v 1-A",3505,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Negative,NULL,NULL,326
1382656,11931583,1004719,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Fragment of a Natural Sequence Molecule","Peptide from protein",LEDPVG,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3, Figure 6",Positive,NULL,NULL,125
1382662,11931583,1004719,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Fragment of a Natural Sequence Molecule","Peptide from protein",SALLED,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3, Figure 6",Positive,NULL,NULL,125
1382661,11931583,1004719,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Fragment of a Natural Sequence Molecule","Peptide from protein",SALLED,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3, Figure 6",Positive,NULL,NULL,125
2373679,25275138,1028428,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Chikungunya virus",37124,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Chikungunya virus strain S27-African prototype",371094,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
2373680,25275138,1028428,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Chikungunya virus",37124,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Chikungunya virus strain S27-African prototype",371094,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1379203,7527933,1004726,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Fragment of a Natural Sequence Molecule","Peptide from protein",KYALADASLKMADPNRFRGKDLP,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Human herpesvirus 1 strain KOS",10306,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4 and Table 5",Positive,NULL,NULL,124
1379204,7527933,1004726,10090,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Fragment of a Natural Sequence Molecule","Peptide from protein",SALLEDPVG,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Human herpesvirus 1 strain KOS",10306,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4 and Table 5",Positive,NULL,NULL,124
1420434,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NISAFIINLSSKNAMGLILN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420386,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",SAFDDNLTAMNAMGLILNKR,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,1,14.3,"Table 1",Positive,NULL,NULL,125
1700274,16271400,1007043,10000067,"7-8 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Bordetella pertussis;","Subcutaneous (s.c.)","3 doses of 20 µg at weeks 0, 3, and 6","Fragment of a Natural Sequence Molecule","Peptide from protein",NSQPEILERTRAELD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"acetylcholine receptor alpha-subunit",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",29,NULL,NULL,"Table 2 and Figure 3",Positive,NULL,NULL,326
2370910,25379726,1028381,10000000,"4 to 6 week","Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"3 doses of 10 µg, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",IGLSQHE,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus",1280,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Results page 2",Negative,NULL,NULL,125
1422390,16504346,1006257,9823,"8-10 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",DYRYAISS,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1422382,16504346,1006257,9823,"8-10 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",KEDYRY,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1422393,16504346,1006257,9823,"8-10 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",TNEIGLL,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1811923,12009948,1020581,9541,NULL,"Administration in vivo",;Other;,"Intravenous (i.v.)",NULL,"Accession Non-Sequence Molecule","Other Non-Sequence",alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc-yl group",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,361
1811927,12009948,1020581,9541,NULL,"Administration in vivo",;Other;,"Intravenous (i.v.)",NULL,"Accession Non-Sequence Molecule","Other Non-Sequence",alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc-yl group",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,361
1420367,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",SAFDDNLTAANAMGLILNKR,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,1,10,"Table 1",Positive,NULL,NULL,125
1420416,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLCSKNAKGGNLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420419,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLCSKNAKGLGLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420437,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NISAFIINLSSKNAMGLDLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420377,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",SAFDDNLTAMNAMGLILNKR,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,1,12.5,"Table 1",Positive,NULL,NULL,125
1420429,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLSSKNAMGLLLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Table 1",Negative,NULL,NULL,125
1420431,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NMSANNNLSSKNAMGLILN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Table 1",Negative,NULL,NULL,125
1420423,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLCSKNAGGLGLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420388,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLSSKNAMGLVLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420427,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLSSKNAMGLMLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1420349,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",NNSAFNNNLCSKNAKGLNLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420420,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NSAFNNNLCSKNAGGLNLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420438,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",SAFNNNLVSKNAMGLILNKR,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,0,0,"Table 1",Negative,NULL,NULL,125
1420440,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",FNNNLTGMNAMGLILNKR,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,0,0,"Table 1",Negative,NULL,NULL,125
1420365,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",SAFDDNLTAANAMGLILNKR,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,2,25,"Table 1",Positive,NULL,NULL,125
1420433,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NVSAFNNNLCSKNAMGLVLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1420401,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NVSAFNNNLSSKNAMGLVLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1420424,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLSSKNAMGLRLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1420406,17588541,1005967,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNSAFNNNLCSKNAGGLNLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1480549,9356486,1006496,10000668,"12 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","1 dose of 7.5 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",GSGVRGDFGSLAPRVARQL,NULL,"Complexed Molecule","Protein conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A12)",12114,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Text page 12549",Negative,NULL,NULL,125
1664174,15307184,1012696,10000067,"5-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Oral,"26 doses of 2 x 10<sup>7</sup> cfu, administered daily",Organism,Organism,"Lactobacillus casei",1582,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","2,4-dinitrophenol",NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1500654,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",TDRLDRCLPAISTDPCF,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500651,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",GMQAFFRPRCAKTLSCA,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500642,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",ASTTNCIGSQCLMTN,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500639,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",AEGCVGRVCDSRAMAVM,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500636,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",GPALKPRGCVGSTCFWA,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500657,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",KCTNTDRPPFCQ,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500659,10814583,1006488,10000000,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",SASRSCIGSQCSTTA,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1501316,10706967,1006489,10000228,"6 weeks old","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"Two 12.5 ug doses, one month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",SGPLKGILEYTEDEVVSSDFVG,NULL,"Complexed Molecule","Protein conjugate","Ovalbumin (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1501317,10706967,1006489,10000662,"5 weeks old","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","Two 50 ug doses, one month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",SGPLKGILEYTEDEVVSSDFVG,NULL,"Complexed Molecule","Protein conjugate","Ovalbumin (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1488616,9141214,1006500,10000000,"3-4 weeks","Administration in vivo",";Freund's complete;",NULL,"4 doses of 100 µg, administered at intervals of [#] weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",VPCSICSNNPTCWAICK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",11,11,100,"Table 2",Positive,NULL,NULL,125
1488617,9141214,1006500,10000000,"3-4 weeks","Administration in vivo",";Freund's complete;",NULL,"4 doses of 100 µg, administered at intervals of [#] weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",VPCSICSNNPTCWAICK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus (subgroup B / strain 8/60)",11258,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table 2",Positive,NULL,NULL,125
1493326,8887481,1006504,10000000,"8-10 weeks","Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)",NULL,Organism,Organism,"Measles virus",11234,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Measles virus CAM/RB",10000462,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1500645,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",DPARDCVHNICIFAG,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
1500648,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",ADREYCKYTVCTYPG,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
2467505,25822571,1029110,10000000,adult,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 100 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",LLRQNEPEDIDCWCNS,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 New Guinea C",10001583,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 7",Negative,NULL,NULL,356
2467504,25822571,1029110,10000000,adult,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 100 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",ITYNCPLLRQNEPEDI,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 New Guinea C",10001583,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 7",Negative,NULL,NULL,356
2375609,25454087,1028491,10000206,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);",NULL,"5 doses of 125 ug, administered ata 2-week intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",HGNAEVHASFFDIGGS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)","Multi-Antigenic Peptide (MAP, branched) containing EYLNKIQNSLSTEWSPCSVT (circumsporozoite protein, Plasmodium falciparum)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis str. Ames",198094,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,7,100,"Table 1, Figures 2 and Supplementary Table",Positive,NULL,NULL,125
1710914,17418903,1007855,10001211,NULL,"Administration in vivo to cause disease",";Freund's complete;",Oral,"4 doses administered orally, and one s.c. injection  of 50 nmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",NSSSSQFQIHGPR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 1, 3, and 4",Positive,NULL,NULL,356
1709827,17418903,1007855,10001211,NULL,"Administration in vivo to prevent or reduce disease",NULL,Oral,"7 dose of 1, 10, or 100 µg, administered every other day.","Fragment of a Natural Sequence Molecule","Peptide from protein",NSSSSQFQIHGPR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 1 and 4",Positive,NULL,NULL,326
1710915,17418903,1007855,10001211,NULL,"Administration in vivo",NULL,Oral,"7 dose of 1, 10, or 100 µg, administered every other day.","Fragment of a Natural Sequence Molecule","Peptide from protein",NSSSSQFQIHGPR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,361
1640014,16630540,1007106,9606,NULL,"No immunization",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1435504,7506298,1006222,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)",4,"Fragment of a Natural Sequence Molecule","Peptide from protein",SNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDM...,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Text page 2573.",Negative,NULL,NULL,125
1436233,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.04 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1, Table 4",Positive,NULL,NULL,125
1459494,2157884,1006226,9913,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 1 mg and 1 dose of 0.2 mg administered at a 6 month interval.","Sequence Molecule No Natural Source","Peptide, no natural source",RHKQKIIAPAKQLLPPSGSGRRGDMGSLAARVVKQ,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,2,100,"Table 3",Positive,NULL,NULL,125
1436248,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 5 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain C3 Indaial)",12117,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,1,20,"Table 4",Positive,NULL,NULL,125
1436216,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 5 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQPLIAPAKQLLPPSASARRGDLAHLAAAHARHPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain C3 Indaial)",12117,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1, Table 4",Positive,NULL,NULL,125
1459493,2157884,1006226,9913,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 1 mg and 1 dose of 0.2 mg administered at a 6 month interval.","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,1,50,"Table 3",Positive,NULL,NULL,125
1459492,2157884,1006226,9913,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 5 mg and 1 dose of 0.2 mg administered at a 28 day interval.","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIIAPAKQLLPPSGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,2,66.7,"Table 3",Positive,NULL,NULL,125
1436137,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.04 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIIAPAKQLLPPSGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1, Table 4",Positive,NULL,NULL,125
1436245,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 5 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,4,80,"Table 4",Positive,NULL,NULL,125
1436215,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.2 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQPLIAPAKQLLPPSASARRGDLAHLAAAHARHPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,1,20,"Table 4",Positive,NULL,NULL,125
1436223,2157884,1006226,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.2 mg","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQPLIAPAKQLLPPSASARRGDLAHLAAAHARHPCG,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,3,60,"Table 4",Positive,NULL,NULL,125
1808206,1720589,1006803,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 50ug epitope at 14-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",SICSNNPTCWAISK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Tables 1 and 2",Positive,NULL,NULL,125
1683102,19504623,1016564,10000000,"6 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","4 doses of 15 mg on days 0, 20, 50, and 80","Fragment of a Natural Sequence Molecule","Peptide from protein",EMEPPFGDSYIVVGRGDKQINHHWHKA,NULL,"Transfected Cell","Transfected Cell"," (Saccharomyces cerevisiae EBY100)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Japanese encephalitis virus Vellore P20778",10001335,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5B",Negative,NULL,NULL,125
1864213,15919893,1133,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",PAKLLKERGFFGAIAGFLE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza B virus (B/Hong Kong/330/2001)",206203,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1864214,15919893,1133,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",PAKLLKERGFFGAIAGFLE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza B virus (B/Yamanashi/166/1998)",416659,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1864299,15919893,1133,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",NVPEKQTRGIFGAIAGFIE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,125
1864300,15919893,1133,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",NVPEKQTRGIFGAIAGFIE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza B virus (B/Ann Arbor/4/55)",10001880,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 7",Positive,NULL,NULL,124
15953,15919893,1133,10000000,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",PAKLLKERGFFGAIAGFLE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza B virus (B/Ann Arbor/4/55)",10001880,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
15945,15919893,1133,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",PAKLLKERGFFGAIAGFLE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza B virus (B/Ann Arbor/4/55)",10001880,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 3 and 7",Positive,NULL,NULL,125
15962,15919893,1133,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);QS21;",Intramuscular,"2 doses, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",NVPEKQTRGIFGAIAGFIE,NULL,"Complexed Molecule","Protein conjugate","outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"H3N1 subtype Influenza A virus (A/Hong Kong/68HA-A/Puerto Rico/8/34NA)",10000841,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,125
1504833,16801138,1006259,10000000,"4-6 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Accession Sequence Molecule",Protein,"Mite group 2 allergen Der p 2 precursor",6956,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Dermatophagoides pteronyssinus",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1472943,7831785,1006729,10000187,"5-8 weeks","Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",ASARGDLAHLTTTHARHLP,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C-S8c1",244367,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3, and Figures 2B and 2D",Positive,NULL,NULL,125
1773029,16555617,1007063,10116,NULL,"Administration in vivo to cause disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",SQTTANPSCPEGT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",26,21,80.8,"Text p 234",Positive,NULL,NULL,356
1773028,16555617,1007063,10116,NULL,"Administration in vivo to cause disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",SQTTAIPSCPEGTVPLYSGFS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",50,0,0,"Text p 234",Negative,NULL,NULL,356
1961183,15845483,1006178,10000667,24-day-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 30 ug 13 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",DANFDSIRVDAVDNVDADLLQ,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus sobrinus 6715",246202,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,125
1961184,15845483,1006178,10000667,24-day-old,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 30 ug 13 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",DANFDSIRVDAVDNVDADLLQ,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus mutans SJ",10000813,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,125
1462715,2470215,1006644,10141,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,1,"Fragment of a Natural Sequence Molecule","Peptide from protein",RYNRNAVPNLRGDLQVLAQK,NULL,"Complexed Molecule","Fatty acid conjugate",NULL,Polyclonal,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Tables 1, 2",Positive,NULL,NULL,125
1483984,10392626,1006612,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",KPNLSSKRSELSQLS,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing PVVEVNGVTIQVGSRGSGGPVVEVNGVTIQVGSR",NULL,NULL,NULL,Organism,Organism,"Measles virus CAM/RB",10000462,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,124
1483139,9499058,1006619,10000000,"6-7 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","2 doses of 25ug  MAP and 8ug T helper administered at a 3 week interval.","Sequence Molecule No Natural Source","Peptide, no natural source",HWSISKPQ,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 1 and 2",Positive,NULL,NULL,125
1498126,7571431,1006789,10000000,"60-90 days old","Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)","2 doses of 50 μg in a oil-in-water emulsion, administred at intervals of 15 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",RYSRNAVPNVRGDLQVLAQKVARTLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Campos)",10000516,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1",Positive,NULL,NULL,125
1513905,1718085,1006639,10000630,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 50 ug, administered at intervals of 14 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",STEELFNEYKLTRPYMARCIRCAVG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Venezuelan equine encephalitis virus (strain Trinidad donkey)",11038,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,125
1513914,1718085,1006639,10000630,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 50 ug, administered at intervals of 14 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",STEELFNEYKLTRPYMARCIRCAVG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Venezuelan equine encephalitis virus (strain Trinidad donkey)",11038,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,9,90,"Table 1",Positive,NULL,NULL,125
1556140,7531779,1006732,10000067,"3 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","100 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",INQDPDKILTY,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing LSEIKGVIVHRLEGVLSEIKGVIVHRLEGV",NULL,NULL,NULL,Organism,Organism,"Measles virus CAM/RB",10000462,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2 and Table 2",Positive,NULL,NULL,125
1556138,7531779,1006732,10000067,"3 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","100 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",INQDPDKILTY,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing LSEIKGVIVHRLEGVLSEIKGVIVHRLEGV",NULL,NULL,NULL,Organism,Organism,"Canine distemper virus strain Onderstepoort",11233,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 1, 3 and Table 2",Positive,NULL,NULL,125
1556628,7531779,1006732,10000067,"3 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","100 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",INQDPDKILTY,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing LSEIKGVIVHRLEGVLSEIKGVIVHRLEGV",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Measles virus CAM/RB",10000462,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,125
2104190,23249976,1027645,10000038,"5 to 7 weeks","Administration in vivo",;Other;,Intramuscular,"3 doses of 12.5 µg, administered at intervals of 3 weeks","Sequence Molecule No Natural Source","Peptide, no natural source",QAEDKVKQSREAKKQVEKALKQLEDKVQ,NULL,"Complexed Molecule","Protein conjugate","toxin CRM197 (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Streptococcus pyogenes MGAS315",198466,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
2372028,21856813,1027657,10000000,"6 to 8 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","2 doses of 100 µg on days 0 and 14","Accession Sequence Molecule",Protein,Ovalbumin,9031,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,Ovalbumin,9031,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,361
2372029,21856813,1027657,10000000,"6 to 8 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","2 doses of 100 µg on days 0 and 14","Accession Sequence Molecule",Protein,Ovalbumin,9031,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,Ovalbumin,9031,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,361
1480808,8645089,1006786,10000204,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","[4] doses of [500ug-1mg], administered at intervals of [2] weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",LFPHWIKKPNRQGLGYYSPSYNDP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human T-lymphotropic virus 2",11909,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,125
1464078,16154668,1006668,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,"2 doses of 50 micrograms, administered at an interval of 1 week.","Fragment of a Natural Sequence Molecule","Peptide from protein",AGGLTTTWKEYSHDLQ,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Figures 4 and 5",Negative,0,NULL,124
1983244,23834899,1026482,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 10ug of the M2e MAP at 2-week interval","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/swine/Heilongjiang/1/05(H3N2))",486630,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1, Figures 2 and 3",Positive,NULL,NULL,125
1983245,23834899,1026482,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 10ug of the M2e MAP at 2-week interval","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"H1N1 subtype A/swine/Guangdong/96/2006(H1N1)",10002033,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1, Figures 2 and 3",Positive,NULL,NULL,125
1983246,23834899,1026482,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 10ug of the M2e MAP at 2-week interval","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,10,100,"Table 1, Figures 2, 3 and 4",Positive,NULL,NULL,124
1464052,16154668,1006668,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,"2 doses of 50 micrograms, administered at an interval of 1 week.","Fragment of a Natural Sequence Molecule","Peptide from protein",CKEDYRYAISSTNEIGLLGAGGLT,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,9,90,"Figures 4 and 5",Positive,90,NULL,124
1464093,16154668,1006668,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,"2 doses of 50 micrograms, administered at an interval of 1 week.","Fragment of a Natural Sequence Molecule","Peptide from protein",SLHKGALLTSVTFELLFDGTN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Figures 4 and 5",Negative,0,NULL,124
1464085,16154668,1006668,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,"2 doses of 50 micrograms, administered at an interval of 1 week.","Fragment of a Natural Sequence Molecule","Peptide from protein",SHDLQLNDGTVKAICVAGSFKVT,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,2,20,"Figures 4 and 5",Positive,90,NULL,124
1464091,16154668,1006668,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intramuscular,"2 doses of 50 micrograms, administered at an interval of 1 week.","Fragment of a Natural Sequence Molecule","Peptide from protein",SFKVTALNVVSRRYLASLHK,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,4,40,"Figures 4 and 5",Positive,40,NULL,124
1469904,12744884,1006680,10000000,"6-8 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","2 doses of 10 μg, administered at an interval of 14 days","Fragment of a Natural Sequence Molecule","Peptide from protein",PTTVKTKNTTTTQTQPSKPTTKQRQNKPPNKPNNDFHFEVFNFVPCSICS...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 1, 3, 4, and 5",Positive,NULL,NULL,125
1469909,12744884,1006680,10000000,"6-8 weeks","Administration in vivo to prevent or reduce disease",;Liposomes;,Intranasal,"2 doses of 15 μg, adminstered at an interval of 14 days","Fragment of a Natural Sequence Molecule","Peptide from protein",IPNKKPGKKTTTKPTKKPTFKTTKKDHKPQTTKPKEVPTTK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 4, 5",Negative,NULL,NULL,125
1466959,11085234,1006699,10000923,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"2 doses of 50 nmol 1 month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",SLKAVNPSDPLVYKRQTAKF,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Echinococcus granulosus",6210,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1643624,16341263,1007004,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",MVGGVV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Chain A, Solution Structure Of The Alzheimer's Disease Amyloid Beta- Peptide (1-42)",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 4",Positive,NULL,NULL,326
1643623,16341263,1007004,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",MVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Chain A, Solution Structure Of The Alzheimer's Disease Amyloid Beta- Peptide (1-42)",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3 and 4",Positive,NULL,NULL,326
1486180,9060673,1006715,10000649,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","One dose of 100 µg peptide conjugate in CFA followed by one boost of the same dose in IFA at 9 days later.","Fragment of a Natural Sequence Molecule","Peptide from protein",NDDASVDFVAEPVK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Theiler's encephalomyelitis virus (STRAIN BEAN 8386)",12125,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 7 and 8",Positive,NULL,NULL,326
1486185,9060673,1006715,10000649,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","One dose of 100 µg peptide conjugate in CFA followed by one boost of the same dose in IFA at 9 days later.","Fragment of a Natural Sequence Molecule","Peptide from protein",TKINADNPVPILELE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Theiler's encephalomyelitis virus (STRAIN BEAN 8386)",12125,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 7 and 8",Positive,NULL,NULL,326
1486186,9060673,1006715,10000649,NULL,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);",Intracerebral,"One dose of 10<sup>6</sup> PFU of virus.",Organism,Organism,"Theiler's encephalomyelitis virus (STRAIN BEAN 8386)",12125,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Theiler's encephalomyelitis virus (STRAIN BEAN 8386)",12125,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 8",Negative,NULL,NULL,326
1477708,18063235,1007639,10000000,"6-8 weeks old","Administration in vivo",NULL,"Subcutaneous (s.c.)","Two doses of fusion protein at day 0 and day 14.","Sequence Molecule No Natural Source","Peptide, no natural source",SLLTEVETPIRNEWGSRSNDSSDP,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 7, 8 and 9",Positive,NULL,NULL,124
1472831,7831785,1006729,10000187,"5-8 weeks","Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",ASARGDLAHLTTTHARHLP,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C-S8c1",244367,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Text p. 301-302, Table 3",Positive,NULL,NULL,125
1472355,8184548,1006795,10141,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"1 dose of 200 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",RYSRNAVPNVRGDLQVLAQKVARTLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Campos)",10000516,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",32,32,100,"Table 1",Positive,NULL,NULL,125
1604157,18771700,1013736,10000000,"7 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Six doses of 20-50 ug of peptide, administered at intervals of 20 days.","Sequence Molecule No Natural Source","Peptide, no natural source",CGRNQKPSRLTRSANNVLLEY,NULL,"Complexed Molecule","Other Complexed Molecule",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei ANKA",5823,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 7",Positive,NULL,NULL,125
1435543,11122460,1006297,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 50 μg, administered at intervals of 3 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",SLLTYMKM,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,NULL,"Entire Antibody",Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,125
1435532,11122460,1006297,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 50 μg, administered at intervals of 3 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",HLLRLSEI,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,NULL,"Entire Antibody",Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1484154,9311797,1006309,10000228,"6-8 weeks","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 100ug, administered at intervals of 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",ANCASILCKCYTTGT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Measles virus strain Edmonston",11235,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1462955,8701588,1006315,10000618,5-weeks-old,"Administration in vivo to prevent or reduce disease",NULL,Intranasal,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",MKQYPSTSTTVEGHT,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Pseudomonas aeruginosa Immunotype 4",10000723,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",32,15,46.9,"Table 2",Negative,NULL,NULL,124
1462963,8701588,1006315,10000618,5-weeks-old,"Administration in vivo to prevent or reduce disease",NULL,Intranasal,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",NATAEGRAINRRVE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Pseudomonas aeruginosa Immunotype 4",10000723,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",50,39,78,"Table 2",Positive,NULL,NULL,124
1462964,8701588,1006315,10000618,5-weeks-old,"Administration in vivo to prevent or reduce disease",NULL,Intranasal,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",NEYGVEGGRVNAVG,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Pseudomonas aeruginosa Immunotype 4",10000723,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",33,13,39.4,"Table 2",Negative,NULL,NULL,124
1494373,7523865,1006318,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50 µg epitope-KLH in FCA and 5 boosts with 25 µg in IFA at 14-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",CRGFTSFKKPPTPPPEPET,NULL,"Complexed Molecule","Protein conjugate","Hemocyanin 2-c chain (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Macaca mulatta polyomavirus 1",1891767,http://purl.obolibrary.org/obo/OBI_0002052,"in vivo assay",NULL,NULL,NULL,"Table 3",Positive,NULL,NULL,560
1494374,7523865,1006318,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50 µg epitope-KLH in FCA and 5 boosts with 25 µg in IFA at 14-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",CGETGIDSQSQGSFQAPQSSNS,NULL,"Complexed Molecule","Protein conjugate","Hemocyanin 2-c chain (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Macaca mulatta polyomavirus 1",1891767,http://purl.obolibrary.org/obo/OBI_0002052,"in vivo assay",NULL,NULL,NULL,"Table 3",Negative,NULL,NULL,560
1494368,7523865,1006318,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50 µg epitope-KLH in FCA and 5 boosts with 25 µg in IFA at 14-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",CGKKSKEFHPDKGGDEEKMKKMN,NULL,"Complexed Molecule","Protein conjugate","Hemocyanin 2-c chain (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Macaca mulatta polyomavirus 1",1891767,http://purl.obolibrary.org/obo/OBI_0002052,"in vivo assay",NULL,NULL,NULL,"Table 3",Negative,NULL,NULL,560
1496512,7690411,1006319,10000000,"10-14 weeks","Administration in vivo",;Saponin;,"Subcutaneous (s.c.)","2 doses 50 ug peptide 8 weeks apart","Sequence Molecule No Natural Source","Peptide, no natural source",GREKFTIRPHYGKEIPFVPRADEPARKGKVH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",34,19,55.9,"Table 4",Positive,NULL,NULL,125
1496518,7690411,1006319,10000000,"10-14 weeks","Administration in vivo",;Other;Saponin;,"Subcutaneous (s.c.)","2 doses 50 ug peptide 8 weeks apart","Sequence Molecule No Natural Source","Peptide, no natural source",PFVPRADEPARKGKVHGREKFTIRPHYGKEI,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",23,3,13,"Table 3",Positive-Low,NULL,NULL,125
1470467,10078602,1007205,10000236,"6-8 weeks","Administration in vivo to prevent or reduce disease",;GM-CSF;,Intramuscular,"3 doses of 100 micrograms of conjugated peptide, administered at intervals of one month.","Fragment of a Natural Sequence Molecule","Peptide from protein",SGPLKGILEYTEDEVVSSDFVG,NULL,"Complexed Molecule","Protein conjugate","ovalbumin [Gallus gallus] (Gallus gallus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 1 and Table 2",Positive,NULL,NULL,125
1711871,7650399,1017051,10001211,"6 to 8 weeks","Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose.","Fragment of a Natural Sequence Molecule","Peptide from protein",QFQIHGPR,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing NCAYKTTQANKAAAAA (Ribonuclease pancreatic precursor, Bos taurus)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Zona pellucida sperm-binding protein 3 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",17,10,58.8,"Tables II and III",Positive,NULL,NULL,356
1477071,12902501,1006363,34839,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 10 µg, administered at intervals of 1 month","Fragment of a Natural Sequence Molecule","Peptide from protein",RSDYKFYEDANGTRDHKKG,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing PSLKLLSLIKGVIVHRLEGVE",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Haemophilus influenzae 86-028NP",281310,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",22,22,100,"Figure 4",Positive-High,NULL,NULL,125
1477069,12902501,1006363,34839,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 10 µg, administered at intervals of 1 month","Fragment of a Natural Sequence Molecule","Peptide from protein",RSDYKFYEDANGTRDHKKG,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing PSLKLLSLIKGVIVHRLEGVE",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Haemophilus influenzae",727,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",22,20,90.9,"Figure 4",Positive-High,NULL,NULL,125
1466756,11085234,1006699,10000923,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"2 doses of 50 nmol 1 month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",TETPLRKHFNLTPV,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Echinococcus granulosus",6210,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1466967,11085234,1006699,10000923,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"2 doses of 50 nmol 1 month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",SALTSAIAGFVFSC,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Echinococcus granulosus",6210,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1463260,3008333,1006818,9913,"6-8 months","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",RHKQKIVAPVKQTL,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,5,41.7,"Table 2",Positive,NULL,NULL,125
2399102,25480293,1028432,10001575,"8-10 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 75 ug on weeks 0, 2, and 4","Accession Non-Sequence Molecule",Carbohydrate,"alpha-Gal glycan",NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei ANKA",5823,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,559
2399103,25480293,1028432,10001575,"8-10 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 75 ug on weeks 0, 2, and 4","Accession Non-Sequence Molecule",Carbohydrate,"alpha-Gal glycan",NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei ANKA",5823,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,559
1494191,9234952,1006406,10000000,"5-6 weeks-old","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 injections given 14 days apart","Fragment of a Natural Sequence Molecule","Peptide from protein",CSICSNNPTCWAICK,NULL,"Recombinant Organism","Recombinant Organism",NULL,NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,8,100,"Table 1",Positive,NULL,NULL,125
1595136,2448796,1006430,10000000,"16 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",LDTNGGTGTAIV,NULL,"Complexed Molecule","Protein conjugate","Thyroglobulin (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Tables 1, 3",Negative,NULL,NULL,125
1595133,2448796,1006430,10000000,"16 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",AFKGGNGAKKG,NULL,"Complexed Molecule","Protein conjugate","Thyroglobulin (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,5,62.5,"Tables 1, 3",Positive,NULL,NULL,125
1595139,2448796,1006430,10000000,"16 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",IVVQGAGKNVVFDG,NULL,"Complexed Molecule","Protein conjugate","Thyroglobulin (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Tables 1, 3",Negative,NULL,NULL,125
2098484,24662712,1027538,10000000,"6-8 weeks","Administration in vivo",";Montanide ISA 720;","Subcutaneous (s.c.)","4 doses of 25ug Trx-L2 peptide at biweekly intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",KTCKQAGTCPPDIIPKVEG,NULL,"Complexed Molecule","Protein conjugate","thioredoxin TrxA (Escherichia coli)",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 31",10585,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,8,88.9,"Figure 6",Positive,NULL,NULL,125
1478076,7523697,1006414,9823,NULL,"Administration in vivo",NULL,Intramuscular,"1 dose of 2 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",TGTTTYTTSARRGDLAHLATAHARH,NULL,"Recombinant Organism","Recombinant Organism","Foot-and-mouth disease virus (strain A12)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,5,NULL,"Table 4",Positive,NULL,NULL,125
1497325,1719985,1006426,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Pseudomonas aeruginosa",287,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Pseudomonas aeruginosa",287,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,8,80,"Figure 2",Positive,NULL,NULL,124
1497324,1719985,1006426,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Pseudomonas aeruginosa",287,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Chain A, Pseudomonas Aeruginosa Exotoxin A, Wild Type",287,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,10,100,"Figure 2",Positive,NULL,NULL,124
1668084,3805548,1005642,10000667,"36-43 days","Administration in vivo",NULL,Intranasal,"10 exposures for 6 hours a day","Accession Non-Sequence Molecule","Other Non-Sequence","trimellitic anhydride",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence","trimellityl group",NULL,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 3, 4",Positive,NULL,NULL,356
1473978,16300867,1006752,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 20 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",CTAVSPTTLRTEVVKTFRREK,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,1,20,"Figure 4",Positive,NULL,NULL,124
1473976,16300867,1006752,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 20 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",CPFDTSPVVKGKYNTTLLNGSAF,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,2,40,"Figure 4",Positive,NULL,NULL,124
1473977,16300867,1006752,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 20 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",NGSAFYLVCPIGWT,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,1,20,"Figure 4",Positive,NULL,NULL,124
1463716,17088351,1006555,10000666,"4.5 months","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",SGALRFYNLKGQLVTGSGWY,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Streptococcus sobrinus 6715",246202,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4B, D",Negative,NULL,NULL,125
1465924,7045684,1007160,10141,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 200 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",VPNLRGDLQVLAQKVARTLP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Table 3",Positive,NULL,NULL,125
1465925,7045684,1007160,10141,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","1 dose of 200 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",RHKQKIVAPVKQTL,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Kaufbeuren)",10000513,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Table 3",Positive,NULL,NULL,125
1789769,20641064,1020988,10000067,"5-8 weeks","Administration in vivo to cause disease",";Freund's complete;Pertussis toxin;","Subcutaneous (s.c.)","1 dose of 25 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",24,23,95.8,"Figure 1C",Positive,NULL,NULL,356
1480597,18081037,1008908,10000067,"8 weeks old","Administration in vivo",NULL,Intranasal,"Two doses of 50 µg of virus-like particles in saline administered i.n. or s.c. at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,"Recombinant Organism","Recombinant Organism","Escherichia virus Qbeta",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1478877,17049758,1007857,10000919,"6 weeks","Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);",Intramuscular,"2 doses, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",YGLLAVDPLFKP,NULL,"Recombinant Organism","Recombinant Organism","Escherichia coli",NULL,NULL,NULL,Organism,Organism,"Avibacterium paragallinarum 0083",10000967,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,4,50,"Table 2",Positive,NULL,NULL,125
1476183,11053254,1007895,10000000,"3-4 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 0.8 g, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",PCSICSNNPTCWAICK,NULL,"Complexed Molecule","Protein conjugate","coat protein (Alfalfa mosaic virus)",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus",11250,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,3,60,"Table 1",Positive,NULL,NULL,125
1341836,7520465,1002913,10000000,"6- week-old","Administration in vivo to prevent or reduce disease",";Freund's complete;",NULL,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Protein conjugate","precore/core protein (Hepatitis B virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table 6",Positive,NULL,NULL,125
1771884,12032491,1007047,10001446,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 10 µmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",SQTTDIPCPHGWIS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,356
1459098,12798606,1006048,10000655,"6 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","3 doses of 50 μg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",IRLRHENKDLKARLENAMEV,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Streptococcus pyogenes",1314,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Positive,NULL,NULL,125
1472679,16999929,1006167,10000000,"6 weeks","Administration in vivo",NULL,"Intraperitoneal (i.p.)","3 doses of 10^12 phage particles, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",KSTQRSTRRNLS,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma japonicum strain Chinese",10000826,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1472680,16999929,1006167,10000000,"6 weeks","Administration in vivo",NULL,"Intraperitoneal (i.p.)","3 doses of 10^12 phage particles, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",LPRRLRPQRSPQ,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma japonicum strain Chinese",10000826,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1472681,16999929,1006167,10000000,"6 weeks","Administration in vivo",NULL,"Intraperitoneal (i.p.)","3 doses of 10^12 phage particles, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",NLLHKKPKITQL,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma japonicum strain Chinese",10000826,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,125
1472678,16999929,1006167,10000000,"6 weeks","Administration in vivo",NULL,"Intraperitoneal (i.p.)","3 doses of 10^12 phage particles, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",AKGHSLPRLVTS,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma japonicum strain Chinese",10000826,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,125
1472526,9261941,1006111,34839,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 100 micrograms with a successive dose of 50 micrograms administered 30 days later.","Fragment of a Natural Sequence Molecule","Peptide from protein",YQWLTRVGKYRPQDKPNT,NULL,"Complexed Molecule","Peptide conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Haemophilus influenzae NTHi 1128",10000833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Negative,NULL,NULL,125
1707271,15725571,1007006,10000206,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"5 doses of 70 ug on days 0, 7, 49, 70, 92","Fragment of a Natural Sequence Molecule","Peptide from protein",RSILPYGDSMDRIEKDRLQGMAP,NULL,"Complexed Molecule","Peptide conjugate","glutathione-S-transferase linked to RSILPYGDSMDRIEKDRLQGMAP (Collagen alpha-1(XVII) chain, Homo sapiens)",Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Bullous pemphigoid antigen 1, isoforms 6/7",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",9,9,100,"Table 1",Negative,NULL,NULL,356
1863957,21832099,1022459,10000000,"5-7 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","Two doses of 5 x 10<sup>5</sup> on days 0 and 14 followed by one dose of 10 µg on day 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",YGKDVKDLFDYAQE,NULL,"Pulsed Cell","Pulsed Cell","Dendritic cell (Mus musculus BALB/c)",NULL,NULL,NULL,Organism,Organism,"Candida albicans 3153A (serotype A)",10001529,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1863978,21832099,1022459,10000000,"5-7 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","Two doses of 5 x 10<sup>5</sup> on days 0 and 14 followed by one dose of 10 µg on day 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",YGKDVKDLFDYAQE,NULL,"Pulsed Cell","Pulsed Cell","Dendritic cell (Mus musculus BALB/c)",NULL,NULL,NULL,Organism,Organism,"Candida albicans",5476,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 9",Positive,NULL,NULL,124
1863973,21832099,1022459,10000000,"5-7 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","Two doses of 5 x 10<sup>5</sup> on days 0 and 14 followed by one dose of 10 µg on day 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",YGKDVKDLFDYAQE,NULL,"Pulsed Cell","Pulsed Cell","Dendritic cell (Mus musculus BALB/c)",NULL,NULL,NULL,Organism,Organism,"Candida albicans",5476,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1863975,21832099,1022459,9986,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",YGKDVKDLFDYAQE,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Candida albicans",5476,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1553702,12805448,1013423,10000668,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",GSGVRGDFGSLAPRVARQL,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A12)",12114,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1435008,1706591,1006145,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's adjuvant;","Intraperitoneal (i.p.)","3 doses of 5-10 μg, administered at intervals of 21 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",NIETVIEFQQKNNRLLE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1435152,1706591,1006145,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's adjuvant;","Intraperitoneal (i.p.)","3 doses of 5-10 μg, administered at intervals of 21 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",ICLTRTDRGWFCD,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus",11250,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1435158,1706591,1006145,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's adjuvant;","Intraperitoneal (i.p.)","3 doses of 5-10 μg, administered at intervals of 21 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",YYVNKQEGKSLYVKG,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1435140,1706591,1006145,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's adjuvant;","Intraperitoneal (i.p.)","3 doses of 5-10 μg, administered at intervals of 21 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",PITNDQKKLMSNN,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1665163,91585,1012996,10001274,"3 months","Administration in vivo to prevent or reduce disease",NULL,"Intravenous (i.v.)","1 dose of 1 mg 4-SABA-Le on day 0","Accession Non-Sequence Molecule","Other Non-Sequence","4-sulfanilamidobenzoic acid",NULL,"Complexed Molecule","Other Complexed Molecule",NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","4-sulfanilamidobenzoic acid",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 2",Positive,NULL,NULL,361
1336572,3316473,1002519,10090,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","Mice were immunized with 50 µg of the conjugate in CFA and boosted i.v. with 50 µg of the conjugate in PBS on day 15.","Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Protein conjugate","tetanus toxin (Clostridium tetani)",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",16,13,81.3,"Table 2",Positive,NULL,NULL,125
1336621,3316473,1002519,10116,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","Rats were immunized with 100 µg of the conjugate in CFA and boosted i.v. with 100 µg of the conjugate in PBS on days 15 and 35.","Fragment of a Natural Sequence Molecule","Peptide from protein",DPPPPNPNDPPPPNPN,NULL,"Complexed Molecule","Protein conjugate","tetanus toxin (Clostridium tetani)",NULL,NULL,NULL,Organism,Organism,"Plasmodium berghei",5821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1473534,7539410,1007709,10116,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"4, administered at intervals of 2 weeks; first dose was 1000 micrograms and remaining doses were 500 micrograms.","Fragment of a Natural Sequence Molecule","Peptide from protein",TDAYNQKLSERRAN,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,NULL,NULL,Organism,Organism,"Pseudomonas aeruginosa Immunotype 6",10000823,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1332736,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",DAEVAGTQWFTPSGKTPVFG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332743,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MHNISQHQSVMKMSDQNS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332723,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MIKAAFLPTGAFMADRYKSH,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,2,25,"Table 1",Positive,NULL,NULL,125
1332726,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KNESKYSNTFQMNAYNMSIR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332744,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MHNISQHQSVMMMSDQNS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332759,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",DNIHVKMFKVIENNDKSELI,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,2,22.2,"Table 1",Positive,NULL,NULL,125
1332730,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",SKYSNTFNINAYNMVIRRSM,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,1,12.5,"Table 1",Positive,NULL,NULL,125
1332753,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",NNNFNNIPSRYNLYDKKLDL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332757,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",DNILVKMFKTMINNDKSELI,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332731,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",WGEEKRASHTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332715,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRFRYSNNYEASDH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332725,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KLMSKYSNTFEVNAYNMSIR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332751,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KMNMHMENVPWIVKNQNLFK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332764,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQKEMKTLNEGTSGTA,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,2,16.7,"Table 1",Positive,NULL,NULL,125
1332750,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KKMNMHMENVIYIMKNQNLFK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332752,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KMNMHLENVPWIMNKQNLFK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,2,28.6,"Table 1",Positive,NULL,NULL,125
1332754,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",NNIPSRYNLYDKMLDLDDL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332747,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",KMNMLKENVDYIQKNQNLFK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332745,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MLNISQHQSVMKMSDQNS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332739,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",DAEVAGTQYFHPSGKSPVFG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,1,20,"Table 1",Positive,NULL,NULL,125
1332740,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",MLNISQHQCVKKQCPQNSY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332741,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MHNISQLQVVKKMVPQK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332742,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MLNISQMQSVKKQSDQNS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332746,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MLNISMLQTVMMMTPQK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",16,3,18.8,"Table 1",Positive,NULL,NULL,125
1332733,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLKEMPWY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332734,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLKEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,1,20,"Table 1",Positive,NULL,NULL,125
1332738,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",DAEVAGTQWFDPSGKSPVFG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332761,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQKEMKTHNEGTSGTA,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332712,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",TDVNRYRYSNNYEAIPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332714,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",VIRYRYSNNYEANDHIS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332762,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQKEMKTDNEGTSGTA,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332755,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",FNNIPSRYNLYDKMLPLDD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",15,2,13.3,"Table 1",Positive,NULL,NULL,125
1332749,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KMNMNLEHVPWIMKNQNLFK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332756,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",YDNILVKMFKTNENNDKSELI,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332760,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",GYSLFQKEKMVLNEGTSGTA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332722,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KASFDVTGAFKAPRYKS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332724,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",KNESKYSNTFINNAYNMSIR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332727,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KNESKYSNTFQVNAYNMSIR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332729,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KIMSKYSNTFEVNAYNMSDF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332732,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",WGEGKRASHTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332713,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNIYEASDK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332719,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",MIKSAFLPTGAFKADRYKSH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332720,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MIKAAFLPTGAFKADRYKSH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332716,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRFRYSNNYMSNPH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332721,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MIKVGFLPTGAFKSPRYKSH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332728,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KNMSMYSNAFDINAYNMANRR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332758,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",DIIHVKMRKVIMNNDKSELI,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332763,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",GYSLFQKEKDNLNEGTSGTA,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332718,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNNYEASDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",15,3,20,"Table 1",Positive,NULL,NULL,125
1332735,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEVAGTQYRLPSGKCPVF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332737,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",EDAEVAGTQWFTPSGKSGC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1332748,16483708,1002268,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",KMNMHMENVAWIMKNQNLFK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
2020846,24131712,1027066,10000000,"6 weeks","Administration in vivo",";Aluminum potassium sulfate (alum);","Intraperitoneal (i.p.)","3 doses of 10 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",YPTFGEHKQEKDLEY,NULL,"Complexed Molecule","Protein conjugate","HBcAg (Hepatitis B virus) linked to HHHHHH",NULL,NULL,NULL,Organism,Organism,"Human enterovirus 71 Subgenogroup C4",10000549,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",15,15,100,"Figure 5",Positive,NULL,NULL,124
1495732,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASMTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1498644,7507280,1001568,10000000,"4-6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","4 doses of 20 ug protein conjugate, administered on weeks 0, 3, 6 and 8","Fragment of a Natural Sequence Molecule","Peptide from protein",LLGCIGSTC,NULL,"Complexed Molecule","Protein conjugate","VP2 (Human parvovirus B19)",NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,6,60,"Table 2",Positive,NULL,NULL,125
1498634,7507280,1001568,10000000,"4-6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of 100 ug peptide, administered on weeks 0, 3, 6 and 8","Fragment of a Natural Sequence Molecule","Peptide from protein",ASLKMADPNRFRGKD,NULL,"Complexed Molecule","Protein conjugate","ovalbumin (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Human herpesvirus 1 McIntyre",10000396,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,6,75,"Table 2",Positive,NULL,NULL,125
1498632,7507280,1001568,10000000,"4-6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of 20 ug protein conjugate, administered on weeks 0, 3, 6 and 8","Fragment of a Natural Sequence Molecule","Peptide from protein",LKMADPNRFRGKD,NULL,"Complexed Molecule","Protein conjugate","VP2 (Human parvovirus B19)",NULL,NULL,NULL,Organism,Organism,"Human herpesvirus 1 McIntyre",10000396,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,7,70,"Table 2",Positive,NULL,NULL,125
16264,11906771,1162,10000000,"4-6 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were given four injections, each 15 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",CEDTITYKCPLLRQNEPEDIDCW,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,Other,NULL,Organism,Organism,"Dengue virus 2",11060,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,124
2383142,25635901,1028607,10000206,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"1 dose of 250 µg and 3 doses of 125 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",GNVTGDDTGKIGGLIG,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)","Multi-Antigenic Peptide (MAP, branched) containing EYLNKIQNSLSTEWSPCSVT (circumsporozoite protein, Plasmodium falciparum)",NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus subsp. aureus NCTC 8325",93061,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 4",Positive,NULL,NULL,125
1345661,9651928,1002822,10000000,"2-4 months old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 30 &mirco;g of the peptide in CFA s.c. followed by 4 boosts of the same amount peptide in IFA s.c.","Fragment of a Natural Sequence Molecule","Peptide from protein",DDNGTEEWRCLLGYKKGEGN,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii",5861,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,124
1342205,9651928,1002822,10090,"2-4 months old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 30 &mirco;g of the peptide in CFA s.c. followed by 4 boosts of the same amount peptide in IFA s.c.","Fragment of a Natural Sequence Molecule","Peptide from protein",EPTPNAYYEGVFCSSSS,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii",5861,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,124
1246101,11040127,1001180,447135,"4-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 dose(s) of 50 ug recombinant proteins","Fragment of a Natural Sequence Molecule","Peptide from protein",MSDLTDIQEDITRHEQQLVVARQKLKDAEKAVEMYPDDVNKNTLQ,NULL,"Complexed Molecule","Protein conjugate","core [Hepatitis B virus] (Hepatitis B virus)",NULL,NULL,NULL,Organism,Organism,"Puumala virus Kazan",10000484,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,3,33.3,"Figure 3; Table 1",Positive,NULL,NULL,125
1955449,22241998,1025003,10000038,"60 days","Administration in vivo",;CpG;,Intramuscular,"3 doses of 10 µg","Accession Sequence Molecule",Protein,Trans-sialidase,5693,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Trypanosoma cruzi strain CL Brener",353153,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2C",Positive,NULL,NULL,125
1473975,16300867,1006752,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 50 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",PIGWTGVIECTAVS,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,1,20,"Figure 4",Positive,NULL,NULL,124
1474740,16300867,1006752,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 20 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",FDGTNPSTEEMGDDFGFGLCPFDT,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,1,20,"Figure 4",Positive,NULL,NULL,124
1473980,16300867,1006752,9823,"8-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 20 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",FRREKPFPHRMDCVTTTVENED,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,3,60,"Figure 4",Positive,NULL,NULL,124
1473015,15780448,1006069,10000668,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Sequence Molecule No Natural Source","Peptide, no natural source",TTYTASARGDLAHPTTTHARHL,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Foot-and-mouth disease virus - type C 2.10b",10000811,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Table 2",Positive,NULL,NULL,125
1473034,15780448,1006069,10000668,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",3,"Sequence Molecule No Natural Source","Peptide, no natural source",TTCTASARGDLAHPTTTHACHL,NULL,NULL,NULL,NULL,Polyclonal,Serum,NULL,Organism,Organism,"Foot-and-mouth disease virus - type C 2.10b",10000811,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,3,75,"Table 2",Positive,NULL,NULL,125
1500758,17974006,1007833,10000000,"5-6 weeks","Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","3 doses.","Accession Sequence Molecule",Protein,"M2 protein",382835,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1500228,17974006,1007833,10000000,"5-6 weeks","Administration in vivo to prevent or reduce disease",";Cholera toxin;CpG;",Intranasal,"3 doses of 3 μg  administered at intervals of 4-5 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",SLLTEVETPIRNEWGSRSNDSSDP,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)","Multi-Antigenic Peptide (MAP, branched) containing SFERFEIFPKE (hemagglutinin, Influenza A virus)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/X-31(H3N2))",132504,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
2468465,25822571,1029110,10000000,adult,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 100 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",FHLTTRNGEPHMIVSR,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 New Guinea C",10001583,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 7",Negative,NULL,NULL,356
2106006,24841626,1027925,10000642,"7 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","Doses of 10 pg, 11 pg, and 12 pg at 0, 2 and 4 weeks, respectively","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,361
2106007,24841626,1027925,10000642,"7 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","Doses of 10 pg, 11 pg, and 12 pg at 0, 2 and 4 weeks, respectively","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",NKFLNQCSVSYLMNSMIPY,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figure 2",Positive-Low,NULL,NULL,361
2106008,24841626,1027925,10000642,"7 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","Doses of 10 pg, 11 pg, and 12 pg at 0, 2 and 4 weeks, respectively","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",KYTMFHYLRAQEFEHGKSR,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,361
2106010,24841626,1027925,10000642,"7 to 8 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)","Doses of 10 pg, 11 pg, and 12 pg at 0, 2 and 4 weeks, respectively","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",NNIMFKLDGCRDTHRYIWI,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table 1 and Figure 3",Positive-Low,NULL,NULL,361
1277886,16177380,1001122,10000618,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","3 doses1 week apart, 20μg","Fragment of a Natural Sequence Molecule","Peptide from protein",KNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLE...,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type E precursor",10000298,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",2,0,0,"Table 2",Negative,NULL,NULL,124
1277885,16177380,1001122,10000618,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","3 doses1 week apart, 20μg","Fragment of a Natural Sequence Molecule","Peptide from protein",KNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLE...,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",441771,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",4,4,100,"Table 2",Positive,NULL,NULL,124
1277891,16177380,1001122,10000618,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","3 doses1 week apart, 20μg","Fragment of a Natural Sequence Molecule","Peptide from protein",KRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYPTNKNQFGIYNDK...,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",441771,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,6,100,"Table 2",Negative,NULL,NULL,124
1324299,16826479,1002089,10000263,NULL,"Administration in vivo to prevent or reduce disease",";Cholera toxin;",Intranasal,"5-6 doses of 30ug weekly","Fragment of a Natural Sequence Molecule","Peptide from protein",DNGKAIYERARERALQELGPC,NULL,"Complexed Molecule","Protein conjugate","diphteria toxin [Corynebacterium diphtheriae] (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Streptococcus sp. 'group A'",36470,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,124
1379651,7805747,1004884,10000000,"6 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","One dose of 60ug followed by 3 boosts of 40ug at 3-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",ASLKMADPNRFR,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,6,60,"Table 3",Positive,NULL,NULL,125
1379650,7805747,1004884,10000000,"6 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;","Intraperitoneal (i.p.)","One dose of 60ug followed by 3 boosts of 40ug at 3-week intervals","Sequence Molecule No Natural Source","Peptide, no natural source",HNGRFSDALRFT,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,6,66.7,"Table 3",Positive,NULL,NULL,125
1341533,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRYRYSNIYEASDK,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,0,0,"Table 1",Negative,NULL,NULL,125
1341535,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",TDVNRYRYSNDYESSDK,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1341570,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVMMYRYSNNYEGQPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341580,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVIRWRWGNNYEGNDHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Negative,NULL,NULL,125
1341080,1709834,1002861,10090,NULL,"Administration in vivo",NULL,"Intravenous (i.v.)","Mice were immunized at 2-week intervals with 3 to 5 x 10^4 irradiated sporozoites.",Organism,Organism,"Plasmodium yoelii yoelii 17XNL",352914,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Plasmodium yoelii yoelii 17XNL",352914,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",12,12,100,"Tables 1 and 2",Positive,NULL,NULL,125
1341103,1709834,1002861,10090,"6-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"Mice were immunized i.m. or i.p. with (QGPGAP)<sub>4</sub>-KLH in CFA and boosted 3 times with conjugate in IFA at 2-3-week intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii yoelii 17XNL",352914,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Text P. 28",Negative,NULL,NULL,125
1647974,16361260,1011667,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"1 dose of 100 ug followed by 3 doses of 25 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 5, 6, Table 1, Suppl Table 1",Positive,NULL,NULL,326
1494357,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",MGVFNYETETTSVIPAARLFKAFI,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",20,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1484543,1360328,1011506,10000206,"12 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","4 doses at intervals of 2 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",SPNVSVPSSSSTPLLY,NULL,"Complexed Molecule","Protein conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human T-lymphotropic virus 1",11908,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,1,14.3,"Table 1, Figure 2, 3",Positive-Low,NULL,NULL,125
1482072,10075164,1008112,10141,NULL,"Administration in vivo",";Freund's complete;",Intramuscular,"1 dose 10 μg","Fragment of a Natural Sequence Molecule","Peptide from protein",KYSAGGMGRRGDLEPLAARVAAQL,NULL,"Complexed Molecule","Fatty acid conjugate","Fatty acid conjugate containing KYSAGGMGRRGDLEPLAARVAAQL",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus - type A (strain A22)",10000989,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 3",Positive,NULL,NULL,125
1482068,10075164,1008112,9913,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 3.5 mg","Fragment of a Natural Sequence Molecule","Peptide from protein",KYSAGGMGRRGDLEPLAARVAAQL,NULL,"Complexed Molecule","Fatty acid conjugate","Fatty acid conjugate containing KYSAGGMGRRGDLEPLAARVAAQL",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus - type A (strain A22)",10000989,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,3,100,"Table 6",Positive,NULL,NULL,125
1482065,10075164,1008112,10000990,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.5 mg or 0.1 mg","Fragment of a Natural Sequence Molecule","Peptide from protein",KYSAGGMGRRGDLEPLAARVAAQL,NULL,"Complexed Molecule","Fatty acid conjugate","Fatty acid conjugate containing KYSAGGMGRRGDLEPLAARVAAQL",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus - type A (strain A22)",10000989,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,7,87.5,"Table 5",Positive,NULL,NULL,125
1484447,12502839,1008911,9913,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",AGARRGDLAHLAAAHARHLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",1,1,100,"Table 1",Positive,NULL,NULL,125
1505910,9382731,1012274,10000000,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 20 ug, administered after 1 and 3 months.","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Protein conjugate","HBsAg protein (Hepatitis B virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii yoelii",73239,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table 1",Positive,NULL,NULL,125
1485270,7622235,1009117,10000659,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TGAQTIKGQKLYFKANGQQVKG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus sobrinus",1310,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,125
1485264,7622235,1009117,10000659,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DANFDSIRVDAVDNVDADLLQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus sobrinus",1310,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,125
1485266,7622235,1009117,10000659,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DANFDSIRVDAVDNVDADLLQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus mutans",1309,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,125
1485271,7622235,1009117,10000659,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TGAQTIKGQKLYFKANGQQVKG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus mutans",1309,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,125
2103926,24802101,1027605,10000000,"4-6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","4 doses of 1.7 nmol E3R4 at 2 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QLYKTCKQAGTCPPDIIPKV,NULL,"Complexed Molecule","Peptide conjugate","immunoglobulin heavy chain IgG1 (Homo sapiens) linked to QLYKTCKQAGTCPPDIIPKVQLYKTCKQAGTCPPDIIPKV",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,L2,10593,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 5",Positive,NULL,NULL,125
2103927,24802101,1027605,10000000,"4-6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","4 doses of 1.7 nmol E3R4 at 2 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QLYKTCKQAGTCPPDIIPKV,NULL,"Complexed Molecule","Peptide conjugate","immunoglobulin heavy chain IgG1 (Homo sapiens) linked to QLYKTCKQAGTCPPDIIPKVQLYKTCKQAGTCPPDIIPKV",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,L2,10598,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 5",Positive,NULL,NULL,125
2103928,24802101,1027605,10000000,"4-6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","4 doses of 1.7 nmol E3R4 at 2 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",QLYKTCKQAGTCPPDIIPKV,NULL,"Complexed Molecule","Peptide conjugate","immunoglobulin heavy chain IgG1 (Homo sapiens) linked to QLYKTCKQAGTCPPDIIPKVQLYKTCKQAGTCPPDIIPKV",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,L2,10580,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 5",Positive,NULL,NULL,125
1980432,NULL,NULL,10090,"4 weeks","Administration in vivo",NULL,Intranasal,NULL,Organism,Organism,"Vaccinia virus Acambis 2000",10001973,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Vaccinia virus Acambis 2000",10001973,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,NULL,Positive-High,NULL,NULL,124
1980433,NULL,NULL,10090,"4 weeks","Administration in vivo",NULL,Intranasal,NULL,Organism,Organism,"Vaccinia virus Acambis 2000",10001973,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Vaccinia virus Acambis 2000",10001973,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,NULL,Positive-High,NULL,NULL,124
1004110,1376012,1000166,10000000,"8-12 weeks-old","Administration in vivo to prevent or reduce disease",NULL,Oral,"Five booster injections were given at 7 day intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",SKAFSNCYPYDVPDYASL,NULL,"Recombinant Organism","Recombinant Organism",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Texas/1/1977(H3N2))",444318,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure  7",Negative,NULL,NULL,125
1498383,16563575,1001674,10000653,"7 weeks","Administration in vivo",NULL,Intramuscular,"3 doses of 100 µg DNA plasmid at 2-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",TTTYTASARGDLAHLTTTHARHLP,NULL,Plasmid,Plasmid,"Plasmid containing YFLIEKGQHEAAIEFFEGMVHDSIKEELRPSIINNYYMQQYQNSM",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C-S8c1",244367,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",31,9,29,"Figure 4",Positive,NULL,NULL,559
1491671,9276446,1010404,10000000,"6 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","1 dose of 36ug, and 5 doses of 20ug given on days 24, 42, 66, 86, and 130","Accession Sequence Molecule",Protein,"Chain A, The Ab Initio Structure Determination And Refinement Of A Scorpion Protein Toxin + AIB(C12, C16, C22, C26, C36, C46, C48, C63)",70175,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Chain A, The Ab Initio Structure Determination And Refinement Of A Scorpion Protein Toxin",70175,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,3,50,"Results Text",Positive,NULL,NULL,124
1478571,10717347,1010655,10000618,"5 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"1 dose of 50 micrograms of virus followed by 3 doses of 10 micrograms of virus, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",TDAYNQKLSERRAN,NULL,"Recombinant Organism","Recombinant Organism","Tobacco mosaic virus",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Pseudomonas aeruginosa Immunotype 4",10000723,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3 and 4",Positive,NULL,NULL,125
1498625,10082167,1010737,10000653,NULL,"Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","1 dose of 37 µg epitope-conjugate in CFA on day 1 and 10 µg in sodium alginate on days 15, 30, 45, 60, 75, and 84","Fragment of a Natural Sequence Molecule","Peptide from protein",KKYRYYLKPLCKK,NULL,"Complexed Molecule","Peptide conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Phospholipase A2 homolog 2 precursor (Myotoxin II)",8722,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive-Intermediate,NULL,NULL,125
1507058,10081767,1009938,10000000,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","3 doses of 10 μg: first in CFA, second in IFA and an i.v. boost without adjuvant.","Accession Sequence Molecule",Protein,"Glutathione S-transferase class-mu 28 kDa isozyme",6184,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma bovis",6184,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Tables 2 and 3",Negative,NULL,NULL,125
1645745,2479704,1014695,10000054,"8 weeks old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Intravenous (i.v.)","3 doses of 0.33 mg","Fragment of a Natural Sequence Molecule","Peptide from protein",PTGPLGPKGQTGELGIAGFKGEQGPK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",18,9,50,"Tables IV and V",Positive,NULL,NULL,326
1483007,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",CDCDRTAA,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,25,100,"Table 5",Positive,NULL,NULL,125
1483008,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",CFGNSEY,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,25,100,"Table 5",Positive,NULL,NULL,125
1482996,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",AGGSGRP,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,25,100,"Table 5",Positive,NULL,NULL,125
1482992,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",AGGSGRP,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,11,44,"Table 4",Positive,NULL,NULL,125
1482993,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",YVHDNC,NULL,"Complexed Molecule","Protein conjugate",NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,24,96,"Table 4",Positive,NULL,NULL,125
2004517,24069479,1026831,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Chikungunya virus",37124,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Chikungunya virus strain LR2006_OPY1 IMT/Reunion Island/2006",10001997,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
2004518,24069479,1026831,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Chikungunya virus",37124,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Chikungunya virus strain S27-African prototype",371094,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",27,27,100,"Figure 6, Table 1",Positive,NULL,NULL,125
1484539,1690176,1011078,9940,NULL,"Administration in vivo",";Freund's complete;",NULL,"2 doses of 200 µg epitope at a 2-week interval","Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1)",73482,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,3,100,"Table 3",Positive,NULL,NULL,125
1484542,1690176,1011078,9940,NULL,"Administration in vivo",";Freund's complete;",NULL,"2 doses of 200 µg epitope at a 2-week interval","Fragment of a Natural Sequence Molecule","Peptide from protein",VPNLRGDLQVLAQKVART,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1)",73482,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,1,33.3,"Table 3",Positive,NULL,NULL,125
1650924,19499518,1014924,10000624,"9 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","3 doses of 5-7 µg at days 0, 42, and 70.","Sequence Molecule No Natural Source","Peptide, no natural source",KFHPKDIPYQVW,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Streptococcus pneumoniae SP-BS293",497963,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1650942,19499518,1014924,10000000,"6 weeks","Administration in vivo",";Freund's incomplete (IFA);",NULL,"1 dose of 50 µg followed by a booster injection 2 weeks later",Organism,Organism,"Streptococcus pneumoniae SP-BS293",497963,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus pneumoniae SP-BS293",497963,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,124
1650939,19499518,1014924,10000624,"9 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)","3 doses of 5-7 µg at days 0, 42, and 70.","Sequence Molecule No Natural Source","Peptide, no natural source",RQFECYTTCVG,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Streptococcus pneumoniae SP-BS293",497963,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Negative,NULL,NULL,124
1500795,15868095,1013036,9031,"4 weeks","Administration in vivo",NULL,Intramuscular,"50 ug of dt-peptide at 2 sites","Fragment of a Natural Sequence Molecule","Peptide from protein",SGGKLVGILTSRNET,NULL,"Complexed Molecule","Protein conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Avian infectious bronchitis virus (strain Vic S)",231428,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,2,33.3,"Tables 4 and 5",Positive,NULL,NULL,125
1500797,15868095,1013036,9031,"4 weeks","Administration in vivo",NULL,Intramuscular,"50 ug of dt-peptide at 2 sites","Fragment of a Natural Sequence Molecule","Peptide from protein",GSQAIENQFYIKLTNGS,NULL,"Complexed Molecule","Protein conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Avian infectious bronchitis virus (strain Vic S)",231428,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,4,66.7,"Tables 4 and 5",Positive,NULL,NULL,125
1500799,15868095,1013036,9031,"4 weeks","Administration in vivo",NULL,Intramuscular,"50 ug of dt-peptide at 2 sites","Fragment of a Natural Sequence Molecule","Peptide from protein",NCPYVSYGKFCIKPDGSIST,NULL,"Complexed Molecule","Protein conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Avian infectious bronchitis virus (strain Vic S)",231428,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,3,50,"Tables 4 and 5",Positive,NULL,NULL,125
1485004,3286503,1012252,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"3 doses of 100ug","Fragment of a Natural Sequence Molecule","Peptide from protein",GKVEYTKYNDDDTFTVKVGD,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Shiga toxin subunit B precursor",622,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",40,NULL,NULL,"Table 4",Positive,NULL,NULL,125
1491783,15295710,1012899,9606,NULL,"Exposure with existing immune reactivity without evidence for disease",NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum",5833,NULL,NULL,NULL,Polyclonal-Monospecific,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1491784,15295710,1012899,9606,NULL,"Exposure with existing immune reactivity without evidence for disease",NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum",5833,NULL,NULL,NULL,Polyclonal-Monospecific,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1496141,2421497,1012162,9986,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",MQWNSTAFHQTLQDPRVRGLYLPAGG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Hepatitis B virus subtype adw",106821,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,2,100,"Figure 2",Positive,NULL,NULL,125
1483513,16337317,1007969,10141,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);",NULL,"1 dose of 0.5 mg virus","Fragment of a Natural Sequence Molecule","Peptide from protein",PNLRGDLQVLA,NULL,"Recombinant Organism","Recombinant Organism","Recombinant Organism containing coat protein (Tobacco mosaic virus)",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus - type O",12118,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",18,18,100,"Table 4",Positive,NULL,NULL,125
1483515,16337317,1007969,9823,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);",NULL,"1 dose of 3 mg virus","Fragment of a Natural Sequence Molecule","Peptide from protein",PNLRGDLQVLA,NULL,"Recombinant Organism","Recombinant Organism","Recombinant Organism containing coat protein (Tobacco mosaic virus)",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus - type O",12118,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,9,100,"Table 6",Positive,NULL,NULL,125
1703215,3498765,1017000,10000662,"8 to 10 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;",Intradermal,"2 doses of 100 µg, 4 weeks apart","Fragment of a Natural Sequence Molecule","Peptide from protein","KSYCEIIVTHFPFDEQNCSLKLG + NLeu(L20)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Acetylcholine receptor subunit alpha",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",7,7,100,"Table VI",Positive,NULL,NULL,356
1688677,19035498,1013879,9606,"24-44 years","Occurrence of autoimmune disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"U1 small nuclear ribonucleoprotein 70 kDa",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Tables 2, 3 and 4, Figures 2, 3 and 4",Positive,NULL,NULL,326
2118469,23549081,1025761,10001381,NULL,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 100 ug on days 0, 7 and 14.","Fragment of a Natural Sequence Molecule","Peptide from protein",LYQEARKIVGAMVQIITYR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myeloperoxidase precursor",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",10,10,100,"Suppl. Figure 5",Positive,NULL,NULL,356
1505663,11273739,1006590,10000000,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"class 1 porin",10000843,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Neisseria meningitidis serogroup B  H44/76",10000843,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",6,6,100,"Figure 2",Positive,NULL,NULL,559
1505632,11273739,1006590,10000000,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"class 1 porin",10000843,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Neisseria meningitidis serogroup B  H44/76",10000843,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",6,6,100,"Figure 2",Positive,NULL,NULL,559
1499807,18190253,1007633,9796,NULL,"Administration in vivo",;TiterMax;,Intradermal,"1st dose of 250 μg, 2nd dose of 125 μg 58 days later.","Fragment of a Natural Sequence Molecule","Peptide from protein",FNCLGMSNRDFLEGVSGATWVDLVLEGDSCVTIMSKDKPTIDVKMMNMEA...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus",11082,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",27,13,48.1,"Table 3",Positive,NULL,NULL,124
1499786,18190253,1007633,9796,NULL,"Administration in vivo",;TiterMax;,Intradermal,"1st dose of 250 μg, 2nd dose of 125 μg 58 days later.","Fragment of a Natural Sequence Molecule","Peptide from protein",FNCLGMSNRDFLEGVSGATWVDLVLEGDSCVTIMSKDKPTIDVKMMNMEA...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus",11082,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",17,10,58.8,"Table 3",Positive,NULL,NULL,124
1499806,18190253,1007633,9796,NULL,"Administration in vivo",;TiterMax;,Intradermal,"1st dose of 250 μg, 2nd dose of 125 μg 58 days later.","Fragment of a Natural Sequence Molecule","Peptide from protein",FNCLGMSNRDFLEGVSGATWVDLVLEGDSCVTIMSKDKPTIDVKMMNMEA...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus",11082,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",36,19,52.8,"Table 3",Positive,NULL,NULL,124
1278003,10930684,1001658,10000000,"6 weeks","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"2 or 3 doses 2 weeks apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",SYTNDKILILYFNKLYKKIKDNSILDMRYENNKFIDISGYGSNISINGDV...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,BoNT/F,10000304,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,5,100,"Figures 4 and 6",Positive,NULL,NULL,124
1489896,18480437,1012329,9598,NULL,"Administration in vivo",NULL,NULL,"3 doses",Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 8 and Table 5",Positive,NULL,NULL,124
1489897,18480437,1012329,9598,NULL,"Administration in vivo",NULL,NULL,"3 doses",Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 8 and Table 5",Positive,NULL,NULL,124
1489895,18480437,1012329,9598,NULL,"Administration in vivo",NULL,NULL,"3 doses",Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 8 and Table 5",Positive,NULL,NULL,124
1500094,18252707,1012398,10000000,"8 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","3 doses of 10 μg 3 weeks apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSS,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing LKQIEDKLEEILSKLYHIENELARIKKLLGE (General control protein GCN4, Saccharomyces cerevisiae)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Influenza A virus (A/X-47(H3N2))",380905,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",33,NULL,NULL,"Figure 2",Positive,NULL,NULL,124
1495734,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1495730,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",WGEMKRASHTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1495702,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLKEKPYY,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,5,50,"Table 1",Positive,NULL,NULL,125
1495726,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",WGEGKRASHTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1495742,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKFAAHTTPVLKEMP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1495774,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",HTTWGEEKRASLTTPVLKEM,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1495772,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",HTTYSEEKRASHTTPVLMEK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1495728,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",WGEEKRASGTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1495724,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",GGEEKRASHTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1495711,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLMMKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,125
1495736,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLMEKPWY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Table 1",Negative,NULL,NULL,125
1495738,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLATPVLMMKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,0,0,"Table 1",Negative,NULL,NULL,125
1495740,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEEMRASHTTPVLKEMPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,0,0,"Table 1",Negative,NULL,NULL,125
1495691,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",WGEEKRASHTTPVLMEKPYY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1495705,12220641,1012414,37293,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125 ug administered at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",YSEMKRASLTTPVLKEMPWY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Table 1",Negative,NULL,NULL,125
1982986,23416200,1026374,9606,NULL,"Exposure with existing immune reactivity without evidence for disease",NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus",1280,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus LAC",867914,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,9,90,"Figures 4, 5 and 6",Positive,NULL,NULL,124
1507984,2154148,1012271,10001097,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","2 doses, administered on day 28 and 59.","Fragment of a Natural Sequence Molecule","Peptide from protein",NGTSKYAVGGSGRRGDMGSLAARVVKQ,NULL,"Complexed Molecule","Peptide conjugate","trp operon (Escherichia coli)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A12)",12114,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Table 5",Positive,NULL,NULL,125
1638064,18596154,1013109,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",HHQKLVFFAEDVGSNK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2, 6",Negative,NULL,NULL,326
1638020,18596154,1013109,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, 3, 4, 5, 6",Positive,NULL,NULL,326
1761830,20333301,1019233,9504,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"3 doses of 125 µg at 20-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",SKYSNTFNINAYNMVIRRSM,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figures 1 and 2C",Positive,NULL,NULL,125
1498347,7571431,1006789,10000000,"60-90 days old","Administration in vivo to prevent or reduce disease",NULL,"Intraperitoneal (i.p.)","1 dose of 5 to 50 μg in oil-in-water emulsion.","Fragment of a Natural Sequence Molecule","Peptide from protein",RYSRNAVPNV,NULL,"Complexed Molecule","Peptide Repeat Sequence (linear)","Peptide Repeat Sequence (linear) containing RYSRNAVPNVRYSRNAVPNV",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1 Campos)",10000516,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Table 3",Positive,NULL,NULL,125
1504439,18639519,1013167,10000000,"7-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50ug, and 4 booster injections administered after 1, 3, 5, and 7 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",INGKTKSVFFEGNGRED,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type B precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive-Low,NULL,NULL,124
1504445,18639519,1013167,10000000,"7-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50ug, and 4 booster injections administered after 1, 3, 5, and 7 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",HRFYESGIVFEEYKDYFCISKWY,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type B precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive,NULL,=,124
1504431,18639519,1013167,10000000,"7-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50ug, and 4 booster injections administered after 1, 3, 5, and 7 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",TSSANGGGIFNSVFGGMKNN,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type B precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive-Low,NULL,NULL,124
1504446,18639519,1013167,10000000,"7-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50ug, and 4 booster injections administered after 1, 3, 5, and 7 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",YKDYFCISKWYLKEVKRKPYNLKLG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type B precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive,NULL,=,124
1504440,18639519,1013167,10000000,"7-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50ug, and 4 booster injections administered after 1, 3, 5, and 7 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",KLEGGGKDIREGGDGDIDRT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type B precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive-Low,NULL,NULL,124
1500687,18786589,1013141,10141,"4-6 weeks old","Administration in vivo",NULL,Intramuscular,"Five injections of 50 ug of recombinant protein.","Fragment of a Natural Sequence Molecule","Peptide from protein",EVHGNAEVHASFFDIGGSVSAGFS,NULL,"Complexed Molecule","Protein conjugate","core protein (Hepatitis B virus)",NULL,NULL,NULL,Organism,Organism,"Bacillus anthracis",1392,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",7,4,57.1,"Figure 8",Positive,NULL,NULL,124
1660285,16125192,1014665,10000054,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9031,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",3,1,33.3,"Table 3",Positive-Low,NULL,NULL,356
2008628,24130862,1026923,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",MSLYRSPSASVMRSASMLSRSGGFDAYGFGGYGAPSLNVADLGSLTRLED...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Trichinella spiralis",6334,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,125
2008627,24130862,1026923,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Other;,"Subcutaneous (s.c.)","3 doses of 50 µg, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",LPWHFKSRHRYQ,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Trichinella spiralis",6334,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
2008623,24130862,1026923,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Other;,"Subcutaneous (s.c.)","3 doses of 50 µg, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",EWMSHGPRPNN,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Trichinella spiralis",6334,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,125
1494387,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",KAEQVKASKEMGETLLRAVESYLLAHSDAYN,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",13,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494388,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",KAEQVKASKEMGETLLRAVESYLLAHSDAYN,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",20,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494376,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",GPGTIKKISFPEGFPFKYVKDRVDEVDHTN,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",13,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494372,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",LFPKVAPQAISSVENIEGNGGPGTIKKISF,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",20,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494383,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",DGGSILKISNKYHTKGDHEVKAEQVKASKE,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",13,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494384,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",DGGSILKISNKYHTKGDHEVKAEQVKASKE,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",20,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494391,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",VDHTNFKYNYSVIEGGPIGDTLEKISNEIK,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",13,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1494392,17911617,1012672,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Pollen from Betula pendula",3505,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",VDHTNFKYNYSVIEGGPIGDTLEKISNEIK,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",20,0,0,"Figure 3, 5, 7, Table I",Negative,NULL,NULL,326
1421782,10456875,1006096,10000067,NULL,"Administration in vivo to prevent or reduce disease",NULL,Intranasal,"2 doses of 50 micrograms per microliter, administered at an interval of 2-3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",GFTTNEERYNVFAE,NULL,"Complexed Molecule","Protein conjugate","Flagellin (Salmonella enterica subsp. enterica serovar Muenchen)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Schistosoma mansoni",6183,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1482241,2174595,1006807,10000668,NULL,"Administration in vivo",NULL,Intramuscular,"Three injections at days 0, 21, and 42.","Sequence Molecule No Natural Source","Peptide, no natural source",YKQKIIAPYKQKIIAPSRRGDLGSLAPRV,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A10-61)",12112,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 1",Positive,NULL,NULL,125
1507977,2154148,1012271,10001097,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","2 doses, administered on day 28 and 59.","Fragment of a Natural Sequence Molecule","Peptide from protein",SASGSGVRGDFGSLAPRVARQLPASFNYGAIK,NULL,"Complexed Molecule","Peptide conjugate","trp operon (Escherichia coli) linked to ASASGSGVRGDFGSLAPRVARQLPASFNYGAIK",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,1,25,"Table 4",Positive,NULL,NULL,125
1507983,2154148,1012271,10001097,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","2 doses, administered on day 28 and 59.","Fragment of a Natural Sequence Molecule","Peptide from protein",NGTSKYAVGGSGRRGDMGSLAARVVKQ,NULL,"Complexed Molecule","Peptide conjugate","trp operon (Escherichia coli)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Table 5",Positive,NULL,NULL,125
1507976,2154148,1012271,10001097,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","2 doses, administered on day 28 and 59.","Fragment of a Natural Sequence Molecule","Peptide from protein",SASGSGVRGDFGSLAPRVARQLPASFNYGAIK,NULL,"Complexed Molecule","Peptide conjugate","trp operon (Escherichia coli) linked to ASASGSGVRGDFGSLAPRVARQLPASFNYGAIK",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A12)",12114,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Table 4",Positive,NULL,NULL,125
1507962,2154148,1012271,9913,"18 months","Administration in vivo",NULL,"Subcutaneous (s.c.)","1 dose.","Fragment of a Natural Sequence Molecule","Peptide from protein",SASGSGVRGDFGSLAPRVARQLPASFNYGAIK,NULL,"Complexed Molecule","Peptide conjugate","trp operon (Escherichia coli) linked to ASASGSGVRGDFGSLAPRVARQLPASFNYGAIK",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A12)",12114,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Table 2",Positive,NULL,NULL,125
1981438,22406169,1026314,10000067,NULL,"Administration in vivo",NULL,"Intraperitoneal (i.p.)","10^5 PFU",Organism,Organism,"Dengue virus type 1 strain 16007",10000961,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 1 Nauru/West Pac/1974",11059,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1507056,10081767,1009938,10000000,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","3 doses of 10 μg: first in CFA, second in IFA and an i.v. boost without adjuvant.","Accession Sequence Molecule",Protein,"Glutathione S-transferase class-mu 28 kDa isozyme",6184,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma bovis",6184,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Tables 2 and 3",Negative,NULL,NULL,125
1645225,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,osteopontin,10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1499596,15214440,1013018,10000067,"8-10 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"3 doses of 50 µg MAP at intervals of 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",ENSYEKSMSVV,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma mansoni",6183,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Text P. 358",Negative,NULL,NULL,125
1499595,15214440,1013018,10000067,"8-10 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"3 doses of 50 µg MAP at intervals of 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",LKNTVDVVSV,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Schistosoma mansoni",6183,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Text P. 358",Negative,NULL,NULL,125
1435693,9712813,1006436,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"2 doses of 50 μg one month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",GFTTNEERYNVFAE,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Other,NULL,Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1435769,9712813,1006436,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"2 doses of 50 μg one month apart","Fragment of a Natural Sequence Molecule","Peptide from protein",GFTTNEPRYNVFAE,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Other,NULL,Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1510520,7945236,1011696,10000618,NULL,"Administration in vivo",;Ribi;,"Intraperitoneal (i.p.)","2 doses of 2ug, administered at intervals of 3 weeks.","Accession Sequence Molecule",Protein,"Chain A, The Crystal Structure Of Neurotoxin-I From Naja Naja Oxiana At 1.9 Angstroms Resolution",8657,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3",Positive,NULL,NULL,125
1507685,9034147,1010662,10000000,NULL,"Administration in vivo",NULL,NULL,NULL,Organism,Organism,"Cryptococcus neoformans",5207,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Cryptococcus neoformans var. neoformans Serotype A",10001132,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1595725,1282493,1013576,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Saponin;,"Subcutaneous (s.c.)","2 doses of 50ug, administered on day 0 and week 9.","Fragment of a Natural Sequence Molecule","Peptide from protein",IQDTRNAVRACRIQYHHDPQPVGREKF,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",15,3,20,"Table 5",Positive,NULL,NULL,124
1489553,17627594,1012259,10000000,NULL,"Administration in vivo",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","3 doses of 50ug, every two weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",NHGNYSAQVGASQ,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing EAWLDSTKAT (polyprotein, Japanese encephalitis virus)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Japanese encephalitis virus strain Nakayama",11076,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",4,1,25,"Figure 6",Positive,NULL,NULL,124
1511769,9276729,1006497,9986,NULL,"Administration in vivo",";Freund's complete;",Intramuscular,"2 doses of 150 μg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",AATTVNGGTVHFK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 4",Negative,NULL,NULL,125
1511773,9276729,1006497,10000618,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","2 doses of 150 μg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",CKTANGTAIPIGGGSANVYVNLAPV,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 5",Positive,NULL,NULL,125
1511774,9276729,1006497,10000618,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","2 doses of 150 μg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",NYARTGGQVTAG,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 5",Negative,NULL,NULL,125
1511775,9276729,1006497,10000618,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","2 doses of 150 μg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",AATTVNGGTVHFK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 5",Negative,NULL,NULL,125
2830714,27181584,1030369,9544,"5-6 years","Administration in vivo",";Aluminum potassium sulfate (alum);",Intramuscular,"8 doses of 100 or 200ug GP at 4-week intervals","Accession Sequence Molecule",Protein,"virion spike glycoprotein precursor",186538,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Zaire ebolavirus",186538,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,4,66.7,"Table 5",Positive,NULL,NULL,124
1419454,8228823,1005301,10000067,"6-8 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intranasal,"3 doses of 100 ug administered at intervals of 1 day.","Fragment of a Natural Sequence Molecule","Peptide from protein",FGISNYCQIYPPNANKIREALAQPQRYCR,NULL,NULL,NULL,NULL,Polyclonal,"Culture Supernatant","Entire Antibody","Accession Sequence Molecule",Protein,"Der P 1",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1510665,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",AATCPSKKPYEEVTC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive-Intermediate,NULL,NULL,125
1513833,10491120,1011890,10000206,NULL,"Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","4 doses of 25 μg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",KEGYLVDKNTGCKY,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing YEQAIVWPLPNKRCS (Beta-mammal toxin Cn2 precursor (Toxin 2) (Toxin II.9.2.2), Centruroides noxius)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-mammal toxin Cn2 precursor (Toxin 2) (Toxin II.9.2.2)",6878,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",20,9,45,"Table 3",Negative,NULL,NULL,124
1513834,10491120,1011890,10000206,NULL,"Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","4 doses of 25 μg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",GYLVDKNTGCKYE,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing QAIVWPLPNKRCS (Beta-mammal toxin Cn2 precursor (Toxin 2) (Toxin II.9.2.2), Centruroides noxius)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-mammal toxin Cn2 precursor (Toxin 2) (Toxin II.9.2.2)",6878,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",18,8,44.4,"Table 3",Negative,NULL,NULL,124
2489859,26390432,1029347,10000667,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 100ug followed by 3 doses of 50ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",DNSPYAGWQVQNNKPFDGKD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae R2866",262728,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,5,50,"Figure 4",Positive,NULL,NULL,125
2489860,26390432,1029347,10000667,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 100ug followed by 3 doses of 50ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",SWDYQKSTSNHAFYRYDKNR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae R2866",262728,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,4,44.4,"Text page 11",Positive-Low,NULL,NULL,125
2489856,26390432,1029347,10000667,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 100ug followed by 3 doses of 50ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",LYNNKTIEKEQRKV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae R2866",262728,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,8,80,"Figure 1",Positive,NULL,NULL,125
2489857,26390432,1029347,10000667,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 100ug followed by 3 doses of 50ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",DHYDTSSKTVKYKD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae R2866",262728,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Figure 1",Positive,NULL,NULL,125
2489858,26390432,1029347,10000667,Adult,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 100ug followed by 3 doses of 50ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",TLNKDDGIYYLNGSQSGKGQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae R2866",262728,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,7,70,"Figure 4",Positive,NULL,NULL,125
1509122,9499101,1006618,9685,"4 month old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","5 doses of 120 μg of FIV peptide (approximately 250 μg of KLH-coupled peptide)","Fragment of a Natural Sequence Molecule","Peptide from protein",QVVKQPDYLVVPGEVMEYKPRR,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Feline immunodeficiency virus (isolate wo)",45409,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,1,25,"Figures 3 and 4",Positive-Low,NULL,NULL,125
1509123,9499101,1006618,9685,"4 month old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","5 doses of 120 μg of FIV peptide (approximately 250 μg of KLH-coupled peptide)","Fragment of a Natural Sequence Molecule","Peptide from protein",KKGLQQLQEWEDWVGWIGN,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Feline immunodeficiency virus (isolate wo)",45409,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",4,3,75,"Figures 3 and 4, Table 3",Positive,NULL,NULL,559
1512328,8613367,1006628,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Streptococcus oralis",1303,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus oralis",1303,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,9,100,"Table 5",Positive,NULL,NULL,125
1512324,8613367,1006628,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Streptococcus oralis",1303,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus oralis",1303,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 5",Negative,NULL,NULL,125
1512327,8613367,1006628,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Streptococcus oralis",1303,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus oralis",1303,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 5",Negative,NULL,NULL,125
1551157,9353015,1008149,10000667,"43 days","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 50 µg peptide construct at 21-day intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",ANDVDNSNPVVQAEQLNWL,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus mutans",1309,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1551155,9353015,1008149,10000667,"43 days","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 50 µg peptide construct at 21-day intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",GGYEFLLANDVDNSNPVVQ,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus mutans",1309,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1497247,15232173,1013044,10000263,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","4 doses of 30ug, administered at intervals of 21 and 10 days.","Sequence Molecule No Natural Source","Peptide, no natural source",QAEDKVKQSREAKKQVEKALKQLEDKVQ,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Streptococcus pyogenes M1 GAS",160490,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1482859,7680514,1008928,9825,"14 weeks old","Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"Two doses of 10 mg of lipopeptide.","Fragment of a Natural Sequence Molecule","Peptide from protein",RYNRNAVPNLRGDLQVLAQK,NULL,"Complexed Molecule","Fatty acid conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) Kaufbeuren",10000556,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
1585481,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIIAPAKQLLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,6,30,"Table 2",Positive,NULL,NULL,125
1542544,3552985,1006157,9913,NULL,"Administration in vivo",NULL,Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",NTFYCCELCCNPACAGCY,NULL,"Complexed Molecule","Protein conjugate","Ovalbumin (Gallus gallus)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli K99",10001146,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3",Positive,NULL,NULL,125
1771880,12032491,1007047,10001446,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 10 µmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",RNDYSYWLSIPALMP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,356
1771881,12032491,1007047,10001446,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 10 µmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",PALMPMNMAPITGRA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,356
1771882,12032491,1007047,10001446,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 10 µmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",APITGRALEPYISRCTVCEGPAI,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,356
1771883,12032491,1007047,10001446,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 10 µmol.","Fragment of a Natural Sequence Molecule","Peptide from protein",CEGPAIAIAVHSQTTD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"alpha-3 type IV collagen",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,356
1553699,9191921,1006625,10000000,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","3 doses administered on days 0, 21, and 38.",Organism,Organism,"Measles virus strain Edmonston",11235,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Measles virus strain Edmonston",11235,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",65,65,100,"Figure 4",Positive,NULL,NULL,124
1581333,1372679,1012188,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 10 μg in IFA, administered at intervals of two weeks. Four days before fusion, a booster dose of 30 μg of OMPs intravenously without adjuvant.","Accession Sequence Molecule",Protein,"Outer membrane protein P2",10001056,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Haemophilus influenzae Serotype B",10000860,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1551142,18716625,1013152,9606,"91-101 years","Exposure with existing immune reactivity without evidence for disease",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/South Carolina/1/1918(H1N1))",59375,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/South Carolina/1/1918(H1N1))",59375,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,5,100,"Table 3",Positive,NULL,NULL,124
1551141,18716625,1013152,9606,"91-101 years","Exposure with existing immune reactivity without evidence for disease",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/South Carolina/1/1918(H1N1))",59375,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/South Carolina/1/1918(H1N1))",59375,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,5,100,"Table 3",Positive,NULL,NULL,124
1584157,3469323,1008942,10000652,"8-12 weeks","Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses using a total of 0.1 mg peptide conjugates, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",YSQFEKSY,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Friend murine leukemia virus",11795,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,0,0,"Table 1",Negative,NULL,NULL,125
1581668,9525458,1005213,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"3 doses of 20 to 60 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",KVLTTGLPALISW,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,melittin,7460,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1581678,9525458,1005213,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","3 doses of 20 to 60 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",IEDNWYTHYLVCNYGPGGND,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Venom allergen 5.01",7441,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive-Low,NULL,NULL,326
1653646,18316151,1012958,10000658,"7–8 weeks","Administration in vivo to cause disease",NULL,"Percutaneous/Skin patch","3 dose of 75 μl of 1% DNCB","Accession Non-Sequence Molecule","Other Non-Sequence","1-chloro-2,4-dinitrobenzene",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence","1-chloro-2,4-dinitrobenzene",NULL,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Table 5",Positive-Intermediate,NULL,NULL,356
1653647,18316151,1012958,10001041,"7–8 weeks","Administration in vivo to cause disease",NULL,"Percutaneous/Skin patch","3 doses of 75 μl of 1% DNCB","Accession Non-Sequence Molecule","Other Non-Sequence","1-chloro-2,4-dinitrobenzene",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence","1-chloro-2,4-dinitrobenzene",NULL,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Table 5",Positive-High,NULL,NULL,356
1653627,18316151,1012958,10000658,"7–8 weeks","Administration in vivo to cause disease",NULL,"Percutaneous/Skin patch","1 dose of 300 μl of 1% DNCB and a 2nd dose of 150μl 0.5% DNCB","Accession Non-Sequence Molecule","Other Non-Sequence","1-chloro-2,4-dinitrobenzene",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence","1-chloro-2,4-dinitrobenzene",NULL,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 1, Tables 2, 3 and 4",Negative,NULL,NULL,356
1496249,18458072,1012335,10000000,NULL,"Administration in vivo",";Freund's complete;",NULL,NULL,"Accession Sequence Molecule",Protein,"immunodominant antigen Gp43",121759,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Paracoccidioides brasiliensis Pb18",502780,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 3 to 6.",Positive,NULL,NULL,125
1488884,18511159,1012318,10000000,"6-8 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","2 doses of 100 ug, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,"Recombinant Organism","Recombinant Organism",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/WSN/1933(H1N1))",382835,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figures 3-6",Positive,NULL,NULL,559
1656907,86500,1005767,10000228,NULL,"Administration in vivo",NULL,"Intravenous (i.v.)","4 doses administered daily","Accession Non-Sequence Molecule","Other Non-Sequence","2,4,6-trinitrophenyl group",NULL,"Complexed Molecule","Protein conjugate",NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","2,4,6-trinitrophenyl group",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure  4",Positive,NULL,NULL,361
1553890,11257359,1011481,10000000,"6-9 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TVKTKNTTTTQTQPSKPTTKQRQNKPPNKPNNDFHFEVFNFVPCSICSNN...,NULL,"Complexed Molecule","Protein conjugate","Chain A, Solution Structure Of The Albumin Binding Domain Of Streptococcal Protein G (Streptococcus sp. 'group G')",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive-High,NULL,NULL,559
1553891,11257359,1011481,10000000,"6-9 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TVKTKNTTTTQTQPSKPTTKQRQNKPPNKPNNDFHFEVFNFVPCSICSNN...,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,559
1556110,11257359,1011481,10000000,"6-9 weeks","Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TVKTKNTTTTQTQPSKPTTKQRQNKPPNKPNNDFHFEVFNFVPCSICSNN...,NULL,"Complexed Molecule","Protein conjugate","Chain A, Solution Structure Of The Albumin Binding Domain Of Streptococcal Protein G (Streptococcus sp. 'group G')",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,559
1556165,11257359,1011481,10000000,NULL,"Administration in vivo",NULL,"Intraperitoneal (i.p.)","2-3 times at 2-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",VPCSICSNNPTCWAICK,NULL,"Complexed Molecule","Protein conjugate","Chain A, Solution Structure Of The Albumin Binding Domain Of Streptococcal Protein G (Streptococcus sp. 'group G')",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive-High,NULL,NULL,125
1556109,11257359,1011481,10000000,"6-9 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TVKTKNTTTTQTQPSKPTTKQRQNKPPNKPNNDFHFEVFNFVPCSICSNN...,NULL,"Complexed Molecule","Protein conjugate","Chain A, Solution Structure Of The Albumin Binding Domain Of Streptococcal Protein G (Streptococcus sp. 'group G')",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",6,3,50,"Figure 1",Positive,NULL,NULL,559
1556162,11257359,1011481,10000000,NULL,"Administration in vivo",NULL,"Intraperitoneal (i.p.)","2-3 times at 2-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",PNKKPGKKTTTKPTK,NULL,"Complexed Molecule","Protein conjugate","Chain A, Solution Structure Of The Albumin Binding Domain Of Streptococcal Protein G (Streptococcus sp. 'group G')",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive-High,NULL,NULL,125
1584704,11257359,1011481,10000000,NULL,"Administration in vivo",NULL,"Intraperitoneal (i.p.)","2-3 times at 2-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",HFEVFNFVPCSIC,NULL,"Complexed Molecule","Protein conjugate","Chain A, Solution Structure Of The Albumin Binding Domain Of Streptococcal Protein G (Streptococcus sp. 'group G')",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human respiratory syncytial virus A strain Long",11260,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive-High,NULL,NULL,125
1326417,9693060,1002155,10090,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"1 dose of 9.7 ng, 39 ng, 156 ng, 625,ng, 2.5 μg or 10 μg polypeptide.","Fragment of a Natural Sequence Molecule","Peptide from protein",NKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTS...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Clostridium botulinum",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,10,100,"Figure 4",Positive,NULL,NULL,124
1772946,16891413,1011666,10001041,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);Ribi;",NULL,"5 doses over 12 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",QQRKESKKPPAKLQPR,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"appetite-regulating hormone preproprotein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1246104,11040127,1001180,447135,"4-10 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 dose(s) of 50 ug recombinant proteins","Fragment of a Natural Sequence Molecule","Peptide from protein",MSDLTDIQEEITRHEQQLVVARQKLKDAERAVEVDPDDVNKSTLQ,NULL,"Complexed Molecule","Protein conjugate","core [Hepatitis B virus] (Hepatitis B virus)",NULL,NULL,NULL,Organism,Organism,"Puumala virus Kazan",10000484,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,4,80,"Table 1",Positive,NULL,NULL,125
1338885,10531206,1002701,10090,NULL,"Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","Three injections (25 μg MAP/injection)","Fragment of a Natural Sequence Molecule","Peptide from protein",GFSPEEMEAVASKFR,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii",5861,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,3,37.5,"Table 2",Positive,NULL,NULL,125
1338992,10531206,1002701,10000253,NULL,"Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","Two injections (25 μg peptide/injection) and one challenge","Fragment of a Natural Sequence Molecule","Peptide from protein",GFSPEEMEAVASKFR,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",GFSPEEMEAVASKFR,NULL,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",9,9,100,"Table 4",Positive,NULL,NULL,125
1338902,10531206,1002701,10000253,NULL,"Administration in vivo to prevent or reduce disease",;TiterMax;,"Subcutaneous (s.c.)","Three injections (25 μg peptide/injection) and one challenge","Fragment of a Natural Sequence Molecule","Peptide from protein",SFPMNEESPLGFSPE,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",SFPMNEESPLGFSPE,NULL,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table 4",Positive,NULL,NULL,125
1377132,15980398,1003837,9986,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",VDVPNGRGDSLAYGLRS,NULL,NULL,NULL,NULL,Polyclonal,"Purified Immunoglobulin","Entire Antibody",Organism,Organism,"Candida albicans",5476,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 1",Negative,NULL,NULL,124
1338446,9466309,1002648,10090,"5-8 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","Mice were immunized at the base of the tail with 30 µg of MAP4-Py1T-Py3 in CFA and boosted twice with 30 µg of conjugate in IFA at 2 weeks and 3-4 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",QGPGAPQGPGAPQGPGAP,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium yoelii nigeriensis",31274,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 4",Negative,NULL,NULL,125
1510660,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",CHTTATIPSSAVTC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive,NULL,NULL,125
1510663,8760280,1011495,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","6 doses of 50 ug every 2 or 3 weeks","Sequence Molecule No Natural Source","Peptide, no natural source",CKMWADAFTSSRGKVVECG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3, Table 1",Positive,NULL,NULL,125
1341470,14985134,1002891,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,3,"Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYEEQPHIS,NULL,NULL,NULL,NULL,Polyclonal,Serum,Fab,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Table 1",Positive,NULL,NULL,125
1383504,1718244,1004041,9913,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);",Intramuscular,1,"Fragment of a Natural Sequence Molecule","Peptide from protein",RHKQKIVAPVKQTL,NULL,"Complexed Molecule","Peptide conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Bovine herpesvirus type 1.1 (strain Cooper)",10323,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Results, page 13.",Positive,NULL,NULL,125
1383503,1718244,1004041,9913,NULL,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);",Intramuscular,1,"Fragment of a Natural Sequence Molecule","Peptide from protein",VPNLRGDLQVLAQKVART,NULL,"Complexed Molecule","Peptide conjugate",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Bovine herpesvirus type 1.1 (strain Cooper)",10323,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Results, page 13.",Positive,NULL,NULL,125
1707264,15725571,1007006,10000206,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"5 doses of 70 ug on days 0, 7, 49, 70, 92","Fragment of a Natural Sequence Molecule","Peptide from protein",WTQEPQPLEEKWQHRVVEQIP,NULL,"Complexed Molecule","Peptide conjugate","glutathione-S-transferase linked to RSILPYGDSMDRIEKDRLQGMAP (Collagen alpha-1(XVII) chain, Homo sapiens)",Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Bullous pemphigoid antigen 1, isoforms 6/7",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",7,7,100,"Table 1, Figures 4, 5, 6",Positive,NULL,NULL,356
1581669,9525458,1005213,10000000,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","3 doses of 20 to 60 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",KNEILKRHNDFRQNVAKGLE,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Venom allergen 5.01",7441,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,326
1581672,9525458,1005213,10000000,"8-10 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"3 doses of 20 to 60 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",KVLTTGLPALISW,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,melittin,7460,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1702602,9627002,1006838,10000662,NULL,"Administration in vivo",NULL,Intranasal,"60 µg daily for ten days","Fragment of a Natural Sequence Molecule","Peptide from protein",VELIPSTSSAVPLIGKY,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Acetylcholine receptor subunit alpha",10116,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Negative,NULL,NULL,361
1488481,17881450,1007632,9598,NULL,"Administration in vivo",NULL,NULL,NULL,Organism,Organism,"Dengue virus 4 Dominica/814669/1981",408871,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 4 Philippines/H241/1956",408686,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Table 2",Positive,NULL,NULL,124
1488482,17881450,1007632,9598,NULL,"Administration in vivo",NULL,NULL,NULL,Organism,Organism,"Dengue virus 4 Dominica/814669/1981",408871,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 4 Dominica/814669/1981",408871,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",4,4,100,"Tables 4 and 5",Positive,NULL,NULL,124
1483736,2479714,1009958,10000668,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 500 µg epitope at an interval of 35 days","Sequence Molecule No Natural Source","Peptide, no natural source",VPNLRGDSQVLAQKVARTLP,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1BFS 1860)",10000514,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,2,66.7,"Table 4",Positive,NULL,NULL,125
1483737,2479714,1009958,10000668,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,"2 doses of 500 µg epitope at an interval of 35 days","Sequence Molecule No Natural Source","Peptide, no natural source",VPNLRGDSQVLAQKVARTLP,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Foot-and-mouth disease virus (strain A12)",12114,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,3,75,"Table 4",Positive,NULL,NULL,125
2444891,25933001,1028955,10000206,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 200ug VLP-epitope at 6-week interval","Fragment of a Natural Sequence Molecule","Peptide from protein",NANPNVDPNANPNANPNANP,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus) linked to EYLNKIQNSLSTEWSPCSVT (circumsporozoite protein, Plasmodium falciparum)",NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,2,100,"Figure 3B,C",Positive,NULL,NULL,125
1645678,10385589,1014021,10000000,"6-8 weeks","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","7 doses of 10 μg on alternate days.","Accession Sequence Molecule",Protein,ovalbumin,9031,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,ovalbumin,9031,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 3 to 6",Negative,NULL,NULL,326
2094851,24269767,1027332,10000000,"6-8 weeks","Administration in vivo",NULL,"Intraperitoneal (i.p.)","1 dose of 250 ug on day 0, then 2 more doses of 100 ug on days 10 and 20.","Accession Sequence Molecule",Protein,"ricin A chain",3988,"Complexed Molecule","Protein conjugate","ricin B chain (Ricinus communis)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"ricin A chain",3988,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Table 2",Positive,NULL,NULL,125
2742524,26905804,1030057,10000000,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses at intervals of 3 weeks",Organism,Organism,"Dengue virus 2 strain 43",10001705,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 4 strain B5",10001706,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 6, 7 and 8",Positive,NULL,NULL,124
1585277,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",RYDSRPPEDVF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Negative,NULL,NULL,125
1585335,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",RANPNPYTSRRSV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Negative,NULL,NULL,125
1585363,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",RVYHNGITGET,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Negative,NULL,NULL,125
1585318,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",TSSSRRYTEVYL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Positive,NULL,NULL,125
1585370,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",GTLVRMAPVIG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Positive,NULL,NULL,125
1585356,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",RIPPENIRRVT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Negative,NULL,NULL,125
1585349,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",RILAGALATYQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Negative,NULL,NULL,125
1585342,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",GAASSYFEYVDTYG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Positive,NULL,NULL,125
1585313,2480389,1009336,10000000,"4-5 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","2 doses of 5 ug at days 1 and 10","Fragment of a Natural Sequence Molecule","Peptide from protein",DNVLDHLTGRSC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"pertussis toxin S1 subunit",520,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table IV",Negative,NULL,NULL,125
1509121,9499101,1006618,9685,"4 month old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","5 doses of 120 μg of FIV peptide (approximately 250 μg of KLH-coupled peptide)","Fragment of a Natural Sequence Molecule","Peptide from protein",RAISSWKQRNRWEWRPD,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Feline immunodeficiency virus (isolate wo)",45409,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Figures 3 and  4",Negative,NULL,NULL,125
1584153,3469323,1008942,10000652,"8-12 weeks","Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses using a total of 0.1 mg peptide conjugates, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",PAGTGDRL,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Friend murine leukemia virus",11795,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,2,28.6,"Table 1",Positive,NULL,NULL,125
1584149,3469323,1008942,10000652,"8-12 weeks","Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses using a total of 0.1 mg peptide conjugates, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",SHRPREAK,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Friend murine leukemia virus",11795,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,1,20,"Table 1",Positive,NULL,NULL,125
1584146,3469323,1008942,10000652,"8-12 weeks","Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses using a total of 0.1 mg peptide conjugates, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",SPHQVYN,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Friend murine leukemia virus",11795,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,125
1503810,18061317,1013348,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Two immunizations given 2 weeks apart","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",8,7,87.5,"Figure 5",Positive,NULL,NULL,124
1796347,2962946,1019547,10000220,"6-12 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Intraperitoneal (i.p.)",NULL,"Accession Non-Sequence Molecule","Other Non-Sequence","trimellityl group",NULL,"Complexed Molecule","Protein conjugate","Ovalbumin (Gallus gallus)",Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence","trimellityl group",NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Tables I, III, IV and Figure 1",Positive,NULL,NULL,361
1601237,1705242,1013958,10000206,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"2 doses of 0.5 to 1.0 mg, administered at intervals of 4 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",ELFTNRWNLQSLL,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"shiga toxin 1B",562,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",2,1,50,"Table 1",Positive,NULL,NULL,124
1500630,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",SASRSCIGSQCSTTA,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,124
1500633,10814583,1006488,10000067,"4-5 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","4 doses of phage in adjuvant, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",GCIGSYCV,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Murine hepatitis virus strain A59",11142,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 4",Negative,NULL,NULL,124
2382087,25381487,1028606,9913,"1 year","Administration in vivo",NULL,Intramuscular,"2 doses of 100ug, administered 21 days apart.","Sequence Molecule No Natural Source","Peptide, no natural source",VYNGTCKYSAPATRRGDLGSLAARLAACLPASFNYGAIRAT,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing YDLDFEALKPHFKSLGQTITPADKSPPSVYNGTCKYSAPATRRGDLGSLA... ",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus A/HuBWH/CHA/2009",10002131,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,7,35,"Table 4",Positive,NULL,NULL,125
1587776,2457635,1012809,9986,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"Three injections of 100 ug at 2-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",RIKNTDGSIS,NULL,"Complexed Molecule","Protein conjugate","Ovalbumin (Gallus gallus)",Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Toxic shock syndrome toxin-1 precursor",1280,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,124
1585484,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1BFS)",10000515,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",18,0,0,"Table 2",Negative,NULL,NULL,125
1585485,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,14,70,"Table 2",Positive,NULL,NULL,125
1585480,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIIAPAKQLLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1BFS)",10000515,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,9,45,"Table 2",Positive,NULL,NULL,125
1585476,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1BFS)",10000515,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,10,50,"Table 2",Positive,NULL,NULL,125
1585477,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,5,25,"Table 2",Positive,NULL,NULL,125
1593309,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.008 to 1.0 mg","Sequence Molecule No Natural Source","Peptide, no natural source",GSGRRGDMGSLAARVVKQGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) Kaufbeuren",10000556,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,0,0,"Table 1",Negative,NULL,NULL,125
1593310,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.008 to 1.0 mg","Sequence Molecule No Natural Source","Peptide, no natural source",GSGRRGDMGSLAARVVKQGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,14,70,"Table 1",Positive,NULL,NULL,125
1593304,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.008 to 1.0 mg","Sequence Molecule No Natural Source","Peptide, no natural source",VPNLRGDLQVLAQKVARTVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,0,0,"Table 1",Negative,NULL,NULL,125
1593303,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 0.008 to 1.0 mg","Sequence Molecule No Natural Source","Peptide, no natural source",VPNLRGDLQVLAQKVARTVPNLRGDLQVLAQKVARTPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) Kaufbeuren",10000556,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,17,85,"Table 1",Positive,NULL,NULL,125
1585488,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIIAPAKQLLPPSGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain O1) (O1BFS)",10000515,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",19,0,0,"Table 2",Negative,NULL,NULL,125
1553685,18524882,1013417,10000067,"6-8 weeks","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","1 dose of 3x10<sup>4</sup> CFU",Organism,Organism,"Cryptococcus neoformans var. neoformans Serotype D",10001120,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule",Carbohydrate,glucuronoxylomannan,10001120,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1, 2, 3A, 4 and 5",Positive,NULL,NULL,326
1553686,18524882,1013417,10000000,"6-8 weeks","Administration in vivo to cause disease",NULL,"Intravenous (i.v.)","1 dose of 200 CFU",Organism,Organism,"Cryptococcus neoformans var. neoformans Serotype D",10001120,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Cryptococcus neoformans var. neoformans Serotype D",10001120,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3C",Positive,NULL,NULL,124
1553482,18524882,1013417,10000000,"6-8 weeks","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","1 dose of 3x10<sup>4</sup> CFU",Organism,Organism,"Cryptococcus neoformans var. neoformans Serotype D",10001120,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule",Carbohydrate,glucuronoxylomannan,10001120,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1, 2, 3A, 4 and 5",Positive,NULL,NULL,326
1678691,6175660,1005630,10000206,NULL,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 200 ug, administered at intervals of 6 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",YGSLPQKAQGHRPQDE,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin basic protein",9986,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Text page 212",Negative,NULL,NULL,356
1498929,7483766,1013026,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 50ug, administered at intervals of 3  weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",GTLVKTITDDQIEV,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Influenza A virus (A/X-31(H3N2))",132504,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",12,1,8.3,"Table 2, figure 2, 3 and 4",Positive-Low,NULL,NULL,124
1498931,7483766,1013026,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 50ug, administered at intervals of 3  weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",ACKRGPGSGFFSRLN,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Influenza A virus (A/X-31(H3N2))",132504,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",12,0,0,"Table 2, figure 2, 3 and 4",Negative,NULL,NULL,124
1594593,7494275,1006629,10000000,"6 weeks","Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","1 doses of 50ug.","Sequence Molecule No Natural Source","Peptide, no natural source",NIIRTKKQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Measles virus CAM/RB",10000462,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 5",Positive,NULL,NULL,124
1799305,8419487,1006799,10000000,"2-4 months","Administration in vivo",NULL,"Intraperitoneal (i.p.)","1 dose of bacteria",Organism,Organism,"Streptococcus pneumoniae WU2",880525,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus pneumoniae WU2",880525,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,5,50,"Figures 2, 3, 6",Positive,NULL,NULL,125
1799346,8419487,1006799,10000000,"2-4 months","Administration in vivo",NULL,"Intraperitoneal (i.p.)","1 dose of bacteria",Organism,Organism,"Streptococcus pneumoniae WU2",880525,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Streptococcus pneumoniae WU2",880525,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",16,4,25,"Figure 5",Positive,NULL,NULL,125
2370895,25379726,1028381,10000000,"4 to 6 week","Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"3 doses of 10 µg, administered at intervals of 2 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",IGMSQSK,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus",1280,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Negative,NULL,NULL,125
1595142,2448796,1006430,10000000,"16 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",LHYTAVVKKSSAV,NULL,"Complexed Molecule","Protein conjugate","Thyroglobulin (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",15,0,0,"Tables 1, 3",Negative,NULL,NULL,125
1595132,2448796,1006430,10000000,"16 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",PQGQGKVT,NULL,"Complexed Molecule","Protein conjugate","Thyroglobulin (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Escherichia coli",562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",11,11,100,"Tables 1, 3",Positive,NULL,NULL,125
1636233,15908227,1014402,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 100 ug on day 1 with CFA, then 2 weeks later with IFA , then at 3 weeks without adjuvant","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 3, 4, 5, 6",Positive,NULL,NULL,326
1598982,19300497,1013929,10000000,"6 weeks","Administration in vivo",";Cholera toxin;",Intranasal,"3 doses of 100 µg formalin inactivated virus at a 2-week interval",Organism,Organism,"Influenza A virus (A/Aichi/2/1968(H3N2))",387139,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Aichi/2/1968(H3N2))",387139,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1599015,19300497,1013929,10000000,"6 weeks","Administration in vivo",";Cholera toxin;",Intranasal,"3 doses of 100 µg formalin inactivated virus at a 2-week interval",Organism,Organism,"Influenza A virus (A/Aichi/2/1968(H3N2))",387139,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/WSN/1933(H1N1))",382835,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1597859,19070878,1013937,10000000,"4 to 6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 20ug i.p. and 2 booster injections of 10ug i.v., administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPIRNEWGCRCNDSSD,NULL,"Complexed Molecule","Protein conjugate","class one outer membrane protein (Neisseria meningitidis)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Puerto Rico/8/1934(H1N1))",211044,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,124
1657201,9268157,1006624,9913,"8-12 months","Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"Two doses of 50 ug peptide.","Fragment of a Natural Sequence Molecule","Peptide from protein",EVTIGDIEEPPILEVVPETH,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Bovine papillomavirus type 4",10562,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,2,33.3,"Figures 1 and 2",Positive,NULL,NULL,125
1989831,23625724,1026782,10000000,"4 to 5 weeks","Administration in vivo",;CpG;,Intramuscular,"2 doses of 20 µg, administered at intervals of 28 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",LVALENQHTIDLTDSEMNKLFEKTRRQLRENA,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Hong Kong/1/1968(H3N2))",506350,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Table II and Figure 6",Negative,NULL,NULL,124
1679728,15093551,1015732,10000067,"6 to 8 weeks","Administration in vivo to prevent or reduce disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)","2 doses of 100µg, administered at intervals of 7 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive-High,NULL,NULL,361
1641533,15596606,1014405,10001286,"2 months","Administration in vivo to prevent or reduce disease",NULL,Other,"4 doses of 8ug DNA, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"amyloid beta (A4) precursor protein",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,326
2445144,25933001,1028955,10000067,NULL,"Administration in vivo",";Montanide ISA 720;","Intraperitoneal (i.p.)","2 doses of VLP-epitope: 20ug and then 10ug","Fragment of a Natural Sequence Molecule","Peptide from protein",NANPNVDPNANPNANPNANP,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus) linked to EYLNKIQNSLSTEWSPCSVTSGNGIQVRIKPGSANKPKDELDYENDIEKK... ",NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figure 5A, 6, S1 Table",Positive-High,NULL,NULL,125
2445143,25933001,1028955,10000067,NULL,"Administration in vivo",";Montanide ISA 720;","Intraperitoneal (i.p.)","2 doses of VLP-epitope: 20ug and then 10ug","Fragment of a Natural Sequence Molecule","Peptide from protein",NANPNANPNANPNANPNANP,NULL,"Complexed Molecule","Protein conjugate","Core antigen (Woodchuck hepatitis virus)",NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figure 5A",Positive-High,NULL,NULL,125
1636263,12151510,1014403,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,"Complexed Molecule","Peptide conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3",Positive,NULL,NULL,326
1685359,16393332,1016763,9606,"14-42 years","Occurrence of allergy",NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence",amoxicillin,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence",amoxicillin,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Tables 2, 3",Negative,NULL,NULL,326
1690198,1693637,1015727,10000206,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 4 mg peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",DMGHGLRLIHYSYDVNSTEKG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1598499,19109379,1013936,10000000,"4-6 weeks","Administration in vivo",";Seppic ISA 720;","Subcutaneous (s.c.)","3 doses of 25 &microg","Accession Sequence Molecule",Protein,hemagglutinin,165512,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Viet Nam/1203/2004(H5N1))",284218,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 3, 4, and 5",Positive,NULL,NULL,124
1599320,19109379,1013936,10000000,"4-6 weeks","Administration in vivo",";Seppic ISA 720;","Subcutaneous (s.c.)","3 doses of 25 &microg","Accession Sequence Molecule",Protein,hemagglutinin,165512,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Viet Nam/1203/2004(H5N1))",284218,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 3 and 4",Positive-Low,NULL,NULL,124
1599322,19109379,1013936,10000000,"4-6 weeks","Administration in vivo",";Seppic ISA 720;","Subcutaneous (s.c.)","3 doses of 25 &microg","Accession Sequence Molecule",Protein,hemagglutinin,165512,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Indonesia/TLL013/2006(H5N1))",472517,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 3, 4, and 6",Positive-Low,NULL,NULL,124
1599070,19109379,1013936,10000000,"4-6 weeks","Administration in vivo",";Seppic ISA 720;","Subcutaneous (s.c.)","3 doses of 25 &microg","Accession Sequence Molecule",Protein,hemagglutinin,165512,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Indonesia/TLL013/2006(H5N1))",472517,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 3, 4, and 6",Positive,NULL,NULL,124
2475712,26201558,1029206,10000000,"6 to 8 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",NULL,"several doses of 100 µg, administered at intervals of 3 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",KHKNLYEFNSSPYETGYI,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus subsp. aureus MRSA252",282458,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,7,70,"Figure 2",Positive,NULL,NULL,124
1604038,19015042,1013685,10000013,"6-8 weeks","Administration in vivo",";Montanide ISA-51;","Subcutaneous (s.c.)","Three doses of 50 μg at 20 day intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KQISSQLTEEWSQGPGAPQGPGAPQGPGAPSYVPSAEQI,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii",5861,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figure 5",Positive,NULL,NULL,125
1604039,19015042,1013685,10000000,"6-8 weeks","Administration in vivo",";Montanide ISA-51;","Subcutaneous (s.c.)","Three doses of 50 μg at 20 day intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KQISSQLTEEWSQGPGAPQGPGAPQGPGAPSYVPSAEQI,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii",5861,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,5,83.3,"Figure 5",Positive,NULL,NULL,125
1684241,8583237,1015211,9606,"32 to 66 years","Occurrence of autoimmune disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Polyclonal,"Cerebrospinal fluid (CSF)","Entire Antibody","Accession Sequence Molecule",Protein,"Myelin basic protein",9606,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figures 3, 4, 5, 6, and 7",Positive,NULL,NULL,361
1785833,6163199,1012194,10000631,NULL,"Administration in vivo",";Freund's complete;","Intraperitoneal (i.p.)","3 doses of 5 ug and 2 doses of 10 ug conjugate","Fragment of a Natural Non-Sequence Molecule","Carbohydrate fragment",[(->3)-alpha-D-Galp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->)]2,NULL,"Complexed Molecule","Protein conjugate","diphtheria toxin (Corynebacterium diphtheriae)",NULL,NULL,NULL,Organism,Organism,"Salmonella typhimurium SH 4809",10000742,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 4",Positive,NULL,NULL,125
1621145,19032063,1013938,10000000,"6 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)",NULL,Organism,Organism,"H5N1 subtype",102793,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"H5N1 subtype",102793,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 1, 2, 3, 4 and Table 2",Positive,NULL,NULL,124
1621146,19032063,1013938,10000000,"6 weeks","Administration in vivo",NULL,"Subcutaneous (s.c.)",NULL,Organism,Organism,"H5N1 subtype",102793,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"H5N1 subtype",102793,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figures 1, 2, 3, 4 and Table 2",Positive,NULL,NULL,124
1667050,709786,1016068,9606,"72 years","Occurrence of allergy",NULL,NULL,NULL,"Accession Non-Sequence Molecule","Other Non-Sequence",penicillin,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule","Other Non-Sequence",benzylpenicillin,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",1,0,0,"Table 1",Negative,NULL,NULL,326
1276329,11195972,1001432,10000618,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,"3 doses 2 wks apart with 15 μg protein.","Fragment of a Natural Sequence Molecule","Peptide from protein",PFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTF...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,0,0,"Table 1",Negative,NULL,NULL,124
1333058,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MIKVGFHPTGAFKSPRWKSH,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Table 1",Negative,NULL,NULL,125
1333078,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",MTDVNRYRYSNNYERPHIS,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 1",Negative,NULL,NULL,125
1333070,15865420,1002270,37293,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 125 µg of peptide polymer in CFA s.c. followed by two boosts of the same in IFA at 20 days intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",KIMSKWVNTFNINAYIMSNF,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",3,0,0,"Table 1",Negative,NULL,NULL,125
1004105,1376012,1000166,10000000,"8-12 weeks-old","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"Three booster injections were given at 14 day intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",SKAFSNCYPYDVPDYASL,NULL,"Recombinant Organism","Recombinant Organism",NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/Texas/1/1977(H3N2))",444318,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6, 7",Positive,NULL,NULL,125
1418361,12704369,1005439,9606,NULL,"Occurrence of allergy",NULL,NULL,NULL,"Derivative of Organism","Product of Organism","Venom from Apis mellifera",7460,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",LIDTKCYKLEHPVTGCGERTEGRCLHYTVDKSKPKVYQWFDLRKY,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,326
2621187,26559836,1029815,10000618,"4 weeks","Administration in vivo",NULL,"Intraperitoneal (i.p.)","2 doses of 10^5 PFU","Fragment of a Natural Sequence Molecule","Peptide from protein",YPTFGEHKQEKDLEY,NULL,"Recombinant Organism","Recombinant Organism","Japanese encephalitis virus",NULL,NULL,NULL,Organism,Organism,"Enterovirus A71 Tainan/4643/98",10002055,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",30,18,60,"Figure 6",Positive,NULL,NULL,124
1488798,11581167,1012827,10000067,"6-8 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 50 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",SNYCQIYPPNANKIR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Der p 1 allergen precursor",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,326
1488721,11581167,1012827,10000067,"6-8 weeks","Administration in vivo to prevent or reduce disease",NULL,Intranasal,"1 dose of 50 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",SNYCQIYPPNANKIR,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Der p 1 allergen precursor",6956,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2, Table 1, Figure 6",Positive,NULL,NULL,326
1276434,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",QLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTI...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",8,0,0,"Table 1",Negative,NULL,NULL,124
1276324,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",VNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTN...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,1,10,"Table 1",Negative,NULL,NULL,124
1335771,3479809,1002454,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);Saponin;","Intraperitoneal (i.p.)","Mice were immunized with 100 µg of conjugate in CFA or saponin and boosted every other week with 50 µg of conjugate in IFA or saponin.","Fragment of a Natural Sequence Molecule","Peptide from protein",QQPPQQPPQQPPQQPP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii yoelii 17XNL",352914,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,1,5,"Table 1 and Figure 5",Negative,NULL,NULL,125
1335780,3479809,1002454,10000000,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);Saponin;","Intraperitoneal (i.p.)","Mice were immunized with 100 µg of conjugate in CFA or saponin and boosted every other week with 50 µg of conjugate in IFA or saponin.","Fragment of a Natural Sequence Molecule","Peptide from protein",EEKKDDPPKDPKKDDPPKEA,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii yoelii 17XNL",352914,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,1,16.7,"Table 1 and Figure 5",Negative,NULL,NULL,125
1480929,11137253,1008107,10000191,"12 months old","Administration in vivo",;Other;,Intradermal,"Two doses of 2 mg peptide in oil adjuvant.","Fragment of a Natural Sequence Molecule","Peptide from protein",AGARRGDLAHLAAAHARHLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,4,20,"Table 1",Positive,NULL,NULL,125
1480930,11137253,1008107,10000191,"12 months old","Administration in vivo",;Other;,Intradermal,"Two doses of 2 mg peptide in oil adjuvant.","Sequence Molecule No Natural Source","Peptide, no natural source",ETQTQRRHHTDVAFVLDRFVAGARRGDLAHLAAAHARHLPC,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",7,1,14.3,"Table 1",Positive,NULL,NULL,125
1473535,7539410,1007709,10116,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);",Intramuscular,"4, administered at intervals of 2 weeks; first dose was 1000 micrograms and remaining doses were 500 micrograms.","Fragment of a Natural Sequence Molecule","Peptide from protein",NATAEGRAINRRVE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,NULL,NULL,Organism,Organism,"Pseudomonas aeruginosa Immunotype 6",10000823,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 1",Positive,NULL,NULL,125
2765023,26710081,1030059,10116,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,polyprotein,63746,"Recombinant Organism","Recombinant Organism","unidentified baculovirus",NULL,NULL,NULL,Organism,Organism,"Hepatitis C virus subtype 1b",31647,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 6 and Supplementary Table 1",Negative,NULL,NULL,559
2765025,26710081,1030059,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"envelope glycoprotein E2",11103,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Hepatitis C virus subtype 1b",31647,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 6 and Supplementary Table 1",Positive,NULL,NULL,559
2765028,26710081,1030059,10116,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,polyprotein,63746,"Recombinant Organism","Recombinant Organism","unidentified baculovirus",NULL,NULL,NULL,Organism,Organism,"Hepatitis C virus subtype 1b",31647,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 6 and Supplementary Table 1",Negative,NULL,NULL,559
2765030,26710081,1030059,10116,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,polyprotein,63746,"Recombinant Organism","Recombinant Organism","unidentified baculovirus",NULL,NULL,NULL,Organism,Organism,"Hepatitis C virus subtype 1b",31647,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 6 and Supplementary Table 1",Negative,NULL,NULL,559
1380777,2476893,1004733,9598,NULL,"Administration in vivo to prevent or reduce disease",;MLP+TDM;,NULL,7,"Fragment of a Natural Sequence Molecule","Peptide from protein","MGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNP + MYRI(G12)",NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,NULL,Organism,Organism,"Hepatitis B virus subtype adw2",10408,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",2,1,50,"Figure 2",Positive,NULL,NULL,125
1481388,9060612,1006716,10000190,"12 months old","Administration in vivo",;Other;,Intradermal,"Two doses of peptide in oil adjuvant.","Sequence Molecule No Natural Source","Peptide, no natural source",ETQTQRRHHTDVAFVLDRFVAGARRGDLAHLAAAHARHLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,NULL,NULL,"Tables 3, 5 and 7",Positive,NULL,NULL,125
1481318,9060612,1006716,10000191,"12 months old","Administration in vivo",;Other;,Intradermal,"Two doses of peptide in oil adjuvant.","Fragment of a Natural Sequence Molecule","Peptide from protein",AGARRGDLAHLAAAHARHLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",34,NULL,NULL,"Tables 3, 5 and 7",Positive,NULL,NULL,125
1481369,9060612,1006716,10000191,"12 months old","Administration in vivo",;Other;,Intradermal,"Two doses of peptide in oil adjuvant.","Fragment of a Natural Sequence Molecule","Peptide from protein",AGVRRGDLAHLAAAHARHLP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus C3",46290,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",18,5,27.8,"Tables 4 and 5",Positive,NULL,NULL,125
1378539,1698994,1003951,10000028,"7 weeks old","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","several doses of 50 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",TGDPKPKKNKKPKNPTPPRP,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Human alphaherpesvirus 1",10298,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3",Positive,NULL,NULL,125
22182,10416374,1428,10141,NULL,"Administration in vivo to prevent or reduce disease",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","1 dose(s) of molar equivalent of 50 ug peptide in terms of peptide-BSA conjugate in 1 ml adjuvant","Fragment of a Natural Sequence Molecule","Peptide from protein",AVPNLRGDLQVLAQKVARTL,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus",12110,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,3,60,"Tables 1 and 2",Positive,NULL,NULL,125
1808852,12115661,1014554,10000032,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",GEPGIAGFKGEQGPK,NULL,"Complexed Molecule","Protein conjugate","procollagen, type 1, alpha 1, isoform CRA_b (Rattus norvegicus)",Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",10116,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Table I and Figure 6B",Positive,NULL,NULL,361
2367944,10698744,1186,10000000,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","3 doses of 2X10<sup>6</sup> FFU of VEE-GP at 1-month intervals","Accession Sequence Molecule",Protein,"surface glycoprotein GP",186538,"Recombinant Organism","Recombinant Organism","Venezuelan equine encephalitis virus",NULL,NULL,NULL,Organism,Organism,"Zaire ebolavirus",186538,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,10,100,"Table 1",Positive,NULL,NULL,124
2367949,10698744,1186,10000000,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","3 doses of 2X10<sup>6</sup> FFU of VEE-GP at 1-month intervals","Accession Sequence Molecule",Protein,"surface glycoprotein GP",186538,"Recombinant Organism","Recombinant Organism","Venezuelan equine encephalitis virus",NULL,NULL,NULL,Organism,Organism,"Zaire ebolavirus",186538,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",10,6,60,"Table 1",Positive,NULL,NULL,124
1634879,11438712,1006196,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",HHQKLVFFAEDVGSNK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3",Positive,NULL,NULL,326
1498932,7483766,1013026,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 50ug, administered at intervals of 3  weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",HHPSTNQEQTSLYVQAS,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Influenza A virus (A/X-31(H3N2))",132504,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",12,5,41.7,"Table 2, figure 2, 3 and 4",Positive-Intermediate,NULL,NULL,124
1498933,7483766,1013026,10000000,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 50ug, administered at intervals of 3  weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",GLFGAIAGFIE,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Influenza A virus (A/X-31(H3N2))",132504,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",11,8,72.7,"Table 2, figure 2, 3 and 4",Positive-High,NULL,NULL,124
2537893,26536114,1029584,9606,NULL,"Occurrence of infectious disease",NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus",1280,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Staphylococcus aureus",1280,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",8,0,0,"Figure 4 and Extended Data Figure 6 and 8",Negative,NULL,NULL,559
1482994,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",CDCDRTAA,NULL,"Complexed Molecule","Protein conjugate",NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,16,64,"Table 4",Positive,NULL,NULL,125
1482995,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",CFGNSEY,NULL,"Complexed Molecule","Protein conjugate",NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,19,76,"Table 4",Positive,NULL,NULL,125
1483006,9461548,1010189,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",YVHDNC,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-bungarotoxin A1 chain precursor",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",25,25,100,"Table 5",Positive,NULL,NULL,125
20420,11372026,1314,10000000,"8 wekks-old","Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Toxic shock syndrome toxin-1",1280,NULL,NULL,NULL,Monoclonal,NULL,NULL,"Accession Sequence Molecule",Protein,"Enterotoxin type A precursor",1280,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",15,15,100,"Figure 4",Positive,NULL,NULL,124
2113849,24962748,1028006,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);",Intramuscular,"3 doses of 5ug peptide plus VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",GTGGRTGYIPLGGRSNTVVDV,NULL,"Recombinant Organism","Recombinant Organism","Escherichia virus Qbeta",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 16",333760,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Figures 3A and 5",Negative,NULL,NULL,125
2882609,27624667,1030758,10000067,"6-8 weeks","Administration in vivo",NULL,Intradermal,"5 doses 50ug of synthetic peptide","Sequence Molecule No Natural Source","Peptide, no natural source",DPNANPNVDPNANPNVNANPNANPNANP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum",5833,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive,NULL,NULL,125
1548771,6425829,1007167,10000206,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","3 doses of 25 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",RKADLEKALEGAM,NULL,"Complexed Molecule","Protein conjugate","Tetanus toxin precursor (Clostridium tetani)",Polyclonal-Monospecific,Serum,"Entire Antibody",Organism,Organism,"Streptococcus pyogenes serotype M24",10000789,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",15,12,80,"Table 3",Positive,NULL,NULL,125
1641376,16908985,1009078,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3b",Negative,NULL,NULL,326
1641851,12566568,1010842,10001241,"12-13 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1642257,12566568,1010842,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1642072,12566568,1010842,10001241,"12-13 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,326
1642109,12566568,1010842,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1641684,12566568,1010842,10001241,"12-13 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1642071,12566568,1010842,10001241,"12-13 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,326
1642491,12559780,1014409,10001241,"16 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,326
1641373,16908985,1009078,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKL,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3b",Negative,NULL,NULL,326
1422392,16504346,1006257,9823,"8-10 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intramuscular,2,"Fragment of a Natural Sequence Molecule","Peptide from protein",ISSTNEI,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,Serum,NULL,Organism,Organism,"Classical swine fever virus Shimen",10000451,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1643847,1398737,1014678,10000054,"6-8 weeks","Administration in vivo to prevent or reduce disease",NULL,"Intravenous (i.v.)","1 dose of 500 µg epitope","Fragment of a Natural Sequence Molecule","Peptide from protein",IAGFKGEQGPK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,326
2621246,26657117,1029810,10000000,"6 to 8 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","3 doses of 100 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",KYAVTVETRLIDERAAHV,NULL,"Complexed Molecule","Protein conjugate","core (Hepatitis B virus) linked to HHHHHH",NULL,NULL,NULL,Organism,Organism,"Chlamydia trachomatis Serovar E",10000764,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 6",Positive,NULL,NULL,125
1643083,17850871,1011664,10001241,"2 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 5, 6",Positive,NULL,NULL,326
1702879,8683141,1016937,10116,NULL,"Administration in vivo",NULL,NULL,NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",NIHPKAPIWGIITSNF,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Acetylcholine receptor subunit alpha",10116,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,3,50,"Figure 3 and Table II",Positive,NULL,NULL,125
1645231,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",9031,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4, and 5",Positive,NULL,NULL,125
1645256,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,osteopontin,10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1645243,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",9031,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4, and 5",Positive,NULL,NULL,125
1645244,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,osteopontin,10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1645250,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,osteopontin,10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1645249,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",9031,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4, and 5",Positive,NULL,NULL,125
1645255,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",9031,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4, and 5",Positive,NULL,NULL,125
1645238,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,osteopontin,10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1645232,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,osteopontin,10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1645224,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",9031,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4, and 5",Positive,NULL,NULL,125
1645237,18576331,1014525,10090,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein",9606,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",9031,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 2, 4, and 5",Positive,NULL,NULL,125
1646670,16672644,1014397,10001241,"4.5 - 6 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 6 and 7",Positive,NULL,NULL,326
1908273,22197813,1022765,9504,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","3 doses of 125ug polymerized peptide","Sequence Molecule No Natural Source","Peptide, no natural source",MHNISQMQSVMKMSDQNS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Plasmodium falciparum FVO",10000369,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Figure 1A",Negative,NULL,NULL,125
1643650,18057195,1009688,10001279,NULL,"Administration in vivo",NULL,"Subcutaneous (s.c.)","50 ug of vaccine were formulated with Quil-A adjuvant with a 2-week interval before the first boost and monthly thereafter.","Sequence Molecule No Natural Source","Peptide, no natural source",DAEFRHDSGYEDAEFRHDSGYE,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1680791,8675697,1015712,10001395,"6-8 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intradermal,"100 ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",KGQGQKAKMRCIPEKGH,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"collagen, type II, alpha 1 isoform 2 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",6,2,33.3,"Table III",Positive-Low,NULL,NULL,326
1680841,8675697,1015712,10001395,"6-8 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intradermal,"100 ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",QTLDHNTMYWYKQDSKKLLKIM,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"collagen, type II, alpha 1 isoform 2 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",7,6,85.7,"Table III",Positive,NULL,NULL,326
1680844,8675697,1015712,10001395,"6-8 weeks","Administration in vivo to prevent or reduce disease",";Freund's complete;",Intradermal,"100 ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein",ATGGTLQQLFYSITVGQV,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"collagen, type II, alpha 1 isoform 2 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",6,1,16.7,"Table I",Positive-Low,NULL,NULL,326
1643638,16341263,1007004,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Chain A, Solution Structure Of The Alzheimer's Disease Amyloid Beta- Peptide (1-42)",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1646623,16341263,1007004,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Chain A, Solution Structure Of The Alzheimer's Disease Amyloid Beta- Peptide (1-42)",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 2, 3 and 4",Positive,NULL,NULL,326
1789284,10433087,1014740,10000218,"2-3 months","Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","1 dose of 200 ug followed by 2 doses of 100 ug at 2 week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",FGISETQAEAILE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"beta-crystallin A1",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",6,4,66.7,"Table III",Positive,NULL,NULL,356
1965539,23178262,1025375,7962,NULL,"Administration in vivo",NULL,NULL,"3 doses of 10E12 PFU, administered at intervals of 14 days.","Sequence Molecule No Natural Source","Peptide, no natural source",SVSEGMKPSPRP,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Vibrio mimicus",674,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",30,30,100,"Table 2",Positive,NULL,NULL,124
1965540,23178262,1025375,7962,NULL,"Administration in vivo",NULL,NULL,"3 doses of 10E12 PFU, administered at intervals of 14 days.","Sequence Molecule No Natural Source","Peptide, no natural source",FSSDSSKVHYPN,NULL,"Object Library","Phage display",NULL,NULL,NULL,NULL,Organism,Organism,"Vibrio mimicus",674,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",30,30,100,"Table 2",Positive,NULL,NULL,124
1653118,19435417,1014888,9986,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 50 µg followed by 2 booster injections in IFA at 2-week intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",LGSTAVSPTTLRGSTAVSPTTLRGSTAVSPTTLRGSTAVSPTTLRGS,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus - C",358812,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
2396846,25370295,1028762,10000000,"6 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","5 doses of 50 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",LQEMPLTALLRNLGKMT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Derivative of Organism","Anatomical Entity","Salivary Gland (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,356
1650254,16339574,1015135,10001309,"4 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 30 µ at a 3-wk interval","Fragment of a Natural Sequence Molecule","Peptide from protein",RGFGFVTFSSMAEVDAAMAAR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,356
1650257,16339574,1015135,10001309,"4 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","2 doses of 30 µ at a 3-wk interval","Fragment of a Natural Sequence Molecule","Peptide from protein",KRGFGFVTFDDHDPVDKIVLQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 5",Negative,NULL,NULL,356
16274,11906771,1162,10000000,"4-6 weeks-old","Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","Mice were given four injections, each 15 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",NSTSTWVTYGTCTTTGEHRREKRSV,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",NULL,Other,NULL,Organism,Organism,"Dengue virus 2",11060,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1650341,16207332,1014661,10000054,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9031,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,356
1650347,16207332,1014661,10000064,NULL,"Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 100 μg and a boost with 50 μg at day 35.","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10116,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,356
1654284,19433543,1015927,10001998,"4 to 8 weeks","Administration in vivo to prevent or reduce disease",;TiterMax;,"Intraperitoneal (i.p.)","4 doses of 1 µg at 3-week intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",NHTPPGSY,NULL,"Complexed Molecule","Protein conjugate","Shiga toxin 1 A subunit (Escherichia coli)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"shiga toxin 2d subunit A",562,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",34,12,35.3,"Table 3",Negative,NULL,NULL,124
1654285,19433543,1015927,10001998,"4 to 8 weeks","Administration in vivo to prevent or reduce disease",;TiterMax;,"Intraperitoneal (i.p.)","4 doses of 1 µg at 3-week intervals.","Fragment of a Natural Sequence Molecule","Peptide from protein",NHTPPGSY,NULL,"Complexed Molecule","Protein conjugate","Shiga toxin 1 A subunit (Escherichia coli)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Shiga toxin 1 A subunit",562,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",5,5,100,"Table 3",Positive,NULL,NULL,124
1585489,1372368,1008932,10000668,NULL,"Administration in vivo",";Freund's incomplete (IFA);","Subcutaneous (s.c.)",NULL,"Sequence Molecule No Natural Source","Peptide, no natural source",CCRHKQKIIAPAKQLLPPSGSGRRGDMGSLAARVVKQPCG,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Foot-and-mouth disease virus (strain A24 Cruzeiro)",12115,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",20,16,80,"Table 2",Positive,NULL,NULL,125
2765022,26710081,1030059,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"envelope glycoprotein E2",11103,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Hepatitis C virus subtype 1b",31647,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figure 6 and Supplementary Table 1",Positive,NULL,NULL,559
2518326,26463341,1029525,10000653,"6-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 100 ug at an interval of 21 days","Fragment of a Natural Sequence Molecule","Peptide from protein",DGSKNEWGWSKSKLG,NULL,Plasmid,Plasmid,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Plasmodium yoelii 17X",1323249,http://purl.obolibrary.org/obo/OBI_0002051,"in vivo assay",NULL,NULL,NULL,"Figures 4, 5",Positive,NULL,NULL,559
1654391,18413606,1012489,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","Three doses of 20 nmol at an interval of four weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",QLYKTCKQAGTCPPDIIPKV,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing SSKKLIPNASLIENCTKAEL",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 16",333760,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figures 5 and 6",Positive,NULL,NULL,125
1654392,18413606,1012489,10000000,"4-6 weeks","Administration in vivo to prevent or reduce disease",NULL,"Subcutaneous (s.c.)","Three doses of 20 nmol at an interval of four weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",QLYKTCKQAGTCPPDIIPKV,NULL,"Complexed Molecule","Peptide conjugate","Peptide conjugate containing SSKKLIPNASLIENCTKAEL",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 45",10593,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,125
1664631,7689589,1015260,9986,"6-8 weeks","Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",GSLPQKSQRSQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",6,6,100,"Table 3",Positive,NULL,NULL,326
1664691,7689589,1015260,10000662,"6-8 weeks","Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",SQRSQDEN,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",3,3,100,"Table 3",Positive,NULL,NULL,326
1664692,7689589,1015260,9986,"6-8 weeks","Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",SQRSQDEN,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",6,6,100,"Table 3",Positive,NULL,NULL,326
1664611,7689589,1015260,10000662,"6-8 weeks","Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",GSLPQKSQRSQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",4,4,100,"Table 3",Positive,NULL,NULL,326
1646848,17761350,1014561,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",VDTYDGRGDSVVYGLRS,NULL,"Complexed Molecule","Protein conjugate","Thyroglobulin (Homo sapiens)",Monoclonal,"Antibody construct","Entire Antibody","Accession Sequence Molecule",Protein,"collagen COL1A2",9541,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 5, 7, and 8",Positive,NULL,NULL,326
1652989,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652769,16585962,1015094,10000054,"6 to 8 weeks","Administration in vivo to prevent or reduce disease",NULL,"Intravenous (i.v.)","3 doses of 300 µg daily for 3 days.","Fragment of a Natural Sequence Molecule","Peptide from protein","SHQESTRGRSRGRSGRSGS + CITR(R7)",NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1652985,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652986,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652987,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652983,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652984,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652988,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652982,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1652980,16585962,1015094,10000054,"6 to 8 week","Administration in vivo",";Freund's complete;",Intradermal,"1 dose of 0.1 ml","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9913,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1657184,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",AGSSIVPLEEYPAEIP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 1",122291,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Table 2",Positive,NULL,NULL,125
1657185,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",VGPLDIVPEVADPGGPTLV,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 1",122291,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 2",Negative,NULL,NULL,125
1657187,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",GGPTLVSLHELPAETP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 1",122291,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,0,0,"Table 2",Negative,NULL,NULL,125
1657179,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",VGPLDIVPEVADPGGPTLV,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 2",10623,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Figure 5 and 6",Positive,NULL,NULL,125
1657182,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",AGSSIVPLEEYPAEIP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 2",10623,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,1,25,"Figure 5",Positive,NULL,NULL,125
1657183,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",VGPLEVIPEAVDPAGSSIV,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 1",122291,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Table 2",Positive,NULL,NULL,125
1657180,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",GGPTLVSLHELPAETP,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 2",10623,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,4,100,"Figure 5",Positive,NULL,NULL,125
1657181,12208958,1015828,10000206,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 500ug peptide at 3 and 4-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",VGPLEVIPEAVDPAGSSIV,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Kappapapillomavirus 2",10623,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",4,2,50,"Figure 5",Positive,NULL,NULL,125
2467502,25822571,1029110,10000000,adult,"Administration in vivo to cause disease",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","3 doses of 100 µg, administered at intervals of 2 weeks.","Fragment of a Natural Sequence Molecule","Peptide from protein",IVSRQEKGKSLLFKTE,NULL,"Complexed Molecule","Protein conjugate","Keyhole limpet hemocyanin (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 New Guinea C",10001583,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 4 and 7",Negative,NULL,NULL,356
1510526,7945236,1011696,10000618,NULL,"Administration in vivo",;Ribi;,"Intraperitoneal (i.p.)","2 doses of 2ug, administered at intervals of 3 weeks.","Accession Sequence Molecule",Protein,"Chain A, The Crystal Structure Of Neurotoxin-I From Naja Naja Oxiana At 1.9 Angstroms Resolution",8657,NULL,NULL,NULL,Monoclonal,"Purified Immunoglobulin","Entire Antibody","Accession Sequence Molecule",Protein,"toxin alpha,bungaro",8616,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 3",Positive,NULL,NULL,125
1660287,16125192,1014665,10000064,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"collagen, type II, alpha 1",10116,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",5,1,20,"Table 3",Positive-Low,NULL,NULL,356
1660250,16125192,1014665,10000054,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9031,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",5,2,40,"Table 3",Positive-Intermediate,NULL,NULL,356
1660283,16125192,1014665,10000054,NULL,"Administration in vivo",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",9031,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",5,5,100,"Table 3",Positive,NULL,NULL,356
1660288,18486939,1015482,10000276,"4-6 weeks","Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 100 nmol","Fragment of a Natural Sequence Molecule","Peptide from protein",DEGGYTCFFRDHSYQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",61,18,29.5,"Figures 1-9, 11 and Tables 1-4.",Positive-Intermediate,NULL,NULL,356
1494324,7516272,1009121,10000000,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Intraperitoneal (i.p.)","1 dose of 50 µg epitope-KLH in FCA and 5 boosts with 25 µg in IFA at 14-day intervals","Sequence Molecule No Natural Source","Peptide, no natural source",CRGFTSFKKPPTPPPEPET,NULL,"Complexed Molecule","Protein conjugate","Hemocyanin 2-c chain (Megathura crenulata)",NULL,NULL,NULL,Organism,Organism,"Macaca mulatta polyomavirus 1",1891767,http://purl.obolibrary.org/obo/OBI_0002052,"in vivo assay",14,7,50,"Figure 3",Positive,NULL,NULL,560
1812734,15289269,1018058,10000038,NULL,"Administration in vivo",";Freund's complete;Freund's incomplete (IFA);","Subcutaneous (s.c.)","4 doses of 50 µg, administered at intervals of 2 weeks.","Accession Non-Sequence Molecule",Glycolipid,lipopolysaccharide,197,NULL,NULL,NULL,NULL,NULL,NULL,"Derivative of Organism","Anatomical Entity","Peripheral Nervous System (Mus musculus)",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 1, 7, 8, and Table 1",Positive,NULL,NULL,356
1662311,9143240,1015664,10000649,"4-6 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",NTWTTCQSIAFPSK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",19,19,100,"Table 2",Positive,NULL,NULL,356
1662313,9143240,1015664,10000649,"4-6 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)",NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",KTTICGKGLSATVT,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",21,7,33.3,"Table 2",Positive,NULL,NULL,356
1789877,20685980,1020946,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",FAEDVGSNKGAIIGLMVGGVVIA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figures 7, 8",Positive,NULL,NULL,326
1789894,20685980,1020946,10001241,"1.5 month","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive-Low,NULL,NULL,326
1789823,20685980,1020946,10001241,"1.5 month","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 6",Positive,NULL,NULL,326
1664903,2437472,1015277,10000206,NULL,"Administration in vivo to cause disease",";Freund's complete;",Intramuscular,"One dose of 1 mg and one dose of 0.5 mg three weeks later.","Fragment of a Natural Sequence Molecule","Peptide from protein",SHHPARTAHYGSLPQK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin basic protein",9986,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",7,4,57.1,"Text p12",Positive,NULL,NULL,356
1665112,8943561,1015514,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 200 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",GQFRVIGPGHPIRALVGDEAE,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin-oligodendrocyte glycoprotein precursor",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",3,0,0,"Table 2",Negative,NULL,NULL,356
1665125,8943561,1015514,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 200 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",SYQEEAAVELKVED,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin-oligodendrocyte glycoprotein precursor",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table 2",Negative,NULL,NULL,356
1665128,8943561,1015514,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 200 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",LHRRLAGQFLEELRNPF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin-oligodendrocyte glycoprotein precursor",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table 2",Negative,NULL,NULL,356
2830715,27181584,1030369,9544,"5-6 years","Administration in vivo",";Aluminum potassium sulfate (alum);",Intramuscular,"8 doses of 100 or 200ug GP at 4-week intervals","Accession Sequence Molecule",Protein,"virion spike glycoprotein precursor",186538,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Zaire ebolavirus",186538,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",6,2,33.3,"Table 5",Positive,NULL,NULL,124
1467259,16083792,1005373,10000000,"7 weeks old","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","3 doses of 5 µg","Accession Sequence Molecule",Protein,"major allergen Bet v 1",3505,NULL,NULL,NULL,NULL,NULL,"Entire Antibody","Accession Sequence Molecule",Protein,"major allergen Bet v 1",3505,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
1467281,16083792,1005373,10000000,"7 weeks old","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","3 doses of 5 µg","Accession Sequence Molecule",Protein,"Pollen allergen Phl p 5a",15957,NULL,NULL,NULL,NULL,NULL,"Entire Antibody","Accession Sequence Molecule",Protein,"Pollen allergen Phl p 5a",15957,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
1467279,16083792,1005373,10000000,"7 weeks old","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","3 doses of 5 µg","Accession Sequence Molecule",Protein,"Major pollen allergen Bet v 1-F/I",3505,NULL,NULL,NULL,NULL,NULL,"Entire Antibody","Accession Sequence Molecule",Protein,"Major pollen allergen Bet v 1-F/I",3505,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
1467280,16083792,1005373,10000000,"7 weeks old","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","3 doses of 5 µg","Accession Sequence Molecule",Protein,"Pollen allergen Phl p 1 precursor",15957,NULL,NULL,NULL,NULL,NULL,"Entire Antibody","Accession Sequence Molecule",Protein,"Pollen allergen Phl p 1 precursor",15957,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
1467277,16083792,1005373,10000000,"7 weeks old","Administration in vivo to cause disease",NULL,"Intraperitoneal (i.p.)","3 doses of 5 µg","Accession Sequence Molecule",Protein,"Pollen allergen Phl p 1 precursor",15957,NULL,NULL,NULL,NULL,NULL,"Entire Antibody","Accession Sequence Molecule",Protein,"Pollen allergen Phl p 1 precursor",15957,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 1",Positive,NULL,NULL,326
2103526,24415460,1027598,10000000,"6 weeks","Administration in vivo",";Freund's incomplete (IFA);",Intranasal,"3 doses of 1 x 10E7 pfu, administered at intervals of 14 days.",Organism,Organism,"Human respiratory syncytial virus A2",11259,"Infected Cell","Infected Cell","Epithelial cell (Homo sapiens)",NULL,NULL,NULL,Organism,Organism,"Human respiratory syncytial virus A2",11259,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",6,6,100,"Figure 5",Positive,NULL,NULL,125
1904478,21950267,1022653,10000000,"6-8 weeks","Administration in vivo",";Cholera toxin;",Oral,"1mg twice per week for 4 weeks","Accession Sequence Molecule",Protein,"Ovomucoid precursor",9031,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,"Ovomucoid precursor",9031,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figures 2 and 3",Positive,NULL,NULL,361
1904479,21950267,1022653,10000000,"6-8 weeks","Administration in vivo",";Cholera toxin;",Oral,"1mg twice per week for 4 weeks","Accession Sequence Molecule",Protein,"Ovomucoid precursor",9031,NULL,NULL,NULL,Polyclonal,Feces,"Entire Antibody","Accession Sequence Molecule",Protein,"Ovomucoid precursor",9031,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,361
1642290,16769900,1014400,10001240,"6-11 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV,NULL,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,326
1640286,16769900,1014400,10001240,"6-11 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Table 1, Figures 2, 3, supp Figures 4, 5, 6",Positive,NULL,NULL,326
1665361,19535627,1014889,9606,NULL,"No immunization",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 4 Philippines/H241/1956",408686,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3, Table S2 and Figure S2",Positive,NULL,NULL,125
1665359,19535627,1014889,9606,NULL,"No immunization",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Dengue virus 2 Thailand/NGS-C/1944",11065,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,125
1688669,19651864,1016524,10000000,NULL,"Administration in vivo",;Ribi;,"Intraperitoneal (i.p.)","Three injections of 100 uL at 2-week intervals","Accession Sequence Molecule",Protein,"botulinum neurotoxin type A",1491,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"botulinum neurotoxin type A",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"FIgure 1",Positive,NULL,NULL,124
2113841,24962748,1028006,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);",Intramuscular,"3 doses of 5ug peptide plus VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",LVEETSFIDAGAP,NULL,"Recombinant Organism","Recombinant Organism","Escherichia virus Qbeta",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 18",333761,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 2",Positive,NULL,NULL,125
2113843,24962748,1028006,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);",Intramuscular,"3 doses of 5ug peptide plus VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",LVEETSFIDAGAP,NULL,"Recombinant Organism","Recombinant Organism","Escherichia virus Qbeta",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 45",10593,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,0,0,"Figure 2",Negative,NULL,NULL,125
2113844,24962748,1028006,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);",Intramuscular,"3 doses of 5ug peptide plus VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",LVEETSFIDAGAP,NULL,"Recombinant Organism","Recombinant Organism","Escherichia virus Qbeta",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 58",10598,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,5,100,"Figure 2",Positive,NULL,NULL,125
2113848,24962748,1028006,10000000,NULL,"Administration in vivo",";Freund's incomplete (IFA);",Intramuscular,"3 doses of 5ug peptide plus VLP","Fragment of a Natural Sequence Molecule","Peptide from protein",GTGGRTGYIPLGTRPPTATDT,NULL,"Recombinant Organism","Recombinant Organism","Escherichia virus Qbeta",NULL,NULL,NULL,Organism,Organism,"Human papillomavirus type 18",333761,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",5,1,20,"Figure 3A",Positive,NULL,NULL,125
1595736,1282493,1013576,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Saponin;,"Subcutaneous (s.c.)","2 doses of 50ug, administered on day 0 and week 9.","Fragment of a Natural Sequence Molecule","Peptide from protein",IQYHHDPQPVGREKFTIRPHYGKEI,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",15,4,26.7,"Table 5",Positive,NULL,NULL,124
1595734,1282493,1013576,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Saponin;,"Subcutaneous (s.c.)","2 doses of 50ug, administered on day 0 and week 9.","Fragment of a Natural Sequence Molecule","Peptide from protein",PFVPRADEPARKGKVH,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Semliki Forest virus",11033,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",15,7,46.7,"Table 5",Positive,NULL,NULL,124
1675586,9973531,1015557,10000632,"5 weeks","Administration in vivo to cause disease",NULL,"Subcutaneous (s.c.)","1 dose of 100 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figures 1 and 2",Positive,NULL,NULL,356
1676843,19175799,1016493,10001332,"8 to 12 weeks","Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","4 doses of 100 µg on a weekly basis","Fragment of a Natural Sequence Molecule","Peptide from protein",GQFRVIGPGHPIRALVGDEAELP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",3,3,100,"Table 4",Positive,NULL,NULL,356
1676844,19175799,1016493,10001332,"8 to 12 weeks","Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","4 doses of 100 µg on a weekly basis","Fragment of a Natural Sequence Molecule","Peptide from protein",GQFRVIGPGHPIRALVGDEAELP,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",3,3,100,"Table 4",Positive,NULL,NULL,356
1666452,9565646,1015417,10000662,"5-6 weeks","Administration in vivo to prevent or reduce disease",NULL,Intramuscular,"1 dose of 800 ug at week 0.","Fragment of a Natural Sequence Molecule","Peptide from protein",HYGSLPQKSQRSQDENPV,NULL,Plasmid,Plasmid,NULL,Polyclonal,Serum,"Entire Antibody","Fragment of a Natural Sequence Molecule","Peptide from protein",HYGSLPQKSQRSQDENPV,NULL,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,361
1667661,11064438,1015390,9606,NULL,"Administration in vivo",NULL,"Intravenous (i.v.)","4 doses of 500 mg","Fragment of a Natural Sequence Molecule","Peptide from protein",DENPVVHFFKNIVTPRT,NULL,NULL,NULL,NULL,Polyclonal,Other,"Entire Antibody","Accession Sequence Molecule",Protein,"MBP protein",9606,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",41,33,80.5,"Figures 2, 3, 4, 5 and Table 2",Positive,NULL,NULL,361
1276404,9014296,1001585,10000216,"4-6 weeks","Administration in vivo to prevent or reduce disease",;Ribi;,"Intraperitoneal (i.p.)","4 injections with 10 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",EVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGT...,NULL,"Complexed Molecule","Peptide conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Botulinum neurotoxin type A precursor",1491,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",9,0,0,"Table 1",Negative,NULL,NULL,124
1677930,19527169,1016562,10000000,NULL,"Administration in vivo",;Ribi;,NULL,"Doses of 25 µg at 3-week intervals.  Final dose was 5 µg.","Accession Sequence Molecule",Protein,"envelope glycoprotein",11082,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus SA58",10001386,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,0,0,"Table 1",Negative,NULL,NULL,125
1677945,19527169,1016562,10000000,NULL,"Administration in vivo",;Ribi;,NULL,"Doses of 25 µg at 3-week intervals.  Final dose was 5 µg.","Accession Sequence Molecule",Protein,"envelope glycoprotein",11082,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus NY-99",10000971,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",10,10,100,"Table 1",Positive,NULL,NULL,326
1677858,19527169,1016562,10000000,NULL,"Administration in vivo",;Ribi;,NULL,"Doses of 25 µg at 3-week intervals.  Final dose was 5 µg.","Accession Sequence Molecule",Protein,"envelope glycoprotein",11082,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus NY-99",10000971,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",10,10,100,"Table 1",Positive,NULL,NULL,125
1677951,19527169,1016562,10000000,NULL,"Administration in vivo",;Ribi;,NULL,"Doses of 25 µg at 3-week intervals.  Final dose was 5 µg.","Accession Sequence Molecule",Protein,"envelope glycoprotein",11082,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"West Nile virus NY-99",10000971,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",10,1,10,"Table 1",Negative,NULL,NULL,326
1799191,12516572,1014553,10001288,newborn,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);",NULL,"1 dose of 100ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein","GIAGFKGEQGPKGET + HYL-GAL(K6)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"collagen, type II, alpha 1 isoform 2 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"page 3781 (data not shown)",Positive,NULL,NULL,326
1799172,12516572,1014553,10000032,newborn,"Administration in vivo to prevent or reduce disease",";Freund's incomplete (IFA);",NULL,"1 dose of 100ug peptide","Fragment of a Natural Sequence Molecule","Peptide from protein","GIAGFKGEQGPKGET + HYL-GAL(K6)",NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"collagen, type II, alpha 1 isoform 2 precursor",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 2B",Positive,NULL,NULL,326
1643982,17517595,1008552,10001241,"3-4 months","Occurrence of disease",NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Amyloid beta A4 protein precursor",9606,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 4",Positive,NULL,NULL,326
1463715,17088351,1006555,10000666,"4.5 months","Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)",2,"Fragment of a Natural Sequence Molecule","Peptide from protein",VVIANNVDKFVSWGITDFEM,NULL,"Complexed Molecule","Multi-Antigenic Peptide (MAP, branched)",NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Streptococcus sobrinus 6715",246202,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 4B, D and 5E, F.",Positive,NULL,NULL,125
1675723,9771980,1015565,10000635,"12-18 weeks","Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 100 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",36,36,100,"Table 1, Figures 1 and 3",Positive,NULL,NULL,356
2000491,23812669,1026658,10032,NULL,"Administration in vivo",NULL,"Intraperitoneal (i.p.)","12 to 13 doses of 2 µg, administered twice per week","Accession Sequence Molecule",Protein,"stromal cell-derived factor 1 isoform alpha precursor",9606,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Collagen alpha-1(II) chain",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive-Intermediate,NULL,NULL,326
1681876,11359852,1015653,10000649,"7-10 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)","One dose of 50 µg.","Fragment of a Natural Sequence Molecule","Peptide from protein","HCLGKWLGHPDKF + PALM(H1)",NULL,NULL,NULL,NULL,Polyclonal,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,0,0,"Table III",Negative,NULL,NULL,356
1838441,21403591,1022243,9555,NULL,"Administration in vivo",NULL,NULL,"Daily injections of 50 mg/kg","Accession Non-Sequence Molecule",Carbohydrate,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc,9823,"Complexed Molecule","Other Complexed Molecule",NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule",Carbohydrate,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc,9823,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",11,11,100,"Figure 1",Positive,NULL,NULL,361
1838438,21403591,1022243,9555,NULL,"Administration in vivo to prevent or reduce disease",NULL,NULL,"Daily injections of 50 mg/kg","Accession Non-Sequence Molecule",Carbohydrate,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc,9823,"Complexed Molecule","Other Complexed Molecule",NULL,NULL,NULL,NULL,"Derivative of Organism","Anatomical Entity","Heart (Sus scrofa)",9823,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",11,3,27.3,"Table 1 and Figure 3",Positive-Low,NULL,NULL,326
1838442,21403591,1022243,9555,NULL,"Administration in vivo",NULL,NULL,"Daily injections of 50 mg/kg","Accession Non-Sequence Molecule",Carbohydrate,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc,9823,"Complexed Molecule","Other Complexed Molecule",NULL,Polyclonal,Serum,"Entire Antibody","Accession Non-Sequence Molecule",Carbohydrate,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc,9823,http://purl.obolibrary.org/obo/OBI_0001693,"in vivo assay",11,11,100,"Figure 1",Positive,NULL,NULL,361
1796744,15488947,1016198,10000067,NULL,"Administration in vivo",";Freund's complete;",NULL,"5 doses of 125 ug protein at intervals of 3 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein","IRCPRPQDFENGEFWPRSPFYNLSDQISFQCYDGYVLRGSA NRTCQENG...",NULL,"Complexed Molecule","Protein conjugate","antibody Fab 4F8 immunoglobulin G1 heavy chain (Mus musculus)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"complement factor B",10090,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,326
1665116,8943561,1015514,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 200 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin-oligodendrocyte glycoprotein precursor",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",5,5,100,"Table 2",Positive,NULL,NULL,356
1665119,8943561,1015514,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 200 ug","Fragment of a Natural Sequence Molecule","Peptide from protein",GRTELLKESIGEGKVALRIQN,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Myelin-oligodendrocyte glycoprotein precursor",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",3,0,0,"Table 2",Negative,NULL,NULL,356
1493401,17371999,1006162,10000000,"5-7 weeks","Administration in vivo",NULL,Intramuscular,"2 doses of 150ug, administered at intervals of 3 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",DYAWDQTHQ,NULL,Plasmid,Plasmid,NULL,NULL,NULL,NULL,Organism,Organism,"Neisseria meningitidis serogroup B",491,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",8,6,75,"Table III",Positive,NULL,NULL,125
1675710,9771980,1015565,10000067,"12-18 weeks","Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 100 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",MEVGWYRSPFSRVVHLYRNGK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",13,11,84.6,"Table 1 and Figure 2",Positive,NULL,NULL,356
1435547,11122460,1006297,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 50 μg, administered at intervals of 3 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",YLLQKLRN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,NULL,"Entire Antibody",Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1435531,11122460,1006297,10000067,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;Freund's incomplete (IFA);",Intradermal,"3 doses of 50 μg, administered at intervals of 3 weeks.","Sequence Molecule No Natural Source","Peptide, no natural source",VLLRRIGG,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus)",Polyclonal,NULL,"Entire Antibody",Organism,Organism,"Schistosoma mansoni Puerto Rico",10000385,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 6",Negative,NULL,NULL,125
1705162,15630133,1016171,10001133,"6 weeks","Administration in vivo to cause disease",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS,NULL,NULL,NULL,NULL,Polyclonal,NULL,NULL,"Accession Sequence Molecule",Protein,"tripartite motif-containing 21",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,356
2925043,27503072,1030938,10090,NULL,"Administration in vivo",NULL,NULL,NULL,"Fragment of a Natural Sequence Molecule","Peptide from protein",TTVAEKNTCQLYIQTDHLFFKYYGTREAVIAQISSHVKAIDTIYQTTDFS...,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Derivative of Organism",Cell,"Other from Gastrointestinal Tract (Homo sapiens)",9606,http://purl.obolibrary.org/obo/OBI_0002052,"in vivo assay",NULL,NULL,NULL,"Figures 6 and 7",Positive,NULL,NULL,560
2723495,25937448,1030020,10000000,NULL,"Administration in vivo to prevent or reduce disease",;Other;,Intramuscular,"3 doses of 15.9 µg, administered at intervals of 14 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",SLLTEVETPTRNEWECRCSDSSD,NULL,"Complexed Molecule","Protein conjugate","precore/core protein (Hepatitis B virus) linked to GTSGSSGSGSGGSGSGGGG",NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/chicken/Kurgan/05/2005(H5N1))",376721,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",12,12,100,"Figure 5",Positive,NULL,NULL,124
1651456,19435417,1014888,9986,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 50 µg followed by 2 booster injections in IFA at 2-week intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",LGSTAVSPTTLRGSTAVSPTTLRGS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus - C",358812,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,125
1651460,19435417,1014888,9986,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 50 µg followed by 2 booster injections in IFA at 2-week intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",LGSTAVSPTTLRGSTAVSPTTLRGSTAVSPTTLRGSTAVSPTTLRGS,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Organism,Organism,"Classical swine fever virus - C",358812,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Figure 2",Negative,NULL,NULL,125
1653115,19435417,1014888,9986,NULL,"Administration in vivo to prevent or reduce disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 50 µg followed by 2 booster injections in IFA at 2-week intervals.","Sequence Molecule No Natural Source","Peptide, no natural source",LGSTAVSPTTLRGSTAVSPTTLRGS,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Classical swine fever virus - C",358812,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Table 2",Negative,NULL,NULL,125
1680093,15210822,1015731,10000649,"8-12 weeks","Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","One dose of 200 µg.","Fragment of a Natural Sequence Molecule","Peptide from protein",HCLGKWLGHPDKF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin/oligodendrocyte glycoprotein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 8",Positive,NULL,NULL,356
1680087,15210822,1015731,10000649,"8-12 weeks","Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","One dose of 200 µg.","Fragment of a Natural Sequence Molecule","Peptide from protein",HCLGKWLGHPDKF,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",NULL,NULL,NULL,"Figure 8",Positive,NULL,NULL,356
1499246,14555282,1005418,10116,NULL,"Administration in vivo to prevent or reduce disease",NULL,"Intragastral / Intracolonic","1 dose of 2 mg","Fragment of a Natural Sequence Molecule","Peptide from protein",VLVNAIVFKGLWEKAFKDEDTQAM,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody","Accession Sequence Molecule",Protein,ovalbumin,9031,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",NULL,NULL,NULL,"Table 3",Positive,NULL,NULL,326
1480044,8578804,1008204,10001998,"4-8 weeks","Administration in vivo",";Freund's complete;Freund's incomplete (IFA);",NULL,"4 doses of 100 ug at intervals of 2 weeks","Fragment of a Natural Sequence Molecule","Peptide from protein",KEGYLVDKNT,NULL,"Complexed Molecule","Protein conjugate",NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"Beta-mammal toxin Cn2 precursor (Toxin 2) (Toxin II.9.2.2)",6878,http://purl.obolibrary.org/obo/OBI_0001710,"in vivo assay",NULL,NULL,NULL,"Tables 3, 2",Negative,NULL,NULL,125
2072691,24057757,1027289,10000000,"6 to 8 weeks","Administration in vivo",NULL,Intramuscular,"2 doses of 50 µg plasmid.","Accession Sequence Molecule",Protein,hemagglutinin,641501,Plasmid,Plasmid,NULL,NULL,NULL,NULL,Organism,Organism,"Influenza A virus (A/California/04/2009(H1N1))",641501,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 2",Positive,NULL,NULL,124
1497233,15232173,1013044,10000263,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","4 doses of 30ug, administered at intervals of 21 and 10 days.","Fragment of a Natural Sequence Molecule","Peptide from protein",LRRDLDASREAKKQVEKALE,NULL,NULL,NULL,NULL,Polyclonal,Serum,"Entire Antibody",Organism,Organism,"Streptococcus pyogenes M1 GAS",160490,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 3",Positive,NULL,NULL,124
1687683,2442406,1015473,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","One dose of 10000 µg on day 0, boosted by two doses of 500 µg on days 7 and 17, and one dose of 250 µg on day 28.","Fragment of a Natural Sequence Molecule","Peptide from protein",SQRSQDEN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus) linked to G9",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",39,39,100,"Tables II, III and IV",Positive,NULL,NULL,356
1687684,2442406,1015473,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 100 or 25 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",GSLPQKSQRSQ,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",8,0,0,"Table III",Negative,NULL,NULL,356
1687685,2442406,1015473,10000662,NULL,"Administration in vivo to cause disease",";Freund's complete;","Subcutaneous (s.c.)","1 dose of 100 µg","Fragment of a Natural Sequence Molecule","Peptide from protein",GSLPQKSQRSQDEN,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",4,4,100,"Table III",Positive,NULL,NULL,356
1687686,2442406,1015473,10000662,NULL,"Administration in vivo",";Freund's complete;","Subcutaneous (s.c.)","One dose of 400 µg Me-BSA-S53","Fragment of a Natural Sequence Molecule","Peptide from protein",SQRSQDEN,NULL,"Complexed Molecule","Protein conjugate","Serum albumin precursor (Bos taurus) linked to G9",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"myelin basic protein",10116,http://purl.obolibrary.org/obo/OBI_0001697,"in vivo assay",18,18,100,"Table V",Positive,NULL,NULL,326
2022133,24054942,1027174,10000000,"4-5 weeks","Administration in vivo",";Alum (Aluminum hydroxide gel);","Subcutaneous (s.c.)","Four doses of 20 ug, administereded at 2-week intervals","Fragment of a Natural Sequence Molecule","Peptide from protein",EVHGNAEVHASFFDIGGSVSAGFS,NULL,"Complexed Molecule","Protein conjugate","core protein (Hepatitis B virus)",NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"protective antigen",1392,http://purl.obolibrary.org/obo/OBI_0001696,"in vivo assay",NULL,NULL,NULL,"Figure 5",Positive,NULL,NULL,124
1687510,7511703,1006845,10000649,"8 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)","2 doses of 50 µg, administered 7 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",KTSASIGSLCADAR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",6,0,0,"Table 1",Negative,NULL,NULL,356
1687508,7511703,1006845,10000649,"8 weeks","Administration in vivo to cause disease",";Bordetella pertussis;Freund's complete;","Subcutaneous (s.c.)","2 doses of 50 µg, administered 7 days apart.","Fragment of a Natural Sequence Molecule","Peptide from protein",NTWTTCDSIAFPSK,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Accession Sequence Molecule",Protein,"proteolipid protein",10090,http://purl.obolibrary.org/obo/OBI_0001711,"in vivo assay",6,6,100,"Table 1",Positive,NULL,NULL,356